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Abstract
Functionalized fullerenes exhibit improved solubility and different chemical and physical
properties that allow applications in multiple fields such as photovoltaic and biological
applications. Currently, perovskite solar cells (PSCs) are the most rapidly developing type of solar
cells with certified efficiencies rising from 3.8% in 2009 to 22.1% in 2016. The good electron
transporting and solution processable properties of most fullerene derivatives make them the most
popular electron transporting materials (ETMs) in inverted perovskite solar cells (PSCs).
The work is reported in 11 chapters. We start with a fullerene overview followed by cleaver
and elegant methodologies that allow the synthesis of unusual multiple-adducts of fullerenes C60
and C70, in a very regioselective manner that are otherwise impossible to obtain. Finally, we
describe the synthesis of new C60 and C70 fullerene derivatives and their use in PSCs as the ETMs,
as well as their remarkable anti-HIV-1 biological applications.
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Chapter 1: Overview of fullerenes
1.1

GENERAL OVERVIEW
Fullerenes, one of the allotropic forms of carbon, were observed for the first time in 1985[1]

and isolated in bulk in 1990.[2] The highly symmetric, icosahedral C60 carbon cage is composed of
12 pentagons and 20 hexagons, and owes its name to the similarity of its molecular structure to the
geodesic domes developed by architect Richard Buckminster Fuller.[3] To date, fullerenes and their
derivatives have been used for different applications such as new materials for molecular electronic
devices and sensors,[4] photovoltaic devices,[5] materials for biomedical applications such as
antivirals,[6, 7] drug delivery,[8] imaging,[9] and photodynamic therapy,[10] among others. Chemical
functionalization of the fullerene cage can be easily achieved, allowing the introduction of
different functional groups that help to tune its physical and electronic properties.[11-13]
1.2

SOLUBILITY
Due to their non-polar character and the tendency to aggregate, fullerenes C60 and C70 are

almost completely insoluble in water and show very low solubility in non-polar solvents. The
solubility in organic solvents is very important for their extraction, chemical functionalization and
purification. The best solubility is observed in carbon disulfide (CS2), aromatic solvents (benzene,
toluene and xylenes) and aromatic-halogenated solvents (chlorobenzene (CB), orthodichlorobenzene (o-DCB) and 1-chloronaphthalene).[14-16]
1.3

FUNCTIONALIZATION
Chemical functionalization of fullerenes has been extensively studied,[17-19] mainly to

increase their solubilities and to tune their electronic properties to expand their applications.[18]
One of the useful properties of fullerenes is that they can be functionalized easily using different
types of reactions, but the biggest problem is that after monoadduct formation, subsequent
additions of one, two, or three symmetrical addends to C60 can yield 8, 46, and 262 possible
regioisomers, respectively.[20, 21] The most common reactions performed with fullerenes are:
1

reduction, nucleophilic addition, cycloadditions, hydrogenation, radical addition, transition metal
complex formation, halogenation, oxidation and reactions with electrophiles.[22-25]
Regiochemically controlled multi-functionalization of fullerenes is crucial to obtain pure
isomers and to avoid challenging chromatographic purifications.[26] There are two well-known
methods to reduce the number of isomers, the tether-directed remote multi-functionalization
introduced by Diederich et al.,[27] and the topologically controlled method introduced by Krӓutler
et al.[28, 29] Both methods have been widely used to synthesize bis, tris, tetra, penta and hexaadducts of C60. A highly regio- and stereo-selective synthesis of fullerene C60 hexa-adducts using
a combination of a Diels-Alder reaction, followed by an addition-elimination of bromoethyl
malonate, then a retro-Diels-Alder and finally by a 1,3-dipolar cycloaddition reaction of
azomethine ylides is presented in chapter 2. (This work was published in Chemistry A European
Journal: Castro, E.; Azmani, K.; Hernandez Garcia, A.; Aghabali, A.; Liu, S.; Metta-Magana, A.;
Olmstead, M.; Rodriguez-Fortea, A.; Poblet, J.; Echegoyen, L. Chem. Eur. J. 2017, DOI:
10.1002/chem.201702866). Using a similar approach (protection deprotection), a fullerene C70 β4-β’ bis-regioisomer is presented in chapter 3. (This work was published in the Journal of Organic
Chemistry: Cerón, M. R.; Castro, E.; Neti, V. S. P. K.; Dunk, P. W.; Echegoyen, L. A. J. Org.
Chem. 2017, 82, 893).
1.4

PHOTOVOLTAIC APPLICATIONS
The sun continuously releases a tremendous amount of energy in the form of

electromagnetic radiation and this almost limitless source of energy is available at no cost.[30]
Photovoltaic solar cells (PVSCs)[31] can convert sunlight into storable energy. The photovoltaic
(PV) effect was first observed by A. E. Becquerel in 1839.[32] Photovoltaic technology is based on
the creation of an electron-hole pair upon photon absorption in cells composed of two different
layers (p-type and n-type) of semiconductor materials. In these cells, absorption of a photon by the
n-type material provides enough energy to move an electron from one layer to the other, leading
to the generation of electrical power.[33]
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Currently, inorganic solar cells based on materials such as silicon, cadmium telluride, or
copper indium germanium selenide exhibit relatively high solar energy conversion efficiencies
above 20%, and dominate commercially available PV technologies.[31, 34, 35] However, inorganic
solar cells present some limitations such as rigidity, weight and high manufacturing costs
compared to those based on organic-inorganic materials, so many alternative materials are under
investigation. In this regard, hybrid inorganic-organic solar cells are promising sources of
renewable energy.
1.4.1 PEROVSKITE SOLAR CELLS
The unique properties of PSCs make them promising candidates for developing nextgeneration PVs that could compete with silicon-based solar cells.[36,

37]

PSCs have shown a

remarkable PCE increase from 3.8% in 2009 to 22.1%, in 2016.[38-40] An inverted planar structure
with a configuration: substrate/PEDOT:PSS/perovskite/fullerene derivative has recently gained
more attention due to its simple structure, low temperature processing and negligible hysteric
behavior.[41] Besides [6,6]-phenyl-C61 butyric acid methyl ester (PC61BM), other studies have
shown that single or double fullerene layers (PC61BM/C60, ICBA/C60, C60/bis-C60), can also work
as efficient electron transporting layers (ETLs) in PSCs.[42-45] An overview of the fullerenes used
in PSCs is presented in chapter 4 (This work was submitted to the Journal of Materials Chemistry
C: Castro, E.; Murillo, J.; Fernandez-Delgado, O.; and Echegoyen, L. J. Mat. Chem. C. 2017).
However, the influence of the functional groups on the fullerene-based PSCs has not been
systematically investigated.
In chapters 5-8, we describe the improved performance and stability of inverted planar
perovskite solar cells using fullerene layers. We investigated the fullerenes’ ability to passivate
charge recombination and extract electrons efficiently, likely the result of improved solubility and
electron mobility. Additionally, specific interactions between the attached groups on the fullerene
derivatives and the perovskite layers, and the effect of the energy disorder in the ETL, were
investigated. (Part of this work has been submitted to the Journal of Materials Chemistry C, and
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part was published in the Journal of Materials Chemistry A, and ASC Applied Materials and
Interfaces: a) Tian, C.; Castro, E.; Betancourt-Solis, G.: Nan, Z.; Fernandez-Delgado, O.; Jankuru,
S.; and Echegoyen, L. J. Mat. Chem. C. Submitted. 2017. b) Tian, C.; Kochiss, K.; Castro, E.;
Betancourt-Solis, G.; Han, H.; Echegoyen, L. J. Mater. Chem. A. 2017, 5, 7326. c)

Tian,

C.; Castro, E.; Wang, T.; Betancourt-Solis, G.; Rodriguez, G.; Echegoyen, L. ACS Appl. Mater.
Interfaces. 2016, 8, 31426. d) Castro, E.; Zavala, G.; Seethraraman, S.; D’Souza, F.; and
Echegoyen, L. J. Mater. Chem. A. 2017. 5, 19485).
1.5

BIOLOGICAL APPLICATIONS
It has been reported that some fullerene derivatives are able to inhibit HIV-1 replication in

human cells at concentrations as low as 0.22 μM and display no cytotoxic effects at concentrations
higher than 100 μM.[6, 46] Molecular docking simulations predicted that fullerene derivatives can
bind to the active site of the HIV-1 protease (PR) due to their size and conformational
complementarity.[6, 46-50] Until the work that we recently published, the accepted fullerene-induced
inhibition mechanism suggested binding to the PR active site,[51, 52] as established by analysis of
the effect of these compounds on the in vitro activity of this enzyme along with in silico
predictions. However, this paradigm was recently challenged by the fact that C60 fullerene
derivatives failed to significantly inhibit HIV-1 PR using an in vitro assay at doses that potently
blocked HIV-1 maturation and infection, as shown in chapter 9. (This work was published in
Antimicrobial Agents and Chemotherapy: Martinez, Z. S.; Castro, E.; Seong, C. S.; Cerón, M. R.;
Echegoyen, L.; Llano, M. Antimicrob. Agents Chemother. 2016, 60, 5731).
C70-water-soluble fullerene derivatives remain poorly investigated. Initial reports
suggested that the biological properties of C70 fullerene derivatives were less significant when
compared with those of their C60-based analogs, in particular their antiviral activity.[53]
Furthermore, the lower symmetry of the D5h-C70 compared to that of the Ih-C60, makes its selective
functionalization more challenging. Therefore, few water-soluble C70 derivatives have been
reported.[46,

54]

N-quaternization of C60-fullerenopyrrolidines is an excellent and high-yielding
4

reaction to synthesize water-soluble C60-fullerenopyrrolidium salts.[55] In chapter 10 we report the
first synthesis and characterization of C70 quaternary ammonium salts, and their strong anti-HIV
properties. (This work was published in the Journal of Medicinal Chemistry: Castro, E.; Martinez,
Z. S.; Seong, C.-S.; Cabrera-Espinoza, A.; Ruiz, M.; Hernandez, G. A.; Valdez, F.; Llano, M.;
Echegoyen, L. A. J. Med. Chem. 2016, 59, 10963).
1.6

GENERAL PROCEDURES
All chemicals were reagent grade, purchased from Sigma Aldrich. Silica gel (Redisep

silica, 40-60 µ, 60 Å) was used to separate the products. HPLC experiments were performed on
an LC-9130NEXT instrument (Japan Analytical Industry Co. Ltd.) monitored using a UV detector
at 320 nm, and toluene as eluent. Three different HPLC columns were used for preparative
separation or to analyze the purity of the samples; Buckyprep column (ϕ = 10 ID x 250 mm), 5PBB (ϕ = 10 ID x 250 mm) or (ϕ = 4.6 ID x 250 mm). MALDI-TOF mass spectrometric
measurements were obtained on a Bruker Microflex LRF mass spectrometer on reflector positive
mode. The UV/Vis-NIR spectra were taken using a Cary 5000 UV/Vis-NIR spectrophotometer
using toluene or chloroform solutions. The NMR spectra were recorded using a JEOL 600 MHz
spectrometer. Cyclic voltammetry (CV) and square wave voltammetry (SWV) experiments were
carried out under an Argon atmosphere at room temperature using a CH Instrument Potentiostat.
The scan rate for the CV experiments was 100 mV/s. A one compartment cell with a standard
three-electrode set up was used, consisting of a 1 mm diameter glassy carbon disk as the working
electrode, a platinum wire as the counter electrode and a silver wire as the pseudo-reference
electrode, in a solution of anhydrous o-DCB containing 0.05 M n-Bu4NPF6. Ferrocene was added
to the solution at the end of each experiment as an internal potential standard.
The current-voltage (J-V) characteristics of the photovoltaic cells were recorded using a
Keithley 2420 source measuring unit with a Photo Emission Tech SS100 Solar Simulator, and the
light intensity was calibrated by a standard Si solar cell. The EQEs were measured using a Bentham
(Bentham Instruments Ltd) measurement system. The light intensity was calibrated using a single5

crystal Si photovoltaic cell as the reference. The J-V and EQE measurements were carried out in
air. The scanning electron microscopy (SEM) images were taken on a ZEISS Sigma FE-SEM. The
SEM images were collected using a ZEISS Sigma FE-SEM, where the electron beam was
accelerated in the range of 500 V to 30 kV. The X-ray diffraction (XRD) patterns were recorded
on a Bruker X-ray diffraction instrument using Cu Kα radiation. Film thicknesses were measured
using a KLA Tencor profilometer. Time-resolved photoluminescence (TRPL) was analyzed using
an Edinburgh instruments FLS980 fluorescence spectrometer. Atomic force microscopic (AFM)
measurements of the surface morphologies of the perovskite and perovskite/fullerenes were
obtained on a ND-MDT NTEGRA instrument using the tapping mode. The system was suspended
on a MINUS® K stiffness vibration isolator, AFM tips from TED PELLA (Silicon Electritap 300
coated with Cr/Pt) were used in semi-contact (tapping) mode resonating at 251 KHz. Samples were
scanned horizontally at 1 Hz side to side. Electrochemical impedance spectroscopic (EIS)
measurements were conducted in the frequency range from 4 MHz to 100 mHz at a bias of 600
mV under dark conditions.
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Chapter 2: Unusual C2h-symmetric trans-1-(bis-pyrrolidine)-tetra-malonate
hexa-adducts of C60. The unexpected regio- and stereo-control mediated by
malonate-pyrrolidine interaction
Abstract: A totally unanticipated regio- and stereo-isomerically pure C2h-symmetric trans1-(bis-pyrrolidine)-tetra-malonate hexa-adduct of C60 was obtained via a topologically controlled
method, followed by a 1,3-dipolar cycloaddition reaction. The structures of the products were
elucidated by 1H- and 13C-NMR and by X-ray crystallography. The unexpected regio- and stereoselectivity observed, supported by theoretical calculations, was found to be a consequence of
malonate-pyrrolidine interactions. Experimental procedures and figures presented here are a prepeer reviewed version of the following article (See Appendix A for the copyright letter): Castro,
E.; Azmani, K.; Hernandez Garcia, A.; Aghabali, A.; Liu, S.; Metta-Magana, A.; Olmstead, M.;
Rodriguez-Fortea,

A.;

Poblet,

J.;

Echegoyen,

L.

Chem.

Eur.

J.

2017,

DOI:

10.1002/chem.201702866.
2.1

INTRODUCTION
The chemical and physical properties of fullerenes and their derivatives are mainly

the result of their unique electron accepting abilities and high charge transport capabilities
in three dimensions.[19] The presence of thirty equivalent [6,6] double bonds on the C 60
carbon cage, all of which exhibit identical reactivity, results in low regioselectivity of
multiple addition products. After monoadduct formation, subsequent additions of one, two,
or three symmetrical addends can yield 8, 46, and 262 possible regioisomers,
respectively.[20, 21] 1,3-dipolar cycloaddition reactions of azomethine ylides to C 60 have been
extensively studied and it is one of the most powerful and versatile methods for derivatizing
fullerenes.[56] Prato and co-workers found that all eight possible bis-adduct regioisomers
were obtained upon 1,3-dipolar cycloaddition to C60 when the azomethine ylide is
symmetric,[26] showing that this reaction is less chemoselective than cyclopropanations of
C60.[57] The purification of regioisomers by column chromatography is challenging because
the bis-adducts exhibit similar polarities.[58]
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There are two well-known methods to reduce the number of regio-isomers of C60
and C70 derivatives, the tether-directed remote multifunctionalization introduced by
Diederich et al.,[59] and the topologically controlled method introduced by Krӓutler et al.[60]
Both methods have been widely used to synthesize bis, tris, tetra, penta and hexaderivatives of C60.[61-63]
Martin and coworkers reported a straightforward procedure catalyzed by silver or
copper acetate to efficiently obtain pyrrolidino[60]fullerenes with stereochemical control
by enantioselective cycloaddition of N-metalated azomethine ylides to C60.[64,

65]

This

methodology was later extended to higher fullerenes and endohedral fullerenes. [66]
Ovchinnikova and coworkers reported an efficient metal-assisted azomethine ylide
cycloaddition method for the diastereoselective synthesis of 5-substituted 3,4fulleroproline esters based on the lithium salt-assisted cycloaddition of azomethine
ylides.[67] In contrast to the thermal reactions that often result in the formation of
diastereomeric mixtures of products, metal-mediated azomethine ylide cycloaddition at low
temperature leads to higher yields and diastereoselectivity. However, this kind of reaction
has been scarcely studied.
Here, we report a regio- and stereo-selective synthesis of hybrid fullerene C60 hexa-adducts
using a combination of a Diels-Alder reaction, followed by an addition-elimination of bromoethyl
malonate, then a retro-Diels-Alder and finally by a 1,3-dipolar cycloaddition reaction of
azomethine ylides. Surprisingly, only one regio- and stereo-selective product corresponding to the
isomer cis-anti-cis hexa-adduct (see Figure 3 for structural nomenclature) was observed. The final
products were fully characterized by matrix assisted laser desorption/ionization time-of-flight
mass

spectroscopy (MALDI-TOF-MS),

1

H

and

13

C-NMR

spectroscopy

and

X-ray

crystallography. The overall regio- and stereo- selectivity observed was explained by theoretical
calculations.
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2.2

RESULTS AND DISCUSSION

2.2.1 Synthesis and NMR studies of 2, 3, 6 and 7
The C60-(e,e,e,e)-tetra-malonate (C60-TM) (Figure 2.1a) was synthesized following a
procedure previously reported.[68] Penta-adduct 2 and hexa-adduct 3 were synthesized by reacting
C60-TM with methyl glycine ester in the presence of diacetoxyiodobenzene (DIB) and sodium
carbonate decahydrate in ortho-dichlorobenzene (o-DCB) under sonication at room temperature
(Scheme 2.1). After 30 min the solution turned orange and compound 2 was the major product,
however after 3 h the solution turned yellow and compound 3 was the main product as monitored
by TLC using a dichloromethane:ethyl acetate (DCM:EA) 30:1 mixture as the eluent. After
column chromatographic purification compounds 2 and 3 were characterized by MALDI-TOFMS and NMR spectroscopy.
The molecular-ion peaks for the penta- and hexa-adduct compounds at m/z 1511.282 and
1670.341, were observed by MALDI-TOF-MS, respectively (Figure 2.8). Because the azomethine
ylide can add to the symmetric or unsymmetrical bonds (Figure 2.1a), two regioisomers are
possible for the penta-adduct. Surprisingly, only one isomer was observed, and by 1H- and

13

C-

NMR and X-ray crystal structure a Cs symmetry was assigned to compound 2.
The 1H-NMR spectrum of 2 (Figure 2.2a) exhibits only one set of signals for the pyrrolidine
addend ( = 4.69, 3.89 and 3.76 ppm), clearly establishing the presence of a plane of symmetry,
indicating that the addition must have occurred on the symmetric bond (Figures 2.1b and 2.1c).
The Cs symmetry of compound 2 was also confirmed by the

13

C-NMR spectrum (Figure 2.2b).

Five resonances for carbonyl groups at  = 169.0 (ester groups of the pyrrolidine addend), 163.8
(x2), 163.7 and 163.4 ppm (four malonates), five resonances for the methyl groups at  = 52.9.0
(methyl groups of the pyrrolidine addend), 14.2 (x2) and 14.1 (x2) ppm (four malonates) indicate
that the four malonate groups are in different chemical environments.
Twenty-four 13C resonances between  = 138.0 and 152.2 ppm were observed for the sp2
carbons of the fullerene cage, two resonances at  = 76.0 and 72.1 ppm from the pyrrolidine ring,
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and four resonances at  = 63.1 x 2, 63.0 and 62.7 ppm assigned to the methylene groups, in
agreement with the four resonances expected for the methylene groups.

Scheme 2.1 Synthesis of penta-adducts 2 and 6 and hexa-adducts 3 and 7.
Finally, the stereospecific cis-addition (Figure 2.1b) was unambiguously established by the
six sp3 signals observed for the fullerene carbon atoms at  = 69.9, 69.8, 69.5, 69.3, 45.5 and 45.1
ppm and the three sp3 signals for the carbons of the four cyclopropane rings at  = 67.8, 67.5 and
44.8 ppm (Figure 2.2b). If the trans-addition had occurred (Figure 2.1c) only four sp3 signals for
the fullerene carbon atoms and two sp3 signals for the cyclopropane rings would have been
observed.
Compound 3 was identified as the hexa-adduct with the pyrrolidines in a trans-1 relative
position, as shown in Figure 3. The 1H-NMR of compound 3 (Figure 2.4a) exhibits only one set
10

of signals for the two pyrrolidines ( = 4.90, 3.82 and 3.69 ppm), showing the presence of a plane
of symmetry, which is only possible if the second addition has occurred on the trans-1 position.
Figures 2.3a-e show front and side views for the five possible trans-1 isomers, where the first and
third descriptors refer to the pyrrolidine stereochemistry and the middle one refers to their relative
orientation. For example, cis-anti-cis refers to the two substituents on the pyrrolidine being in a
cis position but with an anti-orientation with respect to the other pyrrolidine substituents (Figures
2.3a, front and side view).

Figure 2.1 a) symmetric and unsymmetrical double bonds, b) symmetric cis addition, c)
symmetric trans addition.
The 13C-NMR spectrum of compound 3 (Figure 2.4b) showed twelve resonances for the
sp2 carbons of the fullerene cage between  = 152.3-139.1 ppm, two resonances for the pyrrolidines
at  = 74.0 and 72.9 ppm, one resonance for the methoxy groups at  = 52.8 ppm, two resonances
at  = 66.4 and 44.4 ppm for the cyclopropane carbon-bridged atoms, two resonances for the
methylene groups and two for the methyl groups of the malonates at  = 63.0, 62.5 and  = 14.1 x
2, respectively.
Surprisingly, only three carbonyl group resonances were observed, one at  = 169.4 ppm,
assigned to the carbonyl groups of the pyrrolidine addends and two at  = 163.5 and 163.4 ppm,
assigned to the carbonyl groups of the four malonates
11

These observations are consistent with one of two possible structures, one where the
pyrrolidines are both cis but anti relative to each other (Figure 2.3a), or one where the groups in
the pyrrolidine are trans but the two pyrrolidines are staggered (Figure 3d). For structures 2.3b,
2.3c and 2.3e four resonances for the carbonyl groups are expected (one for the carbonyl groups
of the pyrrolidines and three for the carbonyls of the malonates). The sp 3 resonances from the
cyclopropane carbon atoms were crucial to unambiguously identify the structure of compound 3.
Three resonances at  = 70.9, 70.8 and 45.6 ppm clearly prove that the cis-anti-cis isomer (Figure
2.3a) was the product obtained, since only two resonances would be observed for the trans-stagtrans isomer, as shown in Figure 2.3d.

Figure 2.2 1H- and 13C-NMR of compound 2, (CDCl3).
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In view of the surprising and unprecedented regio- and stereo-selectivity observed for
compound 3, we decided to study this reaction using a different substituent (2-pyridyl) on the
pyrrolidine addends (compound 7) (Scheme 2.1).

Figure 2.3 Front and side view of the possible hexa-adduct stereoisomers of C60 (compounds 3
and 7) taking into account only trans-1 additions of the azomethine ylides to C60TM. The red balls represent ethoxycarbonyl groups.
Hexa-adduct 7 was synthesized by reacting C60-TM with 2-picolylamine (4) and 2pyridinecarbaldehyde (5) in o-DCB, under reflux for 30 min. After 30 min the solution turned
yellow, and the main product, compound 7, was purified by silica gel column chromatography
using a chloroform:methanol (CHCl3:MeOH) 15:1 mixture. The reaction was monitored by TLC
using the same mixture of solvents. The isolated product 7 was characterized by MALDI-TOFMS and by NMR spectroscopy.
The MALDI-TOF-MS confirmed the presence of the molecular-ion peak for the hexaadduct derivative at m/z 1746.425 (Figure 2.9). NMR analyses similar to those conducted with
13

compound 3 confirmed the regio- and stereo-selectivity of the C2h-symmetric trans-1 addition of
compound 7, as for compound 3.

Figure 2.4 1H- and 13C-NMR of compound 3, (CDCl3).
The 1H-NMR spectrum of compound 7 (Figure 2.10a) shows a doublet at  = 5.52 ppm,
which corresponds to the four identical pyrrolidine protons. Four signals in the aromatic region
were assigned to the 2-pyridyl groups and a triplet at  = 5.06 ppm was assigned to the NH of the
pyrrolidine addends. One ABX3 and one AMX3 system were observed for the methylene groups
of the four malonates at  = 4.25 and 4.12 ppm, respectively (Figure 2.10a). Two triplets at  =
1.28 and 1.22 ppm reflect the different chemical environments of the methyl groups of the four
malonates.
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The 13C-NMR spectrum (Figure 2.10b) of compound 7 showed similar resonances to those
of compound 3. Two resonances for the carbonyl groups at  = 163.8 and 163.4 ppm, seventeen
resonances between 156.1 and 122.6 ppm (twelve resonances for the sp2 fullerene carbon atoms
and five for the 2-pyridyl groups), two resonances for the pyrrolidine addends at  = 70.6 and 76.5
ppm, two resonances for the methylene groups at  = 62.7 and 62.1 ppm, and two resonances for
the methyl groups at  = 14.1 ppm. Finally, five resonances at  = 72.7, 70.9, 66.2, 45.4 and 44.1
ppm prove the presence of the cis-anti-cis isomer.
2.2.2 Crystallographic studies
To further support the assigned regio- and stereo-chemistry of compound 2, crystals were
grown by slow evaporation in toluene. The crystal structure of compound 2, (Figure 2.5a) clearly
shows a plane of symmetry and confirms the cis orientation of the two substituents (ester groups
at C61 and C64) in the pyrrolidine. The C1-C2 (Figure 2.5a) distance is 1.590(3) Å, longer than
the typical 6:6 distance of 1.38 Å in pristine C60.
Crystal data for 2: a = 12.9239(7), b = 13.9988(7), c = 20.5853(11) Å, α = 88.077(2), ß =
74.686(2), γ = 65.018(2)°, U = 3243.0(3) Å3, T = 100 K, red blocks, space group P1 (no. 2), Z =
2, 35340 reflections measured, 14518 unique (Rint = 0.031), R1(I > 2σ(I)) = 0.0494, wR2(all data)
= 0.1309.
We failed in our attempts to grow single crystals of compound 7 using different solvents
such as toluene, chloroform and dichloromethane. A variety of functionalized terpyridines have
been complexed using different metals including Zn,[69, 70] therefore, crystals of compound 7 were
grown by complexation with ZnBr2 by slow evaporation in a benzene:chloroform:ethanol 9:9:1
mixture (Figure 2.5b).
The X-ray crystallography data shows a discrete molecule where compound 7 was
complexed with two molecules of ZnBr2. These results confirm the exclusive observation of the
cis-anti-cis structure. The crystallographic inversion center found in the structure of 7 confirms
that two pyrrolidines are in a relative trans-1 orientation. The pyridyl substituents at C31 and C32
15

are in a cis orientation, yet they are anti with respect to the other pyrrolidine substituents (Figure
2.5b).

Figure 2.5 Crystal structure of a) compound 2 and b) compound 7 complexed with ZnBr2. Atoms
labelled C1 and C2 are part of the C60 and are symmetrically placed at a 6:6
junction. Atoms are drawn with thermal ellipsoids at the 50% probability level. For
clarity, the pyrrolidine bonds are shown in blue, the hydrogens in the cis position
are yellow, the bromines are gold and the zincs are green.
The coordination geometry at Zn1 is intermediate between trigonal bipyramidal and square
pyramidal. The C1-C2 (Figure 5b) 6:6 bond distance is 1.587(5) Å. Crystal data for 7: a =
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14.8721(7), b = 13.3913(7), c = 27.1851(12) Å, ß = 104.206(3)°, U = 5248.5(4) Å3, T = 100 K,
yellow needles, space group P21/n (no. 14), Z = 2, 72431 reflections measured, 12022 unique (Rint
= 0.083), R1(I > 2σ(I)) = 0.0604, wR2 (all data) = 0.1597. Details of the solution and refinement of
the structures are available in the crystallographic information files (CIF).
2.2.3 Computational analysis
DFT calculations were performed to try to understand the reasons for the selective
formation of the cis-anti-cis isomers (Scheme 2.1). To understand the different factors that
govern the stereoselectivity for this kind of reactions, the addition of one azomethine ylide
to form the mono-pyrrolidine penta-adduct was initially studied. Afterwards, the possible
isomers of the bis-pyrrolidine hexa-adducts were analyzed.
2.2.3.1 The mono-pyrrolidine penta-adduct
Cis (1b) and trans (2.1c) pyrrolidine groups can result from the conformation of the
azomethine ylide, which can exist in a W- or S-shape.[71] Cycloadditions of azomethine
ylides to C60 show differences around 1-2 kcal mol-1 in favor of the cis conformation.[71]
The slightly higher stability of the cis vs the trans isomer is mainly due to the
deformation degree of the pyrrolidine addend. DFT calculations were carried out to find
the reaction energies of the 1,3-dipolar cycloaddition of azomethine ylide to C 60, e,e,e,e(tetramethylene)-C60 ((CH2)4C60) and C60-TM models. Values in Table 2.1 show higher
reaction energies for C60-TM than that of C60 and (CH2)4C60 models. Furthermore,
stabilization of the cis vs the trans conformation is enhanced from energy differences of 12 kcal mol-1 to 2-4 kcal mol-1. These results can be explained by the different interactions
between the malonate groups and the pyrrolidine adduct in each of the two isomers (vide
infra).
The malonate-pyrrolidine adduct interaction (MAI) was quantified as the difference
between the bonding energy (BE) of the pyrrolidine adduct (pa) in C60-TM and that in the
(CH2)4C60 model, where the four malonates are replaced by four methylene groups, MAI =
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BE[pa−C60-TM] - BE[pa−(CH2)4C60]. This definition assumes that there is no interaction
between the pyrrolidine adduct and the methylenes in the reference (CH 2)4C60 compound.
The MAI values range between -4 and -6 kcal mol-1 (see values in Table 2.1) for the
trans and cis isomers of the ester- and pyridyl-substituted pyrrolidine adducts, meaning that
there is a non-negligible attractive interaction between the equatorial malonates and the
substituents of the pyrrolidine addend. To verify this result, we also considered a simplified
model system composed only of the pyrrolidine and the malonates (no carbon cage, see
Figure 2.11), to calculate the interaction energies between these groups (pyrrolidinemalonates) for the cis isomers of the ester- and pyridyl-pyrrolidine adducts. The calculated
interaction energies are very similar to the MAI values, confirming the validity of the latter
as a measure of this interaction (see values in Table 2.4).
To gain additional insight into the nature of the interaction between the pyrrolidine addends
and the malonates, we performed calculations for some of the fragment models without
considering the dispersion corrections (see Table 2.4 and Figure 2.11). The results, which show
positive, i.e. repulsive, interaction energies confirm that the attractive interactions result from
dispersion forces between the pendant groups in the malonates and the pyrrolidine.
We also found that the pyrrolidine-malonates interactions critically depend on the
addition position of the malonate chains. There are two types of malonate addends because
of e-face and e-edge additions (Figure 2.6). The e-edge malonates, are closer to the
pyrrolidine group than the e-face ones, thus resulting a significantly larger interaction.
Indeed, calculations using a series of pyrrolidino C60-dimalonate models confirm that the
e-edge addends are mainly responsible for the total pyrrolidine-malonates interaction
(Tables 2.4 and 2.5).
Calculations were also carried out in o-DCB, which was the solvent used in the
experiments. Both the position and the geometry of the malonate chains were slightly
affected by the solvent, therefore the interaction between the malonates and the pyrrolidine
groups was also affected.
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The results still show the stabilization due to the interaction between the pyrrolidine
groups and the malonates already found in the gas phase calculations. Interestingly, a
different trend was observed depending on the pyrrolidine group substituents. For the ester
group, the value of the MAI, -2.1 kcal mol-1, is affected drastically, decreasing by half in
comparison with the gas phase value, while for the pyridyl compound the MAI, -5.3 kcal
mol-1, does not change appreciably.

Figure 2.6 Optimized structure of mono-(pyridyl-pyrrolidine) penta-adduct of C60.
Table 2.1 Bonding energies (BE, in the gas phase) and MAI values of the mono-pyrrolidine
adducts (ester and pyridyl-substituted) with C60, (CH2)4C60 model and C60-TMa.
BE
C60
(CH2)4C60
C60-TM
MAIb
a

cis (1b)
-28.8
-27.2
-31.8
-4.6

Ester
trans (1c)
-27.9
-26.3
-30.1
-3.8

Pyridyl
cis (1b)
trans (1c)
-30.8
-28.8
-28.5
-26.4
-34.2
-30.4
-5.7
-4.0

All energy values are expressed in kcal mol -1. bMalonate-pyrrolidine adduct

interactions are calculated as MAI = BE[pa-C60-TM] - BE[pa-(CH2)4C60].
These results reflect to the free space available between the pyrrolidine group and
the malonate chains that is accessible to solvent molecules. The bulkier and less flexible
the pyrrolidine group, the smaller the space for the solvent to access the region between the
malonate and the pyrrolidine, therefore the smaller the change of the MAI in the gas phase.
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If the regions of the malonate and the pyrrolidine that interact through dispersion forces are
more effectively solvated, their attractive interactions are decreased and the MAI is
reduced.
2.2.3.2 The bis-pyrrolidine hexa-adduct
The different stereo-isomers resulting from the second 1,3-dipolar cycloaddition on
the symmetric bond (Figure 2.3) can be classified into two sets. On one hand, there are
those isomers with two cis-pyrrolidine groups (Figure 2.3a and 2.3b), and on the other,
those isomers with at least one trans group (Figure 3.3c, 3.3d and 3.3f). The trans
conformation of the pyrrolidine group results in a destabilization relative to the cis
conformation. The second set of isomers, which contains at least one trans-pyrrolidine
group, is around 3-7 kcal mol-1 higher in energy than the first set (see values in Table 2.2).
In general, the higher the number of trans groups, the larger the destabilization. However,
the results do not show a strictly additive effect.
Looking at the first set of isomers, the energy differences between isomers 2.3a and
2.3b are rather small. The only difference between these two isomers is the relative position
of the two cis-pyrrolidine groups, which can be either in a syn or in a anti position relative
to each other (Figure 2.3). In the case of the pyridyl-pyrrolidine group, 3.3b (syn) is slightly
lower in energy than 2.3a (anti). For the ester-pyrrolidine group, the two isomers are almost
degenerate, with 2.3a (anti) being only 0.2 kcal mol-1 lower in energy than 2.3b (syn). These
small differences are exclusively a consequence of the presence of the malonate chains as
the same systems without malonates are degenerate (see Table 2.6). These energy
differences are essentially kept when using hybrid methods (see Table 2.7).
As for the mono-pyrrolidine penta-adduct, we calculated the MAI for 2.3a-e (see
Table 2.2). The results are around two times those of the penta-adduct. For the esterpyrrolidine penta-adduct 2.1b the MAI is -4.6 kcal mol-1 and for the hexa-adduct 2.3a it is
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-8.9 kcal mol-1 (Table 2.2). Therefore, the MAI value is the result of additive independent
interactions for each of the two pyrrolidine adducts with the malonate chains.
As found for the penta-adduct, solvent is a crucial factor to compute the malonatepyrrolidine interaction, which can be seen as the driving force for the formation of these
compounds. The solvent affects the malonate chains, and solvates the adducts, reducing the
strength of this interaction. Stabilization of the 2.3a (anti) isomer, which is the one obtained
experimentally, with respect to 2.3b (syn) is enhanced when o-DCB is present. For the
ester-pyrrolidine group, an increase of the energy difference between the two isomers is
found (from 0.2 to 0.5 kcal mol-1). For the pyridyl-pyrrolidine isomers, an inversion of
relative stability is observed (see Table 2.2). Furthermore, the MAI values are affected by
the solvent in the same way as for the penta-adduct.
Table 2.2 Binding energies (BE), relative energies (ΔE, gas phase and solvent) with MAI
values (in parenthesis), free energies and percentage for different C60 hexa-adductsa.
cis/
trans
2/0
2/0
0/2
0/2
1/1

BE gas

ΔE gas

ΔE solvb

ΔGc

Iso %c

-61.4
-61.2
-59.9
-59.0
-58.4

0.0 (-8.9)
0.2 (-8.8)
4.5 (-6.3)
2.4 (-8.2)
3.0 (-6.6)

0.0 (-3.4)
0.5 (-3.0)
3.2 (-2.3)
1.1 (-4.2)
2.6 (-1.4)

0.0
0.9
2.1
2.1
2.0

75.8
16.8
2.4
2.3
2.7

3a
2/0
-63.5
1.1 (-8.9)
3b
2/0
-64.6
0.0 (-10.0)
3c
0/2
-58.4
6.2 (-8.0)
3d
0/2
-57.9
6.8 (-7.5)
3e
1/1
-61.0
3.7 (-8.4)
a
-1 b
c
Energies in kcal mol ; o-DCB; at 300 K

0.0 (-7.5)
0.7 (-6.8)
7.3 (-4.7)
6.5 (-5.4)
3.2 (-6.6)

0.0
2.4
8.2
5.0
4.9

98.3
1.7
0.0
0.0
0.0

Group

Iso

Ester

3a
3b
3c
3d
3e

Pyridyl

The different interactions with the solvent helps to explain the stabilization of 2.3a
with respect to 2.3b. The optimized structures show that the malonate chains in 2.3a are
compact and close to the pyrrolidine groups. However, in 2.3b they tend to be farther from
the pyrrolidine groups and thus easier to be solvated, consequently reducing the interaction
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strength with the pyrrolidine groups (Figure 2.7). This effect is quite critical for the pyridylpyrrolidine derivative where the MAI value for 2.3a (-6.8 kcal mol-1) is rather similar to
that of the mono-pyrrolidine penta-adduct (-5.3 kcal mol-1).
Finally, we have computed the free energies, within the rigid rotor and harmonic
oscillator (RRHO) approximation, at the temperature and pressure conditions of the
experiment. The results show that isomer 2.3a is favored with respect to 2.3b, by up to
almost 1 kcal mol-1 for the ester- and 2.4 kcal mol-1 for the pyridyl-pyrrolidine. This relative
stabilization is governed mainly by the entropic contribution. We also computed the free
energy for the other three isomers 2.3c, 2.3d and 2.3e. For the pyridyl-substituted hexaadduct, the relative free energies for 2.3c-e are rather high compared to that for 2.3a (more
than 5 kcal mol-1, see Table 2.2. For the ester-substituted hexa-adduct, however, the free
energy differences are not so large, in line with their energy differences (see Table 2.2).

Figure 2.7 Optimized structure in o-DCB of anti and syn isomers of a) pyridyl-substituted
and b) ester-substituted bis-pyrrolidine hexa-adducts of C60.
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Such differences in the free energies lead to relative abundances for the cis-anti-cis
(2.3a) vs cis-syn-cis (2.3b) stereoisomers at experimental conditions of 76% vs 17% for the
ester group and 98% vs 2% for the pyridyl group, in good agreement with experiments. The
percentages for the rest of isomers 2.3c-e are small for the ester group (around 2%) and
negligible for the pyridyl group (0%).
2.3

CONCLUSIONS
We have synthesized a new hexa-adduct derivative of C60 by a 1,3-dipolar cycloaddition

reaction via two different conditions and using C60-TM as the starting material. These reactions
are highly regio- and stereo-selective, surprisingly leading to the exclusive formation of the cisanti-cis isomer. The formation of the cis-anti-cis hexa-adduct isomers as the only observed
products was mainly attributed to the interaction between the pendant groups in the malonate and
the pyrrolidine groups. This interaction, which is very important in the gas phase (van der Waals
type), is attenuated in the presence of the solvent (o-DCB). Determination of the free energies
allowed the estimation of the relative abundances of the cis-anti-cis and cis-syn-cis hexa-adducts,
confirming that the former predominates under the experimental conditions.
2.4

EXPERIMENTAL SECTION

2.4.1 Synthesis of C60-TM
C60-TM was synthesized following a procedure previously reported.[68]
2.4.2 Synthesis of compounds 2 and 3
Penta-adduct 2 and hexa-adduct 3 were synthesized by reacting C60-TM (50 mg, 0.04
mmol) with methyl glycine ester hydrochloride (20 mg, 0.16 mmol) in the presence of
diacetoxyiodobenzene (39 mg, 0.12 mmol) and sodium carbonate decahydrated (37 mg, 0.13
mmol) in o-DCB (10 mL), under sonication at room temperature and covered from light. After 30
min the solution turned orange and compound 2 was the major product, however after 3 h the
solution turned yellow and compound 3 was the main product as monitored by TLC using
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DCM:EA 30:1 mixture, as the eluent. After column chromatography purification compounds 2
and 3 were characterized by MALDI-TOF-MS and NMR spectroscopy.
2.4.3 Synthesis of compound 7
Hexa-adduct 7 was synthesized by reacting C60-TM (50 mg, 0.04 mmol) with 2pycolylamine (17 mg, 0.16 mmol) and 2-pyridinecarbaldehyde (17 mg, 0.16 mmol) in o-DCB (10
mL), under reflux. After 30 min the solution turned yellow and compound 7 was the only product
as monitored by TLC using CHCl3:MeOH 15:1 mixture, as the eluent. After column
chromatography purification compound 7 was characterized by MALDI-TOF-MS and NMR
spectroscopy.
2.4.4 Computational details
The theoretical study of the 1,3-dipolar cycloaddition reactions of azomethine ylides has
been performed by DFT methodology using ADF2016 code.[72, 73] An exhaustive exploration of
the potential products was performed including the relative arrangements of malonates with
respect to pyrrolidine groups (See Figure 2.1 and Table 2.3). The exchange-correlation GGA
density functional of Becke and Perdew (BP86) were employed to calculate all the minima. [74, 75]
Relativistic corrections were included by means of the ZORA (the Zeroth Order Regular
Approximation) formalism.[76-78] Dispersion corrections were also incorporated (D3 method by
Grimme)[79] Solvent effects were included via the conductor-like screening model (COSMO) using
Solvent Excluded Surface (SES).[80, 81] Slater Basis sets of TZP quality were used to describe the
valence electrons of H, C, N and O. Frozen cores of C, N and O were described by means of single
Slater functions
2.5

SUPPORTING INFORMATION

2.5.1 Characterization of compound 2
MALDI-TOF: [M]+ calcd for [C94H49NO20]+ 1511.285; found 1511.282. 1H NMR (600
MHz, CDCl3) δ 4.69 (d, 2H, CH pyrrolidine), 4.42-4.24 (m, 16H, CH2 malonates), 3.89 (t, 1H, NH
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pyrrolidine), 3.76 (s, 6H, OCH3 pyrrolidine), 1.35, 1.32 x 3 (t, 24H, CH3 malonates) ppm.

13

C

NMR (150 MHz, CDCl3) δ 169.0, 163.8, 163.7 x 2, 163.4, 152.1, 152.0, 149.3, 147.2, 147.1 x 2,
146.2, 146.0, 145.8, 145.44 x 2, 145.3, 145.2 x 2, 144.1, 143.8, 143.5, 143.4, 142.9, 142.4, 138.3,
138.2, 138.0, 137.9, 69.9, 69.8, 69.5, 69.3, 67.8, 67.5, 63.1 x 2, 63.0, 62.7, 52.9, 45.1, 44.8, 14.2 x
2, 14.1 x 2 ppm.
2.5.2 Characterization of compound 3
MALDI-TOF: [M]+ calcd for [C100H58N2O24]+ 1670.338; found 1670.341. 1H NMR (600
MHz, CDCl3) δ 4.90 (d, 4H, CH pyrrolidines), 4.31-4.20 (m, 16H, CH2 malonates), 3.82 (s, 12H,
OCH3 pyrrolidines), 3.69 (t, 2H, NH pyrrolidines), 1.29 x 3 (t, 24H, CH3 malonates) ppm.

13

C

NMR (150 MHz, CDCl3) δ 169.4, 163.5, 163.4, 152.2, 147.7, 146.6, 146.1 x 2, 145.5, 144.1, 143.1,
140.0 x 2, 139.2, 139.1, 74.0, 72.9, 70.9, 70.8, 66.4, 63.0, 62.5, 52.8, 45.6, 44.4, 14.1 x 2 ppm.
2.5.3 Characterization of compound 7
MALDI-TOF: [M]+ calcd for [C112H62N6O16]+ 1746.422; found 1746.425. 1H NMR (600
MHz, CDCl3) δ 8.60 (d, 4H, pyridine), 7.64 (td, 4H, pyridine), 7.49 (d, 2H, pyridine), 7.13 (ddd,
4H, pyridine), 5.52 (d, 4H, CH pyrrolidines), 5.06 (t, 2H, pyrrolidines), 4.25 (ABX3, 8H, CH2
malonates), 4.12 (AMX3, 8H, CH2 malonates), 1.28 (t, 12H, CH3 malonates), 1.22 (t, 12H, CH3
malonates) ppm. 13C NMR (150 MHz, CDCl3) δ 163.8, 163.4, 156.1, 153.1, 149.8, 149.7, 146.7,
145.9, 145.3, 145.0, 143.7, 143.1, 140.2, 139.7, 139.4, 138.2, 136.2, 123.3, 122.6, 76.6, 76.5, 72.7,
70.9, 66.2, 62.7, 62.1, 45.4, 44.1, 14.1 x 2 ppm.

25

Figure 2.8 MALDI-TOF spectrum of (a) compound 2 and (b) compound 3 using 1,8,9trihydroxyanthracene (THA) as matrix.

Figure 2.9 MALDI-TOF spectrum of compound 7 using 1,8,9-trihydroxyanthracene (THA) as
matrix.
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Figure 2.10 1H- and 13NMR, 600 and 150 MHz, respectively; CDCl3, 298 K for compound 7.
2.5.4 Computational details
The theoretical study of the 1,3-dipolar cycloaddition reactions of azomethine ylides has
been performed by DFT methodology using ADF2016 code.[72, 73] The exchange-correlation GGA
density functional of Becke and Perdew (BP86) were employed to calculate all the minima. [74, 75]
Relativistic corrections were included by means of the ZORA (the Zeroth Order Regular
Approximation) formalism.[76-78] Dispersion corrections were also incorporated (D3 method by
Grimme).[79] Solvent effects were included via the conductor-like screening model (COSMO)
using Solvent Excluded Surface (SES).[80, 81] Slater Basis sets of TZP quality were used to describe
the valence electrons of H, C, N and O. Frozen cores of C, N and O were described by means of
single Slater functions. Single-point calculations were also done for hexa-adducts using the hybrid
B3LYP functional to compare with BP86 results.3
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We found the structures of the malonates optimizing the experimental structure for the
pyridyl-substituted bis-pyrrolidine hexa-adduct (cis-anti-cis). Once optimized, we suppressed the
two pyrrolidine groups and built up (i) the other five isomeric hexa-adducts (cis-syn-cis, cis-xtrans, trans-eclip-trans and trans-stag-trans, see Figure 2.2) and optimized them; and (ii) the two
penta-adducts, cis and trans, with different possible positions of the pyrrolidine (top or bottom,
see Figure 2.12), and optimized them (see Table 2.3). We also optimized the experimental structure
of the ester-substituted penta-adduct and checked that the conformation of the malonates is quite
similar to the one found by our procedure providing almost identical binding energies and MAI
values. To further assess that our procedure is not missing relevant conformations of the malonates,
we analyzed other different initial conformations, which lead to similar final optimized geometries.
It is important to remark here that the malonates try to optimize their interaction with the
pyrrolidine substituents, especially those in e-edge positions that interact more strongly than those
in e-face positions.
Table 2.3 Relative energy of possible conformation of penta-adduct.
Isomer
Ester
a
0.2
b
0.5
c
0.0
d
0.0
Energy values are in kcal mol-1

Pyridyl
0.0
0.4
2.0
2.7
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Figure 2.11 Simplified model made only by the pyrrolidine and the four equatorial malonate
adducts for a) pyridyl-substituted and b) ester-substituted bis-pyrrolidine hexaadducts of C60.
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Figure 2.12 Conformational isomers of the pyridyl- (top) and ester-pyrrolidine substituent
(bottom) penta-adducts.
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Table 2.4 Malonate-pyrrolidine adduct interaction (MAI) for mono-pyrrolidine penta-adducts in
C60-TM (first row) compared to the interaction energies in the simplified model
systems made only by the pyrrolidine and the malonates (second, third and fourth
row).
Model
C60-TM
TM a

e-edge b

Method

Ester

Pyridyl

BP86/TZP/D3

-4.6

-5.7

BP86/TZP/D3

-4.6

-6.3

BP86/TZP

0.2

2.7

BP86/TZP/D3
BP86/TZP

-3.6
0.5

-5.9
2.5

e-face c

-0.8
BP86/TZP/D3
-0.1
BP86/TZP
-1
Energy values are in kcal mol
a
The four malonates bOnly e-edge malonates cOnly e-face malonates.

-0.4
0.3

Table 2.5 Reaction energies (in the gas phase) and MAI values of the pyrrolidine adducts (ester
and pyridyl-substituted) with (CH2)4C60, (m)2(CH2)2C60 model and C60-TM, m =
malonate group.
Cage
Ester
Pyridyl
(CH2)4C60
-27.2 (0.0)
-28.5 (0.0)
(m)2(CH2)2C60 (e-edge)
-31.8 (-4.6)
-33.8 (-5.3)
(m)2(CH2)2C60 (e-face)
-28.0 (-0.8)
-28.7 (-0.1)
C60-TM
-31.8 (-4.6)
-34.2 (-5.6)
MAI values in parenthesis; Energy values are in kcal mol -1
Table 2.6 Relative energies for ester and pyridyl C60, (CH2)4C60 hexa-adducts models in the gas
phase.
Group
Ester

Isomer
C60
2b
0.0
2c
0.0
Pyridyl
2b
0.0
2c
0.0
-1
Energy values are in kcal mol
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(CH2)4C60
0.0
0.1
0.1
0.0

Table 2.7 Relative energies of ester and pyridyl hexa-adducts in the gas phase using BP86 and
hybrid B3LYP methods.
Isomer

cis/trans
groups

Ester
BP86
B3LYP

Pyridyl
BP86
B3LYP

2b

2/0

0.0

0.0

1.1

0.0

2c

2/0

0.2

0.2

0.0

0.1

2d

0/2

4.5

3.6

6.2

6.3

2e

0/2

2.4

3.1

6.8

6.0

2f

1/1

3.0

2.3

3.7

2.6

Energy values are in kcal mol-1
2.5.5 X-ray crystallography and data collection
Single crystals of the penta-malonate adduct of C60, C94H49NO20, 2, were recrystallized
from toluene:chloroform (1:1) mixture. Intensity data were measured on a Bruker SMART APEX
diffractometer with the use of MoKα radiation to a resolution of 0.77 Å. The asymmetric unit
contains one entire molecule.
Single

crystals

of

the

tetra-malonate-bis-ZnBr2(pyrrolidine)

adduct

of

C60,

C112H62Br4N6O16Zn2•2(CHCl3)•4(C2H6O), 7, were recrystallized from benzene, chloroform and
ethanol. Data for 7 were collected with the use of synchrotron radiation, λ = 0.7749 Å, at the
Advanced Light Source, Lawrence Berkeley National Lab. The crystal belongs to the monoclinic
space group P21/n. The asymmetric unit contains ½ of the hexakis adduct, with the full molecule
being formed by application of an inversion operation. The asymmetric unit also contains two
ethanol molecules and one disordered molecule of chloroform. Details of the solution and
refinement of the structures are available in the crystallographic information files (CIF).
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Chapter 3: Regiochemically controlled synthesis of a β-4-β’ [70]fullerene bisadduct
Abstract: A β-4-β’ C70 bis-adduct regioisomer and an uncommon mono-adduct β-malonate
C70 derivative were synthesized by using a Diels-Alder cycloaddition followed by an additionelimination of bromo-ethylmalonate and a retro Diels-Alder cycloaddition reaction. We also report
the regio-selective synthesis and spectroscopic characterization of Cs-symmetric tris- and C2vsymmetric tetra-adducts of C70, which are the precursors of the mono- and bis-adduct final
products. Experimental procedures and figures presented here are a pre-peer reviewed version of
the following article (See Appendix B for the copyright letter): Cerón, M. R.; Castro, E.; Neti, V.
S. P. K.; Dunk, P. W.; Echegoyen, L. A. J. Org. Chem. 2017, 82, 893.
3.1

INTRODUCTION
Chemical functionalization of fullerenes has been extensively studied,[17-19] mainly to

increase their solubilities and to tune their electronic properties to expand their applications.2
Recently, bis-functionalization of fullerenes such as C60 and C70 has attracted considerable
attention, due to the higher power conversion efficiencies (PCEs) that they exhibit in organic
photovoltaic (OPV) solar cells compared with their respective mono-adduct counterparts.[82-87] It
has also been shown that by replacing C60 with C70, higher short circuit currents and an increase
in the absorption coefficient in the visible region can be obtained.[82]
The effects of bis-adduct isomerism on device performances of OPV solar cells has been
reported, in most of the cases it was observed that regioisomerically pure bis-adducts perform
better than the corresponding regioisomeric mixtures.[82,

88-93]

Consequently, regiochemically

controlled multi-functionalization of fullerenes has become critical to obtain pure isomers and to
avoid challenging chromatographic separations.[26] There are two well-known methods to reduce
the number of isomers, the tether-directed remote multi-functionalization introduced by Diederich
et al.,[27] and the topologically controlled method introduced by Krӓutler et al.[28, 29] Both methods
have been widely used to synthesize bis, tris, tetra, penta and hexa-derivatives of C60. However,
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multi-functionalization of C70 has not been extensively investigated, primarily as a result of the
lower symmetry of the D5h-C70 compared to that of the Ih-C60, which increases the number of
isomers. Thus, using identical addends and considering additions exclusively to [6,6]-bonds, the
number of statistically possible bis-regioisomers are 8 for C60 and 64 for C70. There are very few
examples of tris and tetra-adducts of C70, the first one was reported in 1995 by Diederich et al.[94]
They started from the 5 o’clock or the 12 o’clock bis-adduct (α-9-α’ or α-6-α’ respectively, using
a recently introduced nomenclature[95]) and added an excess of bromo-ethylmalonate to obtain one
tris-adduct and one C2- or C2v-symmetric tetra-adduct isomer, respectively.[96, 97]
The synthesis of all possible C70 bis-adduct isomers in a selective manner has not been
reported. Here we report the synthesis of a bis-regioisomer using a Diels-Alder cycloaddition
followed by an addition-elimination of bromo-ethylmalonate and finally a retro Diels-Alder
cycloaddition reaction to obtain the β-4-β’ bis-regioisomer.
3.2

RESULTS AND DISCUSSION
We synthesized regio-selectively the C70 α-6-α’ bis-anthracene (BA-C70) by using the

previously reported Diels-Alder cycloaddition reaction of C70 with molten anthracene.[98] α-6-α’
BA-C70 was used as a directing group to decrease the number of possible tris- and tetra-adducts.
Starting from BA-C70, a total of 11 tris-adduct isomers including one Cs- and one C2v-symmetric
and 16 tetra-adducts, including one C2v-symmetric, can be obtained (Figure 3.1).
Bis-anthracene mono-Bingel C70 tris-adduct (BA-MB-C70) and bis-anthracene bis-Bingel
C70 tetra-adduct (BA-BB-C70) were synthesized via a Bingel cycloaddition reaction of α-6-α’ BAC70 with bromo-ethylmalonate in the presence of DBU in the dark (Scheme 3.1). BA-MB-C70 and
BA-BB-C70 were purified using silica gel column chromatography and characterized by UV-vis,
1D and 2D NMR spectroscopy, mass spectrometry, thermal gravimetric analysis (TGA) and cyclic
voltammetry (CV). Using matrix-assisted laser desorption/ionization time-of-flight (MALDITOF) mass spectroscopy, we confirmed the addition of one and two ethylmalonate groups to the
[70]fullerene cage (m/z 998.0551 and 1156.1184), respectively. As reported,[98] we were not able
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to observe the molecular ion peak of the C70 mono-anthracene nor of the BA-C70 under these
conditions. Therefore, 1H-NMR spectroscopy was used to verify the presence of the anthracenes.

Figure 3.1 a) 11 possible tris-adducts starting from α-6-α’ BA-C70; b) 16 possible tetra-adducts
starting from the shown tris-adduct. Circled bonds are the Cs- and C2v-symmetric
tris- and tetra-adducts. The α-bonds are depicted in yellow, β-bonds in blue, γbonds in red and δ-bonds in green.

Scheme 3.1 Mono- and bis-additions of ethylmalonate to α-6-α’ bis-anthracene C70.
The 1H-NMR spectrum of BA-MB-C70 exhibits half of the possible number of signals for
the anthracenes (two sets of signals). Two quartets and two triplets corresponding to the
ethylmalonate addends were also observed (Figure 3.2a). These results indicate that BA-MB-C70
is the only Cs-symmetric regio-isomer out of the 11 possible tris-adducts (Figure 3.1a). 30 signals
for the sp2 carbons where observed in the 13C-NMR spectrum (Figure 3.11), in agreement with the
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Cs-symmetry observed in the 1H-NMR. The preferential formation of a single Cs-symmetric trisadduct starting from the α-6-α’ bis-adduct was supported by MO calculations, which showed that
the calculated α-6-α’ bis-adduct has enhanced LUMO coefficients at the Cs-symmetric -bonds.[96]
Addition to any of the other α- or -bonds will result with a sterically congested product.

Figure 3.2 1H-NMR spectrum (600 MHz; CDCl3, 298 K) of a) BA-MB-C70; b) MB-C70.
To unambiguously determine the addition pattern of BA-MB-C70 and to synthesize a new
Bingel C70 mono-adduct, a retro-Diels Alder cycloaddition reaction of this compound was
performed, by heat treatment of BA-MB-C70 at 240 ºC under vacuum. After washing the product
with MeOH, a change in color (from dark green to red brown) and in polarity was observed,
indicating the loss of the anthracene groups (14.20 mg ˃99% yield, Scheme 3.2a). The absence of
the anthracene groups on mono-Bingel-C70 (MB-C70) was verified by 1H-NMR, where only two
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quartets and two triplets corresponding to the ethylmalonate addend were observed (Figure 3.2b).
The

13

C-NMR spectrum of MB-C70 showed 30 signals for the sp2 carbons (Figure 3.20), in

agreement with the Cs-symmetry observed by 1H-NMR. Additionally, we confirmed that MB-C70
corresponds to the β-isomer by comparison of the UV-vis absorption spectrum with those of
previously reported β-pyrrolidine C70 derivatives (Figure 3.18).[62, 82] As far as we know, this
synthetic approach becomes the only methodology to selectively synthesize the uncommon βBingel mono-adduct.[96, 99, 100]

Scheme 3.2 Retro-Diels Alder cycloaddition reaction to yield MB-C70 and BB-C70.
The number of possible tetra-adduct isomers that can be obtained starting from the BAMB-C70 tris-adduct[94, 101] is 16 and only one is C2v-symmetric (Figure 3.1b).20,21
The 1H-NMR spectrum of BA-BB-C70 exhibited half of the possible number of signals for
the two anthracenes and for the two ethylmalonate groups (Figure 3.3a). Therefore, BA-BB-C70
can be unambiguously assigned to the only possible C2v-symmetric regioisomer (Figure 3.1b).20,21
The 13C-NMR spectrum showed 18 signals for the sp2 carbons, in agreement with the presence of
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two planes of symmetry and a C2-rotation (Figure 3.15). The NOESY-NMR spectrum of BA-BBC70 exhibited a weak correlation between the methyl (-CH3) protons of the ethyl malonates and
the methylene protons of the anthracene addends (Figure 3.13).[96] This correlation shows that the
third and fourth additions occurred at the C2v-symmetric -bonds close to the anthracene groups
and not to the other possible α- or β-bonds, for which no correlation would be observed.[101]

Figure 3.3 1H-NMR spectrum (600 MHz; CDCl3, 298 K) of a) BA-BB-C70; b) BB-C70.
To synthesize a totally bis-adduct regioisomer of C70, a thermal retro-Diels Alder reaction
of BA-BB-C70 was performed (Scheme 3.2b). As before we also observed a change of the color
and polarity of the sample, indicating the successful retro Diels-Alder removal of the anthracene
groups (37.17 mg, ˃ 99% yield). The absence of the anthracene groups of the bis-Bingel C70 (BBC70) compound was confirmed by 1H-NMR (Figure 3.3b). The UV-vis absorption spectrum of BB38

C70 (Figure 3.18) was compared with all of the known spectra of pure C70 bis-adducts and no
matches were observed.[61,

62, 82, 94, 95, 98, 100]

Both the 1H-NMR and UV-vis characterization

indicated that this compound corresponds to the previously unreported β-4-β’ bis-adduct regioisomer BB-C70. This approach can be used to synthesize other potentially high-performing bisadduct C70 fullerene acceptors for photovoltaic applications.

Figure 3.4 TGA of BA-MB-C70 (red) and BA-BB-C70 (black) obtained up to 800 oC using a
linear 3 oC min-1 ramp method.
The TGA traces of BA-MB-C70 and BA-BB-C70 were recorded upon increasing the
temperature at a rate of 3 ºC min-1 under a flow of 15 psi of ultra-high purity N2 (Figure 3.4). For
BA-MB- C70 a 13% weight loss was calculated starting at 161 ºC followed by a 13% weight loss
starting at 200 oC, corresponding to two distinct steps due to the consecutive loss of the two
anthracenes. We also observed a 12% weight loss starting at 340 ºC corresponding to the loss of
the ethylmalonate addend. These results confirm the presence of the tris-adduct. For BA-BB-C70
we observed two distinct steps each of 12% weight loss at 149 and 196 ºC respectively, which
correspond to the consecutive loss of the two anthracenes, followed by two indistinct steps of 20%
weight loss at 340 ºC corresponding to the loss of the two ethylmalonate addends.
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Figure 3.5 Cyclic Voltammetry in dichloromethane solutions of BA-MB-C70, BA-BB-C70, MBC70 and BB-C70.
The redox properties of BA-MB-C70, BA-BB-C70, MB-C70 and BB-C70 were measured by
cyclic voltammetry (CV) in dichloromethane solutions using 0.1 M of n-Bu4NPF6, as supporting
electrolyte (Figure 3.5). The results are summarized in Table 3.1. As expected, with more addends
on the C70 cage we observed a higher cathodic shift with respect to the values for the pristine
fullerene C70.[86] The CV of bis-, tris- and tetra-adducts showed irreversible cathodic
electrochemical behavior in agreement with previous reports in which potentials more negative
than -1.2 V lead to irreversible retro-Bingel cycloadditions.[102, 103] In the case of the mono-adduct
the first and second reduction waves were chemically and electrochemically reversible, similar to
the Bingel-C70 α-isomer.[102-104] To achieve retro-cycloaddition of the Bingel-C70 β-isomer a more
negative potential was required, close to -2 V, unlike its α-isomer for which the retro-cycloaddition
is observed at –1.4 V.[61,

104, 105]

We also observed one quasi-reversible oxidation due to the

presence of the anthracene addends for the bis and the tetra-adduct and one reversible oxidation
(E1/2 = 0.76 V) for the tris-adduct.
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Table 3.1 Redox Potentials[a] of BA-MB-C70, BA-BB-C70, MB-C70 and BB-C70.

[a]

Compound

BA-MB-C70

BA-BB-C70

MB-C70

BB-C70

Eox0/+

0.81

0.80

--

1.07

Epc0/-

-1.46

-1.50

-1.20

-1.25

Epc-/-2

-1.81

1.88

-1.55

-1.61

Epc-2/-3

-2.22

--

-1.96

--

LUMO[b]

-3.9

-3.8

-4.0

-4.1

Values obtained by CV in V vs Fc/Fc+. [b] Values obtained using the following formula 𝐸𝐿𝑈𝑀𝑂 =

−(𝐸(𝑜𝑛𝑠𝑒𝑡,𝑟𝑒𝑑 𝑣𝑠 𝐹𝑐 +/𝐹𝑐) + 5.1) 𝑒𝑉.30
3.3

CONCLUSION
We successfully synthesized a β-4-β’ C70 bis-regioisomer and an uncommon β-Bingel C70

mono-isomer by using an addition-retro-addition Diels-Alder reaction and an addition-elimination
of bromo-ethylmalonate this reaction sequence could be useful to synthesize never observed C70
bis-regioisomers. We also report the regio-selective synthesis and spectroscopic characterization
of the Cs-symmetric tris- and C2v-symmetric tetra-adducts of C70.
3.4

EXPERIMENTAL SECTION

3.4.1 Synthesis of BA-MB-C70 and BA-BB-C70
Bis-anthracene-C70 (BA-C70) was synthesized as previously reported and purified
immediately before the next reaction.[98] BA-C70 (20.0 mg, 0.015 mmol, 1 equiv) was dissolved in
8 mL of anhydrous o-DCB and protected from light. Bromo-ethyl malonate (3.6 mg, 0.124 mmol,
8 equiv) and DBU (47.1 mg, 0.309 mmol, 20 equiv) were added, and the mixture was stirred under
a nitrogen atmosphere for 3 h at room temperature. The solvent from the reaction mixture was
removed with nitrogen and the crude product was purified by silica gel column chromatography,
using CS2 as eluent to separate the unreacted BA-C70, followed by CS2:CHCl3 4:1 ratio to collect
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BA-MB-C70 (3.67 mg, 16% yield). Finally, CS2:CHCl3 1:1 ratio was used to collect BA-BB-C70
(14.10 mg, 57% yield). HPLC chromatograms for the crude and the pure compounds are shown in
the supporting Information.
3.4.1.1 Characterization of BA-MB-C70
MALDI-TOF: [M-(356.1565)]+ calcd for [C105H30O4-(C14H10)2]+ 998.0579; found
998.0551. 1H-NMR (CDCl3/CS2 (7/3), 600 MHz, 298 K): δ 7.70 (d, 2HAr, J = 7.17), 7.61 (d, 2HAr,
J = 6.90), 7.56 (d, 2HAr, J = 7.17), 7.51 (d, 2HAr, J = 6.90), 7.39 (t, 2HAr, J = 7.17), 7.34 (t, 2HAr,
J = 7.17), 7.30 (m, 4HAr), 5.57 (s, 1H), 5.36 (s, 1H), 5.26 (s, 1H), 5.24 (s, 1H), 4.52 (q, 2H, J =
7.12), 4.26 (q, 2H, J = 7.12), 1.49 (t, 3H, J = 7.11), 1.21 (t, 3H, J = 7.11) ppm. 13C-NMR
(CDCl3/CS2 (7/3), 150 MHz, 298 K): δ 159.45, 159.08, 155.94, 155.52, 153.32, 153.04, 152.57,
152.15, 151.90, 151.16, 150.79, 150.32, 150.00, 148.80, 148.64, 143.67, 143.09, 141.69, 141.47,
141.36, 141.31, 141.18, 141.15, 140.94, 140.80, 140.34, 139.71, 138.66, 137.81, 136.63, 136.59,
133.81, 132.67, 128.43, 127.15, 127.00, 125.86, 125.74, 125.54, 125.47, 66.40, 65.76, 65.70,
65.64, 63.73, 63.13, 62.83, 59.85, 58.47, 57.47, 55.84, 14.34, 14.10 ppm.
3.4.1.2 Characterization of BA-BB-C70
MALDI-TOF: [M-(356.1565)]+ calcd for [C112H40O8-(C14H40)2]+ 1156.1158; found
1156.1184. 1H-NMR (CDCl3/CS2 (7/3), 600 MHz, 298 K): δ 7.63 (d, 2HAr, J = 6.52), 7.53 (d, 2HAr
J = 6.52), 7.32 (m, 4HAr), 5.36 (s, 1H), 5.24 (s, 1H), 4.49 (q, 2H, J = 7.13), 4.16 (q, 2H, J = 7.13),
1.47 (t, 3H, J = 7.13), 1.19 (t, 3H, J = 7.13) ppm. 13C-NMR (CDCl3/CS2 (7/3), 150 MHz, 298 K):
δ 164.63, 163.94, 160.35, 155.90, 154.20, 149.88, 149.82, 148.96, 148.59, 141.79, 141.66, 141.41,
141.38, 141.30, 140.50, 140.02, 139.88, 136.24, 134.26, 133.34, 127.01, 126.98, 125.72, 125.47,
124.92, 66.42, 66.07, 63.34, 63.07, 62.53, 57.80, 55.71, 41.13, 14.30, 13.88 ppm.
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3.4.2 Retro-Diels Alder reaction, synthesis of MB-C70 and BB-C70
3.4.2.1 Characterization of MB-C70
Laser desorption Fourier transform ion cyclotron resonance mass spectrometery (LD FTICR MS) m/z: [M-] calcd for C70(C7H10O4)- 998.0584; found 998.0589. 1H-NMR (CDCl3, 600
MHz, 298 K): δ 4.53 (q, 4H, J = 7.20), 4.19 (q, 4H, J = 7.10), 1.48 (t, 6H, J = 7.20) 1.20 (t, 6H, J
= 7.10) ppm.

13

C-NMR (CDCl3, 150 MHz, 298 K): δ 163.86, 163.34, 153.15, 151.44, 149.89,

149.57, 149.53, 149.46, 149.14, 148.94, 148.71, 148.70, 148.27, 147.59, 147.45, 147.19, 147.09,
147.06, 146.54, 146.06, 145.37, 145.24, 145.08, 144.93, 144.62, 144.45, 143.64, 143.39, 141.41,
139.75, 138.39, 132.07, 131.93, 131.90, 131.38, 127.89, 63.52, 63.10, 61.41, 38.49, 14.34, 14.06
ppm.
3.4.2.2 Characterization of BB-C70
LD FT-ICR MS m/z: [M-] calcd for C70(C7H10O4)2- 1156.1163; found 1156.1175. 1H-NMR
(CDCl3, 600 MHz, 298 K): δ 4.57 (q, 2H, J = 7.14), 4.16 (q, 2H, J = 7.14), 1.50 (t, 3H, J = 7.14),
1.19 (t, 3H, J = 7.14) ppm. 13C-NMR (CDCl3, 150 MHz, 298 K): δ 164.50, 163.17, 152.44, 149.62,
149.59, 149.20, 147.25, 147.16, 146.85, 146.56, 146.07, 145.80, 144.03, 143.52, 142.59, 140.43,
135.27, 133.22, 133.12, 132.93, 131.77, 124.50, 67.57, 62.92, 61.72, 14.38, 13.92 ppm.
3.5

SUPPORTING INFORMATION

Figure 3.6 MALDI-TOF spectrum of BA-MB-C70 using 1,8,9-trihydroxyanthracene (THA) as
matrix.
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Figure 3.7 MALDI-TOF spectrum of BA-BB-C70 using THA as matrix.

Figure 3.8 UV/vis spectra of BA-MB-C70 and BA-BB-C70 in toluene.

44

Figure 3.9 1H-NMR (600 MHz; CDCl3/CS2 (7/3), 298 K); BA-MB-C70.

Figure 3.10 HMQC-NMR (600 MHz; CDCl3/CS2 (7/3), 298 K) of BA-MB-C70.
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Figure 3.11 13C-NMR (150 MHz; CDCl3/CS2 (7/3), 298 K); BA-MB-C70.

Figure 3.12 1H-NMR (600 MHz; CDCl3/CS2 (7/3), 298 K); BA-BB-C70.
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Figure 3.13 NOESY-NMR (600 MHz; CDCl3/CS2 (7/3), 298 K) of BA-BB-C70.

Figure 3.14 HMQC-NMR (600 MHz; CDCl3/CS2 (7/3), 298 K) of BA-BB-C70.
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Figure 3.15 13C-NMR (150 MHz; CDCl3/CS2 (7/3), 298 K); BA-BB-C70.

Figure 3.16 LD FT-ICR MS of MB-C70 dissolved in toluene without matrix.

Figure 3.17 LD FT-ICR MS of BB-C70 dissolved in toluene without matrix.
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Figure 3.18 UV/vis spectra of a) BB-C70, BP-C70-1 and BP-C70-3 in toluene.[106] b) MB-C70 in
toluene, α-pyrrolidine-C70, β-pyrrolidine-C70 and γ-pyrrolidine-C70 in chloroform.

Figure 3.19 1H-NMR (600 MHz; CDCl3, 298 K); MB-C70.
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Figure 3.20 13C-NMR (150 MHz; CDCl3, 298 K); MB-C70.

Figure 3.21 1H-NMR (600 MHz; CDCl3, 298 K); BB-C70.

50

Figure 3.22 HMQC-NMR (600 MHz; CDCl3, 298 K) of BB-C70.

Figure 3.23 13C-NMR (150 MHz; CDCl3, 298 K); BB-C70.
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Figure 3.24 HPLC chromatograms (toluene, 3 mL/min, 5PBB) a) MB-C70, b) BB-C70, c) BAMB-C70, d) BA-BB and e) crude of the reaction shown in scheme 3.1.
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Chapter 4: Progress in fullerene-based hybrid perovskite solar cells
Abstract: In this review, we summarize recent advances that have resulted in fullerenebased high-efficiency perovskite solar cells (PSCs) by new processing methods of the perovskite
films, by adding fullerenes as interfacial selective electron extraction layers and improving device
stability or by incorporating fullerene derivatives to eliminate hysteretic behavior of both regular
and inverted PSC structures. Finally, we outline some perspectives for further advancing PSCs for
large-scale and commercial applications. Experimental procedures and figures presented here are
a pre-peer reviewed version of the following article (See Appendix C for the copyright letter):
Castro, E.; Murillo, J.; Fernandez-Delgado, O.; and Echegoyen, L. 2017., DOI:
10.1002/chem.201702866.
4.1

INTRODUCTION
Solar energy is one of the most promising alternatives to meet world energy demands. [107,

108]

In this regard, PSCs have emerged as a very promising new type of photovoltaic technology

due to their low-cost, ease of fabrication and high power conversion efficiency (PCE) above 22%,
which is higher than that obtained with polycrystalline silicon, while using 1000 times less light
harvesting material.[39, 109-113]
Perovskites with general formula ABX3, where A is a monovalent cation;
methylammonium (MA) or formamidinium (FA), B is Pb(II) and X is a halogen (chlorine, bromine
or iodide), are the most investigated materials.[113-115] These perovskite materials exhibit very
interesting properties, such as tunable bandgaps, high absorption coefficients, long charge carrier
(electron-hole) diffusion lengths, and low-temperature solution processability.[116-119] The
exceptional properties of these materials allow for the fabrication of devices either with the regular
n-i-p or the inverted p-i-n configurations (p refers to a p-type semiconductor, n to an n-type
semiconductor, and i to an undoped semiconductor).[109, 115, 120] The latter has recently attracted
more attention due to the relatively simple device architecture and low-temperature manufacturing
process that make them suitable for commercial applications.[121, 122]
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Herein, we focus on the recent advances that enable the development of high-efficiency
PSCs through processing of the perovskite films, approaches based on their composition (presence
of additives), compact and interfacial layers, and device stability as well as on the use of fullerene
derivatives in different device architectures (regular and inverted). Finally, we outline some
perspectives on how to further advance PSCs for large-scale and commercial applications. There
are other reviews that describe in more detail the different perovskite structures,[108] working
principles,[123] photophysics,[124] chemical and thermal stability,[114, 125] deposition techniques,[126,
127]

4.2

and comparison with other photovoltaic technologies.[113]
DEVICE STRUCTURE
PSCs have been traditionally fabricated with mesoscopic and planar heterojunction

structures (Fig. 4.1). The mesoscopic structures (Fig. 4.1a) are composed of fluorinated-doped tin
oxide (FTO), a mesoporous metal oxide scaffold that works as an electron transporting material
(ETM) such as titanium oxide (TiO2) or aluminum oxide (Al2O3), the perovskite material, which
can infiltrate into the mesoporous scaffold or be used as a capping layer on top of the ETM, and a
hole transporting material (HTM) such as spiro-OMeTAD, and a metal contact (Ag or Au)
electrode.[115] Later it was found that PSCs can also be fabricated with planar configurations (Fig.
4.1b and 4.1c) for which efficiencies above 20% have been reported.[128-130]

Figure 4.1 PSCs devices a) mesoporous b) planar (regular) n-i-p c) planar (inverted) p-i-n.
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The planar configurations include regular (n-i-p)[130] and inverted (p-i-n)[120] devices. For
these devices, the hole and electron transporting layers are crucial because they determine the
polarity of the device, improve stability, passivate surface charge traps, and help charge extraction
and transport from the active layer to the electrodes.[131-134]
The best performing devices thus far are those based on mesoscopic structures (21.8%
PCE).[135] However, it is worth noting that the efficiencies of planar devices have also improved
to values of 20.8%, and the fabrication of planar devices is relatively easier compared to those of
TiO2-based mesoporous devices.[130]
4.3

DEPOSITION- AND SOLUTION-PROCESSED PEROVSKITE THIN FILMS
There are many reported procedures to deposit the organic-inorganic perovskite material,

each based on the same principle-the reaction of an organic material (MAI or FAI) and an inorganic
material (PbI2, PbBr2 or PbCl2) that yield different crystalline and film quality, and different
degrees of surface coverage. It has been reported that pin hole free perovskite layers highly
improve device performance.[111, 124] One area of focus for improving device efficiencies is the
optimization of film crystallinity. Two different methodologies have shown high quality, uniform
and smooth thin films; vapor deposition and solution processing techniques, see below.
4.3.1 Vapor-assisted film deposition methods
The vapor-assisted method for perovskite film formation was introduced by Liu et al.[136]
who achieved an efficiency of over 15% for planar PSCs (Fig. 4.2a). In this dual-source method,
MAI and PbI2 are heated at 120 oC and 325 oC, respectively, and deposited on a TiO2 layer under
high vacuum. Using this method, Momblona et al.[137] reported PCEs up to 20% for n-i-p and
16.5% for p-i-n configurations. This technique offers a uniform layer (~500 nm), grain sizes in the
nanometer scale, pin-hole free perovskite films and the ability to prepare multi-stack thin films. A
variant of this method is the deposition of the perovskite at low temperature by a vapor-assisted
solution process (Fig. 4.2b). The as-prepared PbI2 layer is treated with MAI (vapor) under a N2
atmosphere for 2 h. The perovskite film derived from this approach exhibits full surface coverage,
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uniform grain structure with grain sizes up to micrometers, and 100% precursor transformation
completeness.[138] The vapor-assisted deposition techniques have been reviewed in more detail by
Ono et al.[126]

Figure 4.2 Different deposition methods for high quality perovskite films. a) Adapted with
permission from ref. [136], Copyright 2013 Nature Publishing Group. b) Adapted
with permission from ref. [126], Copyright 2013 American Chemical Society. c)
Reproduced with permission.[139] Copyright 2015, Nature Publishing Group. d)
Reproduced with permission.[140] Copyright 2016, John Wiley and Sons. e)
Reproduced with permission.37 Copyright 2016, American Chemical Society. f)
Reproduced with permission.[141] Copyright 2016, American Chemical Society. g)
Reprinted with permission from Ref. [142] Copyright 2014, Nature Publishing
Group.
4.3.2 Solution methods
Despite the good results obtained with the vapor-deposition techniques, most research has
been focused on solution methods because they offer more alternatives for preparing perovskite
films at relatively low temperatures. The solution methods can be categorized into one-step and
two-step Fig. 4.2c-4.2d and 4.2e-g, respectively. Solution deposition methods have been reviewed
in more detail by Zhou et al.[127] and Liu et al.[120]
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4.3.2.1 One-step
In this method stoichiometric amounts of the precursors (organo-halide and metal-halide)
are mixed to form the perovskite solution,[139] which is spin coated directly onto the substrate
followed by an annealing process at 100 to 150 oC (Fig. 4.2c). High performing devices can be
fabricated using different MAI:PbI2 composition ratios from 1:2 to 3:1, respectively.[143-145] Lee et
al.[36] reported for the first time that devices prepared by the one-step solution method can achieve
10.9% PCE values. Since then, many advanced solvent engineering techniques have been
developed and efficiencies above 20% have been achieved.[130, 146-148]
The one-step is the simplest technique for preparing perovskite thin films, however the
morphological control for the perovskite films based on this method is challenging[149] and the
incorporation of additives such as DMSO,[150, 151] 1,8-diiodooctane[152] (DIO), HI[153] and HBr[140]
to slow down crystal growth to improve the surface morphology of spin-coated perovskite films
has been employed (Fig. 4.2d).
On the contrary, Jeon et al.[154] have reported that the addition of an antisolvent that does
not dissolve the perovskite films, such as toluene, on top of the wet perovskite film during spincoating results in fast crystallization. Thus, a dense small-grain perovskite film can form uniformly
across the substrate.
The addition of other antisolvents such as chlorobenzene, benzene, diethyl ether and xylene
have also been reported.[147, 155]
4.3.2.2 Two-step
In 2013, Burschka et al.[156] first reported the application of this method for PSCs
fabrication and a PCE of 15% was achieved. Typically, in this method a PbI2 layer is converted
into MAPbI3 by dipping the substrate into a MAI solution,[156] spin coating MAI on top of the PbI2
layer[142] (Fig. 4.2f and 4.2g) or by exposing the PbI2 film to a MAI vapor atmosphere[138] (Fig.
4.2b). High quality and more reproducible perovskite films can be prepared using this method.
Additionally, varying the concentration of the MAI solution, the perovskite grain sizes can be
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improved.[142] Using the two-step method, Yang et al.[157] have reported efficiencies exceeding
20%. The addition of additives to control the formation of the perovskite film by this method has
also been extensively studied (Fig. 4.2e).[147, 158, 159]
4.4

THE USE OF FULLERENES IN PSCS
In 2013, fullerene C60 (1) and its derivatives phenyl-C60-butyric acid methyl ester

(PC61BM) (2) and tetrahydro-di[1,4]methanonaphthaleno[5,6]fullerene-C60 (3) indene bis adduct
(ICBA) (Fig. 4.3) were introduced into PSCs for the first time by Jeng et al.[160] and PCEs of 3.0,
3.9 and 8.31% were achieved, respectively, when used as ETMs. Recently, Grätzel[129] and coworkers reported efficiencies above 20% for an inverted PSC device with the configuration of
ITO/PEDOT:PSS/perovskite/PC71BM (4)/CaAl, whereas a PCE of 18.5% was reported by
Huang[161] and coworkers for a PSC device based on a pure ICBA isomer (trans-3) (5) (Fig. 4.3).
It has been widely demonstrated that the use of fullerenes either as ETMs[44, 45, 107, 121, 134, 162-200] or
as additives[148, 169, 190, 201-204] in the perovskite layer can play an important role in passivating the
charge traps at the surfaces and grain boundaries of the thin films, which significantly reduces the
hysteresis and leads to higher device performances. Additionally, fullerenes can also act as a
barrier for moisture, thus enhancing long-term stability and also as a template for perovskite crystal
growth and to decrease or even completely avoid ion migration.[205]
In recent years much work has been dedicated to reduce the hysteretic J-V behavior in
hybrid perovskite devices. One phenomenon believed to contribute to this behavior is the creation
of charge trap states at layer interfaces and crystal grain boundaries within devices. Work done by
Wojciechowsk et al.[183] has shown the usefulness of fullerene derivatives in reducing charge
trap/de-trapping processes in PSC devices, which contribute significantly to this behavior.
When considering the effect of fullerenes on the performance of a PSCs, electronic
properties should not be the only factors examined. Indeed, morphology of the fullerene and the
fullerene/surface layer has been shown to be an important parameter for the quality of the PSC
characteristics. Some fullerene derivatives can form dimers and polymers in the device layers,
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rather than discrete molecular species. Huemueller et al.[206] studied the effect of polymeric
fullerenes on device efficiencies and stabilities. Their study showed a direct correlation between
the amount of polymerized fullerene and Jsc/Voc efficiency losses. In addition, the authors reported
an annealing method that allows the polymerization of the photoactive layer while still maintaining
monomeric crystallinity of the fullerene species. With their proposed process, fullerenes are more
evenly dispersed in the polymer layer, thus reducing the likelihood of fullerene to fullerene exciton
driven dimerization. Along the same lines, Lin et al.[207] found that by promoting PC61BM
aggregation into large domains within the ETL by using a block co-polymer (PS-b-PEO) with a
large disparity in polarity, they could improve the electron transport ability. Although PC 61BM
aggregation did not lead to crystallinity in the ETL, by controlling the amount of block co-polymer,
the authors were able to tune the phase separation in the ETL and improve the PCE by 4% relative
to the control devices. Beyond the morphological considerations of the fullerene/perovskite layers,
fullerene functionalization can also have a remarkable effect on device performance.

Figure 4.3 Structure of the fullerene derivatives used as ETMs in PSCs.
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4.4.1 Fullerenes as compact layers
Fullerenes and their derivatives are the most used n-type ETMs in inverted PSCs due to
their efficient electron transporting and solution processable properties, low temperature
fabrication, suitable energy level alignment with that of the perovskites, and acceptable electron
mobilities.[208, 209]
Besides PC61/71BM[44, 168, 178] (2 and 4, Fig. 4.3) or PC61BM as additives,[107, 182] other
fullerene derivatives have also been used as efficient ETMs in PSCs (Fig. 4.3).[162-164, 166, 170, 172,
174, 176, 183, 188, 210, 211]

To date, it is still not fully understood why fullerenes and their derivatives act

so well as ETMs in PSCs. In this section, we review the most import findings based on PC61/71BM
and different fullerene derivatives that have been synthesized to study the role of the functional
group.
Recently, we reported the synthesis and photovoltaic applications of DMEC60 and
DMEC70, compounds 6 and 7, respectively (Fig. 4.3). We found that inverted PSCs based on 6 or
7 as ETMs exhibited both higher PCE and higher device-stability compared to devices based on
the PC61/71BM. These results were attributed to the ability of the DMEC60/70 to extract electrons
more efficiently, likely due to specific interactions between the pyrrolidine groups (carbonyls and
amino groups) and the perovskite crystals at the interfaces, as determined by infrared (IR)
spectroscopy.[162, 212] Due to the suitable energy levels and good electron mobility of PC61BMdimers, they have been used as efficient electron acceptors in organic solar cells OSCs. [213, 214]
Taking this into account, we have reported,[163] for the first time, the use of a PC61BM-dimer, (DC60) compound 8 (Fig. 4.3), as the ETM in inverted PSCs. The results showed improved PCE and
device stability as compared to devices based on PC61BM. This improved performance was
attributed to effective perovskite film surface passivation as well as improved electron extraction
and transport efficiency, as determined by photoluminescence (PL) techniques and
electrochemical impedance (EIS).
Xing et al.[164] synthesized several C60 and C70 fullerene derivatives functionalized with
oligoether chains, compounds 9-13 (Fig. 4.3), and used as ETMs to study trap passivation
60

mechanisms in inverted PSCs. These new materials are good candidates for replacing PC61/71BM
layers. The results show that the length of the oligoether chains affect the energy levels, charge
carrier mobilities, surface energy and dipole layer features at the interfaces. In many cases,
improved device performance has been attributed to the fullerene design for both electronic and
morphological reasons. Meng et al.[170] reported that by using C5-NCMA, compound 14 (Fig. 4.3),
as the ETM in inverted PSCs, both higher efficiencies and longer device-stabilities, as compared
to those of PC61BM-based devices, were achieved. The high PCE values were attributed to the
high electron mobility, efficient charge extraction and improved electron transport ability of 14
(Fig. 4.3). The Improved stabilities of devices based on 14 was mainly due to its hydrophobicity.
One common issue in PSCs is the light-soaking-effect (performance variation under
illumination). To address this phenomenon Shao et al.[172] studied how fullerene derivatives with
different dielectric constants (compound 15, dielectric constant 5.9) (Fig. 4.3) can eliminate the
light-soaking-effect. As shown in Fig. 4, the photo-generated electrons are injected into the ETL,
where they are either collected by the cathode or captured by surface traps, resulting in nonradiative recombination (rc). The latter can be determined using equation 4.1:
q2

𝑟𝑐 = 4πε

0 𝜀𝑟 kT

(4.1)

Where q, T, ε0 and εr are the elementary charge, temperature, vacuum permittivity and the
dielectric constant of the ETM, respectively. The electrons that are within rc distance have higher
probability to be trapped. From equation 1, the higher the εr the smaller the rc.
Erten-Ela et al.[166] reported the synthesis and application of the benzoic acid fullerene bisadduct 16 (Fig. 4.3). Although the PCE for devices based on this compound are not better than for
PC61BM-based devices, higher Jsc values were obtained when 16 was used as the ETM in PSCs.
Chang et al.[174] reported that IBF-Ep compound 17 (Fig. 4.3) can be used as the ETM in
both regular and inverted PSCs, though better results were obtained when 17 (Fig. 4.3) was used
in inverted structures. Wolff et al.[188] investigated how fullerenes 1, 2 and 18 (Fig. 4.3) affect the
Voc values in inverted PSCs, when a thin layer of an insulator polymer is in between the perovskite
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and the ETM interface. The results showed that the insulator interlayer reduces the recombination
process and improves the electron extraction from the perovskite layer, which is more effective
than raising the LUMO level of the ETMs (compound 18) (Fig. 4.3).
Zhang et al.[215] reported that due to the low electron mobility of compounds 19-21 (Fig.
4.3), charge carriers can accumulate at the perovskite/fullerene interface, leading to an electric
field that gives rise to the notorious hysteretic behavior.
The influence of additives in the fullerene layer has also been studied. It was reported that
the addition of polystyrene (PS) into the PC61BM solution, leads to the formation of a smooth and
uniform

ETL,

resulting

in

an

improved

overall

device

performance.[182]

When

cetyltrimethylammonium bromide (CTAB) was added into the PC61BM layer, good film coverage
was observed, and both improved PCE values and device stabilities were obtained. This approach
was also used to fabricate large-area devices (1.2 cm2) to prove the applicability of the method.[216]
Pyridine has also been used as an additive to improve electron mobility, decrease series resistance
and smooth the surface of the PC61BM layer.[217]

Figure 4.4 Proposed mechanism for the light-soaking-effect, reproduced with permission from
ref. [172] Copyright 2016, Royal Society of Chemistry.
Umeyama et al.[176] reported for the first time the use of C60 thin films as the ETM in regular
PSCs, after thermal retro-Diels-Alder reaction on as-prepared glass/FTO/C60-9-methylanthracene
(22) (Fig. 4.3). Higher fill factor (FF) values and lower charge-transfer resistance from
ETM/perovskite interfaces compared with the commonly used TiO2-based devices were obtained.
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Recently, Wang et al.[218] reported that compound 23 (Fig. 4.3) can be covalently anchored onto
the ITO surface, and used as the ETM in regular PSCs as represented in Fig. 4.5. Compound 23
(Fig. 4.3) shows good electron mobility and HOMO/LUMO values that match those of the
perovskite. Devices based on this compound as the ETM showed negligible hysteretic behavior
and a remarkable device stability, achieving maximum PCE values of 18.39% and 17.04% for
rigid and flexible devices, respectively.

Figure 4.5 Schematic device structure of planar regular perovskite solar cells using fullerene 23
as the ETL. Reproduced with permission.[218] Copyright 2017, John Wiley and
Sons.
4.4.2 Fullerenes as interlayers
Although PSCs based on meso-porous TiO2 are leading the race in terms of PCE values,
PSCs based on planar structures are becoming more popular due to their simple architecture and
lower temperature processability. Lower temperature processed TiO2 can also serve as an ETM in
regular PSCs due to its good conduction band match with those of the hybrid perovskites and its
deep valence band, which can block the holes.[115] However, the low electron mobility of the
compact TiO2 layer leads to charge accumulation at the interface, resulting in chargerecombination.[219]
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Snaith and other groups have demonstrated that coating the TiO2 with a thin layer of
PC61BM or by modifying the TiO2 surface with a self-assembled monolayer (SAM) of fullerene
derivatives (compounds 24-31, Fig. 4.6), reduces the non-radiative recombination channels at the
interface thus reducing the hysteresis and enhancing device performance.[179, 183-185, 189, 193, 196, 200,
220]

The SAMs not only provide a valuable reference to explore the fundamentals of hysteresis, but

also introduce a technical and viable concept to large-area processing of hysteresis-free solar cells.
In a similar approach, water soluble fullerene derivatives (compounds 30-31, Fig. 4.6) were
deposited between the PC61BM/perovskite layer in regular PSCs.[186, 194] The second fullerene layer
not only improves the wettability of the perovskite film on the ETL but also increases the electron
transport ability across the interface between the perovskite and TiO2 layers. To avoid damage of
the C60 layer deposited on top of the ITO, the latter was coated with polyethylenimine ethosylated
(PEIE) to keep the integrity of the C60 film.[167] Results showed that the ETL is an effective
template to grow high-quality MAPbI3-based perovskite layers.

Figure 4.6 Structure of the fullerene derivatives used as interlayers in inverted PSCs.
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4.4.3 Fullerenes as additives
Huang and coworkers[173, 221] demonstrated that the spun PC61BM layer can permeate into
the perovskite layer throughout the grain boundaries during the annealing process below 100 oC
(Fig. 4.7a). Xu et al.[201] showed the formation of a PC61BM radical by UV-Vis spectroscopy.
These results suggest that PC61BM is passivating the iodide trap sites on the surface grains. As
shown in Fig. 4.7b, iodide reacts with PC61BM or C60 to form a bond by direct electron transfer to
the fullerene.

Figure 4.7 a) Passivation process mediated by PC61BM permeation. Adapted with permission
from ref. [173] Copyright 2014, Nature Publishing Group. b) UV-Vis absorption
spectrum of the hybrid solution showing the interaction between PC61BM and
perovskite ions. Adapted with permission from ref. [201] Copyright 2015, Nature
Publishing Group.
Different approaches have been developed to modify the morphology of perovskite solar
films, aimed at improving stability and large-scale production capability. The use of fullerenes as
additives within the perovskite solution,[169, 190, 202, 203, 222] in chlorobenzene as antisolvent[148, 204]
or by immersion of the as-prepared perovskite thin films into a fullerene solution,[165] has shown
remarkable FFs up to 86.7%, negligible hysteretic behavior, improved long-term-device stability,
and last but not least, high PCE values for large-area-based devices. Fullerene derivatives 32-39
used as additives are shown in Fig. 4.8.
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Figure 4.8 Structure of fullerene derivatives used as perovskite-additives.
4.4.4 Fullerenes as cathode buffer layers, cross-linkable and double layers
The role of a cathode buffer layer in PSCs is to improve the metal electrode efficiency in
collecting charge carriers. As discussed above fullerenes are excellent ETMs. However, a barrier
exists at the contact interface between the Fermi level of different metal electrodes such as Al, Ag
or Au and the LUMO of the fullerenes, which leads to poor electron injection and extraction. To
minimize this barrier a quasi-ohmic contact at the fullerene/metal interface is needed.[223-228]
Jen’s and Huang’s groups, among others, have reported the use of different double
fullerene layers to improve device performance in PSCs (compounds 40-43, Fig. 4.9).[44, 45, 121, 173,
187, 199, 221, 229, 230]

Cross linkable fullerene derivatives (31, Fig. 4.6 and 44-46, Fig. 4.9) that enhace

water and moisture stability have been reported,[171, 175, 191] as well as the use of fullerene salts (40,
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47 and 48, Fig. 4.9 ),[44, 177, 195] and polymers (49, Fig. 4.9)[192, 197] to reduce the work function of
the metal electrodes and prevent degradation caused by humidity. Compounds 41 and 50 were
used as interlayers to reduce the interface barrier and also to enhance the stabily of PSC devices.[180,
198, 199]

Figure 4.9 Structure of fullerene derivatives used as cathode buffer layers and double layers.
4.5

DEVICE STABILITY

4.5.1 Humidity, oxygen and light exposure
One of the external factors that affects the stability of PSCs is humidity. Exposure of the
device to the atmosphere can completely degrade it in just a few days, even when stored in the
dark. Yang et al.[231] reported that the degradation rate is affected not only by the relative humidity
(RH) but also by the nature of the HTM. Christians et al.[232] reported that the degradation of the
perovskite starts with the formation of a hydrate at the perovskite surface, and then propagates
through the entire perovskite layer[232] as represented in equation 4.2.
Additionally, Leguy et al.[233] found that the degradation process occurs in two steps and
is water exposure dependent (Fig. 4.10). When heat is combined with moisture, unlike the previous
processes, it leads to a complete irreversible degradation of the perovskite layer, yielding PbI2 and
the degraded organic counterpart.[234]
CH3 NH3 PbI3 + H2 O → (CH3 NH3 )4 PbI6 ∙ 2H2 O
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(4.2)

Several studies have tried to overcome these problems and increase device stability under
atmospheric conditions. Noh et al.[116] reported that the use of Br- as the halide in the perovskite
film strengthens the hydrogen bonding between CH3NH3+ and [PbI6 ]4- and avoids the formation
of hydrates.

Figure 4.10 Hydration process for the perovskite film. Reproduced with permission.[235]
Copyright 2017, American Chemical Society.
Similar work, done by Jiang et al.[236, 237] introduced SCN- instead of Br- to increase device
stabilities. With this modification, no degradation of the device was observed under conditions up
to 70% RH.
Another strategy to improve device stability relies on the use of fullerene derivatives,
which have high hydrophobicity and form compact self-assembled layers, thus avoiding water
insertion and subsequent device degradation.[170, 174]
Oxygen also influences device degradation, it oxidizes the organic material in the cell, but
unlike moisture degradation, oxygen can have a greater effect when exposed to light.[238, 239] This
phenomenon has been observed to occur by a well-studied photo-oxidation process.[240] This
process is dominated by electron transfer and oxidation rates. Oxidation of the semiconductor is
prevalent except for the case when the electron transfer rate is dominant.[234, 240] The mechanism
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by which the perovskite degrades in the presence of oxygen and light is represented in equations
4.3, 4.4 and 4.5.[235, 241]
When light strikes the perovskite, it forms a non-equilibrated population of electrons and
holes (equation 4.3). Then electrons from the conduction band form a superoxide anion with the
adsorbed oxygen from the atmosphere (equation 4.4). Finally, methylammonium cation is
deprotonated and the iodide anion is oxidized by the superoxide anion (equation 4.5).[235, 241]
hν>Eg

CH3 NH3 PbI3 →

CH3 NH3 PbI3 ∗

CH3 NH3 PbI3 ∗

O2 →

O2 ∎−

(4.3)

(4.4)

1
O2 ∎− + CH3 NH3 PbI3 → CH3 NH2 + PbI2 + I2 + H2 O
2

(4.5)

Aristidou et al.13 reported that the O2.- formation rate can be decreased by using interlayers
that are able to extract electrons from the perovskite film before they can react with the oxygen to
form the superoxide.[241, 242] To date, the best way to delay the degradation process caused by
moisture and oxygen is by device encapsulation.[114, 234, 235]
Recent reports showed that decomposition can occur in the absence of humidity.[241-243]
Decomposition is accelerated in the presence of light and oxygen as shown in equations 2-4.[235,
241]

4.5.2 Thermal instability
To understand the thermal decomposition, different parameters have been considered.[244246]

Yang et al.[247] reported that after heating the perovskite layer decomposes to generate PbI2 in

one step. It has also been reported that decomposition depends on the heating time, applied
temperature and the nature of the ETL, as shown in Fig. 4.11a and 4.11b. [247-249] Device
decomposition was characterized by XRD studies.[244, 247]
The mechanism represented in equations 4.6 and 4.7 was proposed to explain the
degradation process due to temperature.[235, 250] It was reported that degradation can also occur at
100 °C and without exposure to moisture.[251, 252]
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Figure 4.11 Decomposition of the perovskite layers using different ETLs, under varied times and
temperatures. a) Adapted from ref. [247] with permission. Copyright 2015, American
Chemical Society. b) Adapted from ref. [249] with permission. Copyright 2014,
American Chemical Society.
OH − + CH3 NH3 I → CH3 NH3 OH + I−
heat

CH3 NH3 OH →
4.6

CH3 NH2 ↑ + H2 O ↑

(4.6)
(4.7)

SUMMARY AND PERSPECTIVES
PCEs based on both regular and inverted PSC configurations have exceeded 20%, the latter

using fullerene derivatives as the ETMs. Several fullerene derivatives with higher electron
mobilities and hydrophobic properties, have been designed for improving device performance as
well as device stability. By tuning the physical and chemical properties of fullerenes, enhanced
charge extraction and transport capabilities were obtained.
By decreasing the structural disorder of fullerene derivatives layers, inverted PSCs with an
improved Voc comparable with that of TiO2-based PSCs, can be fabricated. It is worth mentioning
that PSCs based on fullerenes as the ETMs, perform better at eliminating the J-V hysteresis and
can be fabricated at relatively low-temperature compared with those that use TiO2 as the ETM.
Although a tremendous progress has been made toward increasing PCE values and device
stability of PSCs, there are still many barriers to further overcome to compete with the inorganic70

based solar cells that currently lead the market. One of the main concerns for commercializing this
technology is the long-term stability. PSCs are being exposed to drastic conditions such as longtime light-soaking conditions in the presence of air, but they have not yet been studied nor
overcome the stability under atmospheric conditions. In this regard, PSCs are still lacking critical
innovation to improve their long-term device-stability. Cost-wise, less expensive organic materials
are being used either as the ETMs or HTMs, which has motivated the research community to
design new efficient materials.
Given the current trajectory of progress in this field of study, we foresee the development
of new fullerene based PSC devices that will soon find commercial viability and rival older silicon
based technology for market supremacy.
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Chapter 5: Fullerene derivative with a branched alkyl chain exhibits
enhanced charge extraction and stability in inverted planar perovskite solar
cells
Abstract: Fullerene derivatives are known for their excellent electron transport properties,
which can effectively serve as electron transport layers (ETL) deposited from solution at low
temperatures in perovskite solar cells (PSCs). However, it remains unclear how functional groups
attached to the fullerene derivatives influence device performances. Herein, the performance of an
ETL based on [6,6]-phenyl-C61 butyric acid 2-ethylhexyl ester (PC61BEH) was investigated. It was
demonstrated that the branched alkyl chain of the fullerene derivative can highly influence the
solubility, film morphology, passivation ability, ETL-perovskite contact, and electron extraction
ability of the fullerene derivative. Overall device performance and stability are dependent on these
characteristics. The results suggest that further design and improvement of fullerene-based PSCs
performance may be possible through optimization of the addend structure and functionality.
Experimental procedures and figures presented here are a pre-peer reviewed version of the
following article (See Appendix D for the copyright letter): Tian, C.; Castro, E.; Betancourt-Solis,
G.: Nan, Z.; Fernandez-Delgado, O.; Jankuru, S.; and Echegoyen, L. 2017. DOI:
10.1002/chem.201702866.
5.1

INTRODUCTION
Perovskites (typically CH3NH3PbI3) have become the preferred photovoltaic materials due

to their exceptional properties such as high light absorption coefficients,[38,

238]

long carrier

diffusion lengths and high charge carrier mobilities.[117, 118, 253, 254] Perovskite solar cells (PSCs),
have attracted much attention due to the rapid improvement of photoelectric conversion
efficiencies.[39] Inverted planar structured PSCs employing fullerene derivatives as the electron
transport material (ETM) have become very popular due to their simple device architectures, lowtemperature preparation processes,[255, 256] negligible hysteric behavior and feasible application on
flexible substrates.[173, 227, 257]
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PC61BM is the most widely used electron extraction and transport material, as well as
solution processing material.[208, 209, 258] It was first employed and verified as an efficient ETM for
PSCs by Jeng and co-authors in 2013, achieving an efficiency of 3.8%.[160] The efficiencies of the
devices with PC61BM as the ETM were soon improved by changing the perovskite fabrication
procedure, resulting in improved coverage, grain size, and a significantly increased device
efficiency of 18%.[168,

259]

Recently, Huang and co-workers demonstrated that LUMO energy

dispersion in the fullerene ETL can also significantly influence the PSCs’ performance. Employing
a simple annealing process for a fullerene-based ETL, a remarkable efficiency, as high as 19.4%,
for inverted planar PSCs was obtained.[260] At the same time, double-fullerene layers as the electron
extraction and hole blocking layers in PSCs have also been studied by other groups.[122, 161, 173] Jen
et al. demonstrated that a double fullerene layer, such as PC61BM/C60 and PC61BM/bis-C60, are
efficient ETLs that can enhance the electron-transporting ability and the overall deviceperformance.[44, 45, 121, 173] Other fullerene derivatives were also studied in PSCs, such as PC71BM,
DMEC60 and DMEC70, among others.[162-164, 166, 170, 172, 174, 176, 183, 188]
It is important to realize that fullerene layers in PSCs can not only serve as the ETM to
extract electrons from the perovskite layer, they can also efficiently passivate the charge traps at
the surfaces and grain boundaries of the perovskite layer, thus effectively eliminating electronhole recombination events and enhancing the performance of the PSCs.[258] However, the explicit
influence of the functional groups of fullerene derivatives on the PSCs’ performance is still unclear
and in need of investigation. Understanding these effects could lead to more effective fullerene
derivative design and to better PSC devices.
Here we studied the effect of a branched alkyl chain of a PC61BM-like fullerene derivative,
PC61BEH, in inverted planar PSCs using charge extraction analysis, PSCs device performance,
and device stability tests to understand the effects of the functional group. Due to the high
solubility of PC61BEH in chlorobenzene (146 mg/mL compared to PC61BM 46 mg/mL, as
determined by UV-vis), highly homogenous films, enhanced passivation, improved electron
extraction ability and efficiencies as high as 16.26% were obtained from devices using PC 61BEH
73

as the ETM. This performance was better than that of PC61BM-based PSCs (14.9% PCE).
Additionally, the resulting dense and hydrophobic films of PC61BEH-based devices resulted in
improved device stabilities when compared with those of PC61BM based devices. These results
clearly indicate that there is significant room for improvement of device performance via further
design and modifications of the functional groups of fullerene derivatives.
5.2

EXPERIMENTAL AND METHODS

5.2.1 Materials
PC61BM, 99%, was bought from Nano-C. PC61BEH was synthesized following the
methodology developed by Hummelen et al.[261] for the preparation of PC61BM. The chemical
structure of PC61BEH is shown in Figure 5.1a. After the compound was synthesized, it was
purified by silica gel column chromatography. The final product was characterized by 1H-NMR,
13

C-NMR and matrix assisted laser desorption/ionization-time-of-flight-mass spectrometry

(MALDI-TOF-MS). The solubilities of PC61BM and PC61BEH in chlorobenzene were obtained
using a Varian Cary 5000 UV Spectrometer, constructing calibration curves at a wavelength of
434 nm, using the Lambert-Beer law (see figure 5.11, supporting information).
5.2.2 Device fabrication
Methylammonium iodide (CH3NH3I) was prepared following a previously reported
procedure.[262] PSC devices with a configuration of FTO/PEDOT:PSS/CH3NH3PbI3/PC61BM (or
PC61BEH)/Al were fabricated on FTO-coated glass substrates with a resistivity of 10 Ω/cm2. The
patterned FTO glass substrates were washed sequentially with detergent, deionized water, and
ethanol, each step for 15 min, then, dried with nitrogen gas and finally treated in a UV-ozone oven
for 20 min. After passing through a 0.45 μm PVDF filter, the PEDOT:PSS solution (Baytron P VP
AI 4083) was spin-coated onto the treated FTO substrates at 5000 rpm for 30 s, and heated at 150
o

C for 15 min in air. Then a solution of 1 M PbI2 in DMF was spin-coated at 5000 rpm for 30 s on

top of the PEDOT:PSS coated substrates, and dried on a hot plate at 70 oC for 10 min. The
FTO/PEDOT:PSS/PbI2 substrates were then transferred to a vacuum oven to be converted to
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CH3NH3PbI3 by means of a vapor-assisted gas–solid crystallization process following previously
reported methods.[138, 263] After the CH3NH3PbI3 films were formed they were cooled to room
temperature and 2 wt% PC61BM (or PC61BEH) dissolved in chlorobenzene was spin-coated onto
the CH3NH3PbI3 layer at 1200 rpm for 30 s. To complete the devices, aluminum electrodes (100
nm) were deposited by thermal evaporation under a pressure of 2×10-6 Torr through a shadow
mask. The active area of the devices was controlled by the mask with a 7 mm 2 aperture in the
middle.
5.3

RESULTS AND DISCUSSION
PC61BEH (Figure 5.1a) was prepared following a previously reported procedure.[261]

PC61BEH has a branched alkyl chain, a 2-ethylhexyl ester group that can significantly improve the
solubility of the compound,[264] which ensures efficient surface perovskite coverage and higher
passivation of the perovskite grain boundaries.
The energy levels of the fullerene derivatives are crucial to assess their electron extraction
and hole blocking properties in PSCs. The estimated HOMO/LUMO energy values from cyclic
voltammetry (CV) reveal that the PC61BEH has well matched values with those of the perovskite
layer. The estimated LUMO energy levels of PC61BEH and PC61BM were obtained using cyclic
voltammetry (CV).[265] As shown in Figure 5.1b, PC61BEH exhibits three well-defined reversible
reduction waves. The half-wave potentials of the fullerene derivatives are listed in Table 5.3. The
LUMO energy levels of the compounds were calculated from their onset reduction potentials
𝑜𝑛
𝑜𝑛
(𝐸𝑟𝑒𝑑
) using the formula LUMO energy level = -e (𝐸𝑟𝑒𝑑
+ 4.80) (eV).[265] Table 5.1 shows the

LUMO energy levels of PC61BEH -3.89 eV. By comparing the LUMO energy values of PC61BM
and PC61BEH, the results indicate that PC61BEH can serve as an efficient ETMs in PSCs.[258]
Very similar HOMO energy values were obtained when combining the value of their
maximum absorption onsets (Figure 5.9) with the LUMO energy levels. The HOMO energy levels
of PC61BEH and PC61BM were estimated at -5.61 and -5.63 eV, respectively, very similar values.
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To understand the influence of the 2-ethylhexyl ester group on the intrinsic properties of
PC61BEH based ETMs, the electron mobility was measured by the space-charge limited current
(SCLC) method and the Mott–Gurney law.[266] Electron-only devices with the structure of
ITO/Cs2CO3/fullerene derivative/Ca/Al were fabricated, and the mobilities of PC61BM and
PC61BEH were determined to be 4.62×10-4 and 4.76×10-4 cm2 V-1 s-1, respectively, see Figure
5.1c. The comparable mobility to that of PC61BM suggests that PC61BEH can work as a suitable
ETM in PSCs.[44]
Table 5.1 Electrochemical and photo-physical data of PC61BEH and PC61BM

Compound

λabs (nm)

Eg (eV)

𝐨𝐧
𝐄𝐫𝐞𝐝
(V)

LUMO (eV)

HOMO (eV)

PC61BEH

720

1.72

-0.91

-3.89

-5.61

PC61BM

718

1.73

0.90

-3.90

-5.63

Figure 5.1 (a) Molecular structure of PC61BEH and PC61BM. (b) Cyclic voltammetry scans for
PC61BEH and PC61BM at a scan rate of 100 mV/s. (c) Measured space-charge
limited J-V characteristics of the PC61BEH and PC61BM for electron-only devices.
To study the ability of PC61BEH to work as an efficient ETM, inverted planar PSCs with
a configuration: FTO/PEDOT:PSS/CH3NH3PbI3/fullerene/Al were fabricated. The energy-level
alignment of all materials employed in the device is shown in Figure 5.2a. The perovskite layer
was prepared on the PEDOT:PSS coated substrate following a previously reported procedure.[263]
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SEM images of the perovskite layers are shown in Figure 5.2b and 5.2c. The top-view image
(Figure 5.2b) clearly shows that the perovskite layer was homogeneous and exhibits large
crystalline grains without apparent pinholes. Perovskite films with larger, compact and
homogeneous grains were obtained, which can effectively reduce the grain boundary and be
adequate for device fabrication. From the cross-section image (Figure 5.2c), the hole transporting,
electron transporting and perovskite layers can be clearly distinguished. Therefore, device
performance differences can be attributed to the different fullerene derivative layers, since PSCs
based on PC61BM and PC61BEH were fabricated under the same conditions.

Figure 5.2 (a) Energy level diagram of the materials used in PSCs, (b) Top-view SEM image of
the perovskite film, and (c) Cross-sectional SEM image of the device
FTO/PEDOT:PSS/perovskite/fullerene derivative film.
As displayed in Figure 5.3a, the J-V curves of PSCs were measured under AM 1.5G
irradiation (100 mW cm-2). The corresponding key parameters (VOC, JSC, FF, and PCE) of the
devices are summarized in Table 5.2. Compared to PC61BM, PC61BEH based devices exhibit
improved performances, mainly due to the higher JSC and higher FF values. Thus, the functional
group on the fullerene derivative is important for the performance of the device.
A statistical histogram of the efficiencies of 20 individual devices based on PC 61BM and
PC61BEH as the ETMs are shown in Figure 5.3c. The average efficiencies for PC61BM and
PC61BEH based devices are 14.55±0.56% and 16.02±0.25%, respectively. The external quantum
efficiency (EQE) spectra of the fullerene derivative based PSCs are shown in Figure 5.3b. The
EQE curves for the two fullerene derivatives based devices are similar, but the EQE values of
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PC61BEH based devices are higher than those of PC61BM based devices, which indicates that more
efficient incident photon-to-current conversion efficiencies are obtained from PC61BEH based
devices.
Table 5.2 Summary of device performance. The calculated JSC values were obtained from the
EQE curves.

Compound

VOC (V)

JSC
(mA/cm2)

Calculated JSC
(mA/cm2)

FF (%)

PCE (%)

PC61BEH

0.95

22.05

21.19

77.61

16.26

PC61BM

0.95

21.47

20.49

74.52

15.19

PC61BEH based PSCs yielded a JSC values of 22.05 mA/cm2, higher than that of PC61BM,
21.47 mA/cm2. The calculated JSC from the EQE curves are very consistent with the values
obtained from the J-V curves.
To confirm device efficiencies, the maximal steady-state power and photocurrent outputs
were studied. As shown in Figure 5.10, PC61BM and PC61BEH based cells yielded 18.6 mA/cm2
and 19.8 mA/cm2 at 0.80 V and 0.81 V, corresponding to PCEs of 14.9% and 16.0%, respectively.
The results are very similar to the values obtained from the J-V curves.
Additionally, device stabilities were conducted under a 45-50% humidity in air at room
temperature without encapsulation. As displayed in Figure 5.3d, PC61BEH based devices exhibit
better stabilities. This can be the result of their hydrophobicity and film morphology, resulting
from the branched functional group. The results also show that the functional group significantly
affects the solubility compared to that of PC61BM and solution processing, thus affecting film
morphology. AFM images were obtained to explore the surface morphologies of the perovskite,
perovskite/PC61BM and perovskite/PC61BEH layers.
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Figure 5.3 Device performance and reproducibility of perovskite solar cells fabricated by using
PC61BEH and PC61BM as ETMs. (a) J-V curves of devices using PC61BEH and
PC61BM. (b) EQE spectra for perovskite solar cells fabricated by using PC61BEH
and PC61BM as the ETMs. (c) The statistic diagrams of the device PCE measured
for 20 individual devices based on PC61BEH and PC61BM as the ETMs. (d)
Normalized PCE of perovskite solar cells employing PC61BEH and PC61BM as the
ETMs as a function of storage time in air.
As shown in Figures 5.4a-d, the perovskite film exhibits a crystalline structure with a
calculated root-mean-square (RMS) roughness of around 54 nm. The perovskite/PC61BM film
shows a morphology with a reduced RMS roughness of around 19.3 nm, whereas an even smoother
surface morphology with a smaller RMS roughness of around 13.7 nm was observed for the
perovskite/PC61BEH film. The surface morphology of the PC61BEH based films is more
homogenous than that of PC61BM films, likely due to better molecular packing in the PC61BEH
based films. Figures 5.4e-f show the water droplets on the PC61BM and PC61BEH layers and
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contact angle values of 81º and 97º were obtained, respectively, which must result from the more
hydrophobic branched carbon chain of PC61BEH.

Figure 5.4 AFM images of a) Perovskite, b) 3D perovskite c) 3D perovskite/PC61BM and d) 3D
perovskite/PC61BEH thin films. Images of the water droplet contact angles on the
surfaces of fullerene derivative films, e) PC61BM and f) PC61BEH.
To further probe the influence of the functional group on the performance of PSCs, steady
state and time-resolved photoluminescence (PL and TRPL) experiments were conducted. As
displayed in Figure 5.5a, the steady-state PL spectra of the perovskite, perovskite/PC61BM and
perovskite/PC61BEH thin films were obtained on glass substrates. A significant PL quenching
effect was observed after the perovskite layer was coated with PC61BM or PC61BEH. It is clear
that the perovskite layer coated with PC61BEH exhibits a more efficient PL quenching when
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compared to that coated with PC61BM, thus PC6BEH inhibits electron-hole recombination more
efficiently.[152] The TRPL spectra was obtained by monitoring the emission peak of the different
fullerene derivative coated perovskite layers as a function of time. As displayed in Figure 5.5b,
the PC61BEH coated perovskite layer exhibits the shortest PL decay time (10.2 ns). PC61BM coated
perovskite layers showed a decay time of 13.4 ns. The shorter PL decay time of the PC61BEH
coated perovskite layer suggests that carriers are transferred much faster to the PC 61BEH layer
than to the PC61BM layer. The PL decay times are consistent with the PL quenching results, which
suggests that PC61BEH has a greater ability to suppress electron-hole recombination and to
significantly improve the performance of the device.[152]

Figure 5.5 (a) steady-state photoluminescence spectra, and (b) TRPL decay transient spectra of
FTO/perovskite/PC61BM (or PC61BEH).
Finally, the charge transfer processes at the perovskite/fullerene interface were studied by
EIS measurements. Results obtained for Perovskite/PC61BM and perovskite/PC61BEH were fit to
a relatively simple equivalent circuit (Figure 5.6) consisting of a contact resistance (Rct) between
the fullerene/perovskite or perovskite/PEDOT:PSS interface and the recombination resistance
(Rrec). As shown in the Nyquist plots in Figure 5.6 and Table S2, PC61BEH based devices display
a lower Rct and larger Rrec values than those devices based on PC 61BM. Since the
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PEDOT:PSS/perovskite interface is identical in both cases,[248] the results demonstrate that
electron extraction is more efficient at the perovskite/PC61BEH interface than that for
perovskite/PC61BM. It is also clear that PC61BEH can inhibit charge recombination more
efficiently than PC61BM at the perovskite/fullerene interface. The decreased charge recombination
efficiency at the perovskite/PC61BEH interface indicates that PC61BEH passivates the charge traps
more efficient than PC61BM. This result is consistent with the higher PL quenching observed for
perovskite/PC61BEH devices.

Figure 5.6 Nyquist plots of the perovskite solar cells based on PC61BM and PC61BEH.
5.4

CONCLUSIONS
In this work, PC61BEH with a branched alkyl chain was synthesized and used as an efficient

ETM in PSCs. The effect of the fullerene addend on the PSCs performance was systematically
explored by AFM film morphology, SCLC, PL, TRPL, EIS and device performance studies. The
improved efficiency and stability of PC61BEH based devices can be attributed to the presence of
the branched group that enhances solubility, improves film morphology, and increases both
passivation and electron extraction ability compared to PC61BM based devices. Given that the only
difference between these two compounds is their solubility, we speculate that the higher solubility
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enhances the penetration of the compound into the intergrain spaces in the perovskite film, thus
passivating the charge traps and facilitating the charge mobilities. These results indicate that
further optimization of the functional group of fullerene derivatives could result in improved
device performances.
5.5

SUPPORTING INFORMATION

Figure 5.7 1H-NMR (600 MHz; CDCl3, 298 K) of PC61BEH.
1

H NMR (600 MHz; CDCl3, 298 K) δ(ppm) 7.92 (d, J = 12.7 Hz, 2H), 7.55 (d, J = 13.2 Hz, 2H),

7.52 (t, J = 13.5, Hz, 1H), 3.99 (q, J = 12.3 Hz, 2H), 2.91 (m, 2H), 2.52 (t, J = 13.8 Hz, 2H), 7.92 (m, 2H),
1.32 (m, 9H), 0.88 (m, 6H).
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Figure 5.8 13C-NMR (150 MHz; CDCl3, 298 K) of PC61BEH.
13

C NMR (150 MHz; CDCl3, 298 K) δ (ppm) 173.28, 148.85, 147.83, 145.88, 145.21, 145.17,

145.11, 145.06, 144.81, 144.69, 144.53, 144.45, 144.03, 143.78, 143.14, 143.05, 143.01, 142.95, 142.27,
142.20, 142.16, 141.01, 140.77, 138.08, 137.58, 136.77, 132.13, 128.45, 128.26, 79.92, 67.10, 51.95, 38.73,
34.25, 33.73, 30.42, 28.96, 23.83, 23.03, 22.50, 14.14, 11.07.

Figure 5.9 UV-Vis absorption spectra of PC61BEH and PC61BM in toluene solution.
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Figure 5.10 Maximal steady-state photocurrent output at the maximum power point for PC61BM
(at 0.8 V) and PC61BEH (at 0.81 V) based device and its corresponding power
output.

Figure 5.11 Calibration curves for PC61BM and PC61BEH in chlorobenzene at 434 nm.
Table 5.3 Redox Potentials of PC61BM and PC61BEH.
Compound

E0/-

E-/-2

E-2/-3

PC61BM

-1.03

-1.41

-1.90

PC61BEH

-1.03

-1.41

-1.89
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Table 5.4 Rct and Rrec values obtained from PC61BM and PC61BEH based devices.
Device
PC61BM
PC61BEH

Rct(Ω)
3119
1711
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Rrec(Ω)
16658
18331

Chapter 6: A dimeric fullerene derivative for efficient inverted planar
perovskite solar cells with improved stability
Abstract: Fullerene derivatives can efficiently passivate the interfacial defects of
perovskite layers to improve the performance of perovskite solar cells. In this work, a new dimeric
fullerene derivative (D-C60) with two [6,6]-Phenyl-C61-butyric acid methyl ester (PC61BM) units
was designed, synthesized and applied as the electron transporting material (ETM) in perovskite
solar cells (PSCs) taking advantage of its appropriate energy levels, relatively fast electron
mobility, easy solution processability. Compared to the widely used PC61BM, D-C60 can efficiently
passivate the trap states between the perovskite and fullerene layers, leading to improved electron
extraction and overall photovoltaic performance. Devices based on D-C60 as the ETM achieved
power conversion efficiencies (PCEs) of 16.6%, which is significantly higher than that observed
with PC61BM (14.7%). In addition, the more hydrophobic and compact D-C60 layer resulted in
higher device stability than that with PC61BM. These results show that covalently linked dimeric
fullerene derivative can act as efficient electron transporting materials (ETMs) for high
performance PSCs. Experimental procedures and figures presented here are a pre-peer reviewed
version of the following article: Tian, C.; Kochiss, K.; Castro, E.; Betancourt-Solis, G.; Han, H.;
Echegoyen, L. J. Mater. Chem. A. 2017, 5 (16), 7326-7332. Reproduced by permission of the
Royal Society of Chemistry.
6.1

INTRODUCTION
The unique properties of organic-inorganic hybrid perovskite materials (typically

CH3NH3PbI3), such as high light absorption coefficients,[38, 267] long carrier diffusion lengths,[118,
253, 268]

high electron/hole mobilities,[254] simple device architectures, low-temperature fabrication

processes,[255] compatibility with flexible substrates,[227, 257] negligible hysteric behavior,[173] and
efficiencies comparable to those of commercial standards,[269] make them promising candidates for
the development of the next-generation photovoltaic solar cells for commercial applications.
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Currently, PSCs are the most rapidly developing class, with certified efficiencies rising from 3.8%
in 2009 to 22.1% in 2016.[38, 39]
In inverted planar PSCs, the perovskite layer is surrounded by an electron transporting
layer (ETL) and a hole transporting layer (HTL). The HTL, PEDOT:PSS or NiOx,[227],[270] is
connected to the anode, ITO or FTO, while the ETL is typically a fullerene derivative that is direct
contact with the metal cathode, Al. PC61BM is the most widely used fullerene derivative in
photovoltaic applications, and has become the standard in the field, due to its efficient electron
transporting and solution processable properties.[41, 208]
In 2013, Jeng and co-workers reported a PCE of 3.9% for inverted planar PSCs using
PC61BM as the ETM. The reasonable efficiency of this type of devices demonstrated that fullerene
derivatives were promising ETMs in PSCs.[160] Recently, Nie and Im’s group reported a device
with an efficiency of 18% by developing a new perovskite deposition technique.[168, 259] Huang’s
group recently obtained a remarkable efficiency, as high as 19.4%, which is comparable to those
of mesoporous perovskite solar cells, by means of a simple solvent annealing process to improve
the surface of the perovskite, resulting in a better electron extraction into the fullerene layer.[260]
To explore the effect of functional groups on the performance of fullerene-based PSCs,
double fullerene layers or fullerene derivatives with different functional groups have been
studied.[43, 45, 162, 164, 169, 170, 180, 199] However, up to now, all of the fullerene derivatives reported in
PSCs are monomeric derivatives and to the best of our knowledge, dimeric fullerene derivatives
as ETMs in PSCs have never been explored. There is a limited number of dimeric fullerene
derivatives that were investigated in polymer solar cells.[213, 214] Due to the excellent performance
of PC61BM-based PSCs,[271] a dimeric fullerene with two PC61BM units was expected to show
improved performance in PSCs.
Herein, we report the synthesis, characterization and photovoltaic properties of a fullerene
dimer derivative (D-C60), the structure of which is shown in Scheme 1. Due to suitable energy
levels and adequate electron mobility of D-C60, the best efficiency obtained from a device based
on this compound was 16.6%. This value was higher than that for the analogous PC61BM based
88

PSCs, 14.7%. Meanwhile, the higher hydrophobicity of D-C60 compared to that of PC61BM
resulted in better device stability.
6.2

EXPERIMENTAL AND METHODS

6.2.1 Materials and synthesis
[6,6]-phenyl-C61-butyric acid (PC61BA) was synthesized by following previously reported
procedures.[261] The synthetic procedure followed to prepare (D-C60) is presented in Scheme 1.
EDC (25.6 mg, 0.13 mmol) was added slowly to a pre-cooled solution of 2,2-diethyl-1,3propanediol (6.6 mg, 0.05 mmol), PC61BA (100.0 mg, 0.11 mmol), and a small amount of DMAP
in 40 mL of dry dichloromethane. The mixture was stirred for 36 h at room temperature. After
drying under vacuum, the residual mixture was purified by silica gel column chromatography
(toluene as eluent). D-C60 was precipitated from methanol as a dark-brown solid. 1H NMR (CDCl3,
400 MHz) (Figure 6.6): δ (ppm) 0.88 (6H, t, J=5.16 Hz), 1.42 (4H, m), 2.19 (4H, m), 2.53 (4H, t,
J=7.52 Hz), 2.91 (4H, m),3.68 (4H, s), 7.47 (2H, t, J=7.32 Hz), 7.55 (4H, t, J=7.46 Hz), 7.93 (4H,
d, J=7.52 Hz). 13C NMR (CDCl3, 100 MHz) (Figure 6.7): δ (ppm) 173.48, 148.80, 147.81, 145.85,
145.19, 145.15, 145.08, 145.03, 144.79, 144.66, 144.50, 144.42, 144.01, 143.76, 143.12, 143.03,
142.99, 142.93, 142.23, 142.18, 142.13, 142.11, 140.99, 140.75, 138.03, 137.57, 136.73, 132.09,
128.44, 128.24, 79.86, 51.85, 51.68, 33.88, 33.67, 29.70, 22.37. MALDI-TOF-MS m/z: calcd
1888.3, found 1888.6.
6.2.2 Device fabrication
Methylammonium iodide (CH3NH3I) was prepared using a previously reported
procedure.[272] PSCs with a configuration of FTO/PEDOT:PSS/CH3NH3PbI3/PC61BM (or DC60)/Al were fabricated on FTO-coated glass substrates with a resistivity of 10 Ω/cm2. The
patterned FTO glass substrates were cleaned sequentially with detergent, deionized water, and
ethanol, each step for 15 min dried with nitrogen gas and finally treated in a UV-ozone oven for
20 min. After passing through a 0.45 μm PVDF filter, the PEDOT:PSS solution (Baytron P VP AI
4083) was spin-coated onto the treated FTO substrates at 5000 rpm for 30 s, and heated at 150 oC
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for 15 min in air. Then a solution of 1 M PbI2 in DMF was spin-coated at 3000 rpm for 30 s on top
of the PEDOT:PSS coated substrates, and dried on a hot plate at 70 oC for 10 min. The
FTO/PEDOT:PSS/PbI2 substrates were then transferred to a vacuum oven to be converted to
CH3NH3PbI3 by means of a vapor-assisted gas–solid crystallization process following previously
reported methods.[162,

273]

After the CH3NH3PbI3 films were formed and then cooled to room

temperature, 2 wt% PC61BM (or D-C60) dissolved in chlorobenzene was spin-coated onto the
CH3NH3PbI3 layer at 1200 rpm for 30 s. To complete the devices, Aluminum electrodes (100 nm)
were deposited by thermal evaporation under a pressure of 2×10-6 Torr through a shadow mask.
The active area of the devices was determined by a mask with an aperture in the middle (7 mm2).
6.3

RESULTS AND DISCUSSION
The synthetic approach to prepare D-C60 is presented in Scheme 5.1. In this approach the

two fullerenes are linked by an alkyl bridge between the ester functional groups on the PC 61BMs.
D-C60 exhibits a slightly higher lowest unoccupied molecular orbital (LUMO) energy level than
the mono-adduct fullerene derivatives,[271] making it a good candidate to act as the ETM in PSCs.
2,2-diethyl-1,3-propanediol was used to connect the two PC61BM units in order to increase the
solubility of the dimer and to result in a homogeneous and compact film, with high hydrophobicity
to improve water inclusion and enhance the device stability.
PC61BM (99%) was bought from Nano-C. PC61BA was synthesized heating PC61BM and
hydrochloric acid under reflux in toluene for 12 h. D-C60 was obtained from the reaction of PC61BA
with 2,2-diethyl-1,3-propanediol in anhydrous dichloromethane. The final product was
characterized by MALDI-TOF mass spectrometry, 1H and 13C NMR (see supporting information).
Due to the flexible connecting group, D-C60 exhibits excellent solubility in normal organic solvents
such as dichloromethane, chloroform, and chlorobenzene, which makes it suitable for solutionprocessed PSCs.
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Scheme 6.1 The synthetic route for the synthesis of D-C60.
The energy levels of fullerene derivatives are important to assess their electron extraction
and hole blocking properties in PSCs. The electrochemical properties of PC61BM and D-C60 were
studied via cyclic voltammetry (CV) in the range of 0 to -2.0 V vs. Fc/Fc+. Both exhibit three
independent well-defined reversible reduction waves (see Figure 6.1a and Figure 6.8). The halfwave potentials for the reduction processes are listed in Table 6.3. The LUMO energy levels of
𝑜𝑛
the compounds were calculated from their onset reduction potentials (𝐸𝑟𝑒𝑑
) using the equation;
𝑜𝑛
LUMO energy level = -e (𝐸𝑟𝑒𝑑
+ 4.80) (eV).[265] These values are listed in Table 6.1. The LUMO

energy levels were estimated at -3.88 and -3.90 eV for D-C60 and PC61BM respectively, which are
similar to previous reports.[214] These values indicate that both compounds can be used as efficient
ETMs in PSCs.
Based on their maximum absorption onsets, as shown in Figure 6.1b and Table 6.1, and
the values of the LUMO energy levels, D-C60 and PC61BM were estimated to have HOMO values
of -5.61 and -5.63 eV, respectively, deep enough to block holes.
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Figure 6.1 a) Cyclic voltammetric scans for D-C60 and PC61BM at a scan rate of 100 mV/s. b)
UV-Vis absorption spectra of D-C60 and PC61BM in toluene solution.
Table 6.1 Electrochemical and photo-physical data of D-C60 and PC61BM

Compound

λabs (nm)

Eg (eV)

𝐨𝐧
𝐄𝐫𝐞𝐝
(V)

LUMO (eV)

HOMO (eV)

D-C60

717

1.73

0.92

-3.88

-5.61

PC61BM

718

1.73

0.90

-3.90

-5.63

For PSC devices, photovoltaic performance is heavily influenced by the carrier mobilities
of the charge transporting layers. High electron mobility of the fullerene derivatives improves the
short-circuit current density (Jsc) and thus the PCEs. The electron mobility of D-C60 and PC61BM
were measured by the space-charge limited current (SCLC) method (Figure 6.9) and the Mott–
Gurney law,[266] based on electron-only devices with the structure ITO/Cs2CO3/fullerene
derivative/Ca/Al, and found to be 9.83×10-4 and 6.85×10-4 cm2 V-1 s-1, respectively. The higher
electron mobility of D-C60 suggests that the fullerene cages are better packed for D-C60 than for
PC61BM. The higher electron mobility of D-C60 leads to a higher short-circuit current density and
PCE than that of PC61BM-based PSC devices.
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To test the performance of D-C60 as the ETM in PSCs, planar structure devices were
prepared, as shown in Figure 6.2a, with a configuration: FTO/PEDOT:PSS/CH3NH3PbI3/PC61BM
(or D-C60)/Al. The energy-level alignment of all materials involved in the device is shown in
Figure 6.2b. The perovskite layer of the device was prepared by a vapor-assisted gas–solid
crystallization process, previous reported.[272] After this process, the perovskite layer on
PEDOT:PSS, as shown in Figure 6.2c, exhibits homogeneous and well packed grains with no
pinholes. As shown in the cross-section of the device (Figure 6.2d), excellent contact results
between the perovskite and the fullerene layers. The thickness of each layer was measured using
a profilometer, showing that the PEDOT:PSS layer, perovskite layer and fullerene derivative layer
are around 40 nm, 350 nm and 60 nm, respectively.

Figure 6.2 (a) Configuration scheme of the inverted structure planar perovskite solar cells, (b)
Energy level diagram of the materials used in PSCs, (c) Top-view SEM image of
the perovskite film, and (d) Cross-sectional SEM image of the device
FTO/PEDOT:PSS/perovskite/fullerene derivative film.
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The current-voltage (J-V) curves of PSCs with PC61BM and D-C60 as the ETMs were
obtained under AM 1.5G irradiation (100 mW cm-2) in air. The J-V curves of the devices are shown
in Figure 6.3a and the key photovoltaic performance parameters Voc, Jsc, FF, and PCE are listed
in Table 6.2. The most efficient device using D-C60 as ETM yielded a PCE of 16.6%. The
efficiencies are significantly higher than those of devices based on PC61BM as ETM, which
resulted in an optimal PCE of 14.7%.
In order to better compare the device performances, a statistical histogram of the
efficiencies of 20 individual devices using PC61BM and D-C60 as the ETMs are shown in Figure
6.3c. The average efficiencies for D-C60 and PC61BM based devices are 16.1±0.5% and
13.9±0.7%, respectively. The narrower distribution of the key photovoltaic parameters illustrate
that D-C60 is an excellent ETM for inverted planar structure PSCs.
The higher Jsc values of the D-C60 based devices were verified by the incident photon-toelectron conversion efficiency (IPCE) spectrum, as shown in Figure 6.3b. The integrated current
densities from the IPCE curve for devices involving D-C60 and PC61BM as the ETMs are 21.5 and
20.4 mA cm-2, respectively, which are consistent with the values from the J-V curves. Furthermore,
the higher Jsc and FF of D-C60 based devices can be related to the higher electron mobility and
electron extraction ability.
The maximal steady-state power and photocurrent outputs were used to further verify
device efficiencies. As shown in Figure 6.3d, D-C60 based devices resulting in 20.1 mA cm-2 at
0.82 V had PCEs of 16.5%. PC61BM based devices resulting in 18.2 mA cm-2 at 0.80 V, had PCEs
of 14.5% (Figure 6.10). Both efficiencies are very similar to the values determined from the J-V
data.
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Figure 6.3 Device performance and reproducibility of perovskite solar cells fabricated by using
D-C60 and PC61BM as ETMs. a) J-V curves of devices using D-C60 and PC61BM.
(b) EQE spectra for perovskite solar cells fabricated by using D-C60 and PC61BM as
ETMs. (c) Histograms of device PCE measured for 20 individual devices based on
PC61BM and D-C60 ETMs. d) Maximal steady-state photocurrent output at the
maximum power point for D-C60 based device at 0.82 V and its corresponding
power output.
Table 6.2 Summary of device performance analysis in Figure 6.3. The calculated Jsc values are
obtained from the EQE curves.

Type

Voc (V)

Jsc
(mA/cm2)

Calculated Jsc
(mA/cm2)

FF (%)

PCE (%)

PC61BM

0.94

20.96

20.4

74.4

14.7

D-C60

0.96

21.89

21.5

78.8

16.6
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It is worth noting that the D-C60 based devices exhibited a slightly higher Voc than those of
PC61BM based devices, which can be reasonably attributed to the slightly higher LUMO energy
level of D-C60,[274] higher charge mobility and shorter charge carrier lifetimes and recombination
rates.[275] The hysteresis effects of the devices were also studied. As shown in Figure 6.11, no
obvious J-V curve differences were observed, regardless of the scan direction for the D-C60 based
devices. The negligible hysteresis effect in the PSCs with D-C60 as the ETMs further indicate that
the fullerene derivatives effectively passivate the charge traps at the fullerene/perovskite
interface.[173, 201]
To investigate the recombination losses, steady state and time-resolved photoluminescence
(PL, TRPL) spectra were recorded. Figure 6.4a shows the steady-state PL spectra of perovskite,
perovskite/PC61BM and perovskite/D-C60 thin film substrates. When the perovskite layer forms a
contact with PC61BM or D-C60, a significant PL quenching effect was observed. Notably, devices
based on D-C60 show more efficient PL quenching than those based on PC61BM, which indicates
that D-C60 more efficiently inhibits electron-hole recombination.[257] Additionally, TRPL, was
measured by monitoring the emission peak of the perovskite layer as a function of time as shown
in Figure 6.4b. Perovskite/D-C60 devices exhibit a shorter PL decay time (11.1 ns) than that
observed for the perovskite/PC61BM (14.0 ns) devices, which implies that electrons are more
efficiently transferred to D-C60 than to PC61BM. The faster decay is the result of PL quenching
due to electron transfer at the interface, which suppresses electron-hole recombination and
increases the Jsc and FF of the device.[152]
To probe charge transfer processes at the perovskite/D-C60 interface, electrical impedance
spectroscopy

(EIS)

measurements

were

conducted

for

both

perovskite/D-C60

and

perovskite/PC61BM devices. The data were fit to a relatively simple equivalent circuit (Figure
6.12)

consisting

of

a

contact

resistance

between

the

fullerene/perovskite

or

perovskite/PEDOT:PSS interface and the recombination resistance (Rrec). The Nyquist plots for
the perovskite/D-C60 devices show lower contact resistances and larger recombination resistances
than those for perovskite/PC61BM devices, thus D-C60 can decrease charge recombination more
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efficient than PC61BM at the fullerene/perovskite interface and electron extraction into the ETL is
facilitated with D-C60. This must be associated with the differences of charge recombination
efficiencies

at

the

perovskite/D-C60

or

perovskite/PC61BM

interface

since

the

PEDOT:PSS/perovskite interface is identical for both cases.[248] This result is totally consistent
with the higher PL quenching observed for perovskite/D-C60 devices.

Figure 6.4 (a) steady-state photoluminescence spectra, and (b) TRPL decay transient spectra of
FTO/perovskite/PC61BM and FTO/perovskite/D-C60.
Assessment of the stability of devices with D-C60 and PC61BM as the ETMs was conducted
under a 50% humidity in air at room temperature without encapsulation. As shown in Figure 6.5b,
the devices with D-C60 retained more than 75% of its original performance after 10 days, while
devices with PC61BM as the ETM retained only 25% after 10 days. The higher stability of the DC60-based devices may result from the higher hydrophobicity of D-C60 as well as the more compact
self-assembled layer. As shown in Figure 6.5a, the hydrophobic properties of the different
fullerene derivatives were investigated. Water droplets on perovskite/PC61BM and perovskite/DC60 layers result in contact angles of 82° and 96°, respectively. These values indicate that the two
C60 subunits in D-C60 make the fullerene derivative more hydrophobic than PC61BM.
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Figure 6.5 (a) The images of the water droplet contact angles on different surfaces of fullerene
derivative film. (b) Normalized PCE of perovskite solar cells employing D-C60 and
PC61BM ETMs as a function of storage time in air.
6.4

CONCLUSIONS
In summary, we synthesized a dimeric fullerene derivative D-C60 and applied it as an ETM

for PSCs taking advantage of its appropriate energy levels, relatively fast electron mobility, easy
solution processability and device stability. As evidenced by CV, SCLC, EIS, PL and TRPL
studies, D-C60 can effectively passivate the surface defects of the perovskite film, as well as
efficiently extract and transport electrons. As a result, using D-C60 as ETM, PSC devices reached
up to 16.6%, PCEs, higher than those of PC61BM based devices. Due to its higher hydrophobicity
D-C60, also enhanced the stability of the devices compared to PC61BM. We believe that the
composition and structure of D-C60 is responsible for the improved performance, and dimeric
fullerene derivatives have the potential to become high performance alternatives for ETMs in
PSCs.
6.5

SUPPORTING INFORMATION
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Figure 6.6 1H-NMR (400 MHz; CDCl3, 298 K) of D-C60.

Figure 6.7 13C-NMR (100 MHz; CDCl3, 298 K) of D-C60.
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6.5.1 Electrochemical properties
The electrochemical properties of PC61BM and D-C60 were measured by cyclic voltammetry (CV)
on a glassy carbon electrode with o-dichlorobenzene (o-DCB) as solvent and n-Bu4NPF6 as supporting
electrolyte. The reduction potentials are shown in Table 6.1. The reduction potentials of PC61BM and D-

C60 are similar.

Figure 6.8 Cyclic voltammetric curves of D-C60 at a scan rate of 100 mV/s.

Figure 6.9 Measured space-charge limited J-V characteristics of the PC61BM and D-C60 for
electron-only devices. The devices with a structure of ITO/Cs2CO3/ D-C60
(PC61BM)/Ca/Al were fabricated.
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Figure 6.10 Maximal steady-state photocurrent output at the maximum power point (for PC61BM
based device at 0.80 V, and D-C60 based device at 0.82 V) and their corresponding
power output.

Figure 6.11 J-V curves of the inverted planar perovskite solar cells based on D-C60 and PC61BM
with respect to forward and reverse scan directions (The scanning rate was 100
mV/s).
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Figure 6.12 Nyquist plots of the perovskite solar cells based on PC61BM and D-C60.
Table 6.3 Redox Potentials of PC61BM and D-C60.
E0/-

Compound

PC61BM
D-C60

E-/-2

-1.03
-1.05

-1.41
-1.44

E-2/-3

-1.90
-1.92

Table 6.4 Fitting parameters for EIS data under 1 sun illumination.
Device
PC61BM
D-C60

Rs(Ω)
8.80
8.26

Rco(Ω)
30.43
23.68

Cco(F)
1.959E-8
5.353E-8
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Rrec(Ω)
92.85
146.7

CPEμ-T(F)
0.02028
0.02879

CPEμ-p(F)
0.5734
0.9543

Chapter 7: Improved performance and stability of inverted planar perovskite
solar cells using fulleropyrrolidine layers
Abstract: Inverted planar structure perovskite solar cells (PSCs), due to their low
temperature precessing and lack of hysteretic problems, are attracting increased attention by
researchers around the world. Fullerene derivatives are the most widely used electron transport
materials (ETMs) in inverted planar perovskite solar cells, especially [6,6]-phenyl-C61-butyric acid
methylester (PC61BM), which exhibits very good performance. However, to the best of our
knowledge, the influence of adducts on fullerene-based PSCs performance has not been fully
explored to date.

In this work, two fullerene derivatives, 2,5-(dimethyl ester) C60

fulleropyrrolidine (DMEC60) and the analogous C70 derivative (DMEC70), were synthesized in
high yield via a 1,3-dipolar cycloaddition reaction at room temperature and incorporated into
CH3NH3PbI3 perovskite solar cells as electron transport materials. Possibly because the attached
pyrrolidine ester groups are able to coordinate with the perovskite layer, the devices based on
DMEC60 and DMEC70 achieved power conversion efficiencies (PCE) of 15.2% and 16.4%,
respectively. Not only were both devices’ efficiencies higher than those based on PC 61BM and
PC71BM, but their stabilities were also higher than those for PCBM based devices. The results
suggest that DMEC60 and DMEC70 are better alternatives than PC61BM and PC71BM as the ETMs
in PSCs. Experimental procedures and figures presented here are a pre-peer reviewed version of
the following article (See Appendix B for the copyright letter): Tian, C.; Castro, E.; Wang, T.;
Betancourt-Solis, G.; Rodriguez, G.; Echegoyen, L. ACS Appl. Mater. Interfaces. 2016, 8, 3142631432.
7.1

INTRODUCTION
The unique properties of organic-inorganic hybrid perovskite materials make them

promising candidates for developing next-generation photovoltaic cells for commercial
applications to compete with silicon solar cells.[36, 38, 117, 118, 254] PSCs based on such materials have
shown a remarkable increase from 3.8% in 2009, to 22.1%, in 2016.[38-40, 136, 154, 157, 238, 262, 276, 277]
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In order to meet comercial demand, the inverted planar structure PSCs with the
configuration substrate/PEDOT:PSS/perovskite/fullerene derivative have recently attracted more
attention due to their simple structure, low temperature processing and negligible hysteric
behavior.[209] For the hole transporting material (HTM), besides PEDOT:PSS, NiOx and CuI have
also been reported by some research groups.[121, 136, 160, 227, 278, 279] However, the good electron
transporting and solution processable properties of most fullerene derivatives have made them the
most popular ETMs in PSCs.[208, 209]
In 2013, Guo and co-workers first tried PC61BM as the ETM in inverted planar PSCs, and
obtained a PCE of 3.9%. This result suggested that PC61BM can work as a relatively efficient ETM
in PSCs.[160] In 2014, Lam et al. reported an efficiency of 7.4% for PSCs using PC 61BM as the
ETM after optimizing the conditions for the preparation of the perovskite layers.[280] Nie and Im’s
group, by further optimization of the conditions of perovskite deposition, obtained even higher
PCEs, as high as 18%.[168, 259]
Besides PC61BM, several studies have shown that other fullerene derivatives or unique
double fullerene layers, can also work as efficient ETLs in PSCs. Wu and co-workers reported a
device with a PCE of 16.3% by employing PC71BM as the ETM, in which a solvent annealing
procedure was utilized.[42] In order to further opitimize the PSCs’ performance, Jen’s and Huang’s
groups, among others, have reported using different double fullerene layers (consisting of
PC61BM/C60, ICBA/C60, C60/bis-C60 etc.) as the interface layer to get high effiencies.[44, 45, 121, 180,
209, 221, 260, 281]

Meanwhile, conjugated polymer electrolytes and inorganic oxide materials have also

been developed as efficient interfacial materials with a PC61BM layer by Snaith and others.[181, 227,
282-284]

These results demonstrate that fullerenes or fullerene derivatives are excellent ETMs for

high performance PSCs. However, the influence of the functional groups on the fullerene-based
PSCs has not been systematically probed.[44, 221] Therefore, designing novel structures of fullerene
derivatives to probe the fundamental principles that underlie their structure–perovskite
performance are of utmost importance.
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Here, we report the design and synthesis of two pyrrolidine ester functionalized fullerene
derivatives, DMEC60 and DMEC70, and their performance as the ETMs in PSCs. The best
efficiencies obtained for the devices based on DMEC60 and DMEC70 were found to be 15.2% and
16.5%, respectively. These values were higher than those obtained for the corresponding PC61BM
and PC71BM based PSCs, 14.5% and 15.0%, respectively. We propose that specific binding of
these fullerene derivatives with the perovskite layer surface can not only effectively enhance the
electron extraction efficiency, they can also increase the stability of the corresponding devices.
7.2

EXPERIMENTAL AND METHODS

7.2.1 Materials and synthesis
DMEC60 was synthesized following a reported procedure,[285] and DMEC70 was
synthesized following the same procedure (Scheme 7.1). The 1H NMR of DMEC70 shows signals
for the amino group at 3.55, 3.44, and 3.23 ppm, which indicates the presence of three isomers.
The ratio of the mono-adducts in the mixture was 82:9:9 (endoexo), respectively as determined
by 1H NMR (Figure 7.11), and the molecular mass was determined by matrix assisted laser
desorption/ionization-time-of-flight-mass spectrometry (MALDI-TOF-MS) (Figure 7.10).
7.2.2 Device fabrication
PC61BM (99%) and PC71BM (99%) were brought from Nano-C. The purity of DMEC60
and DMEC70 was determined using NMR (>99%). Methylammonium iodide (CH3NH3I) was
synthesized using a previously reported method.[262] Perovskite solar cells with the configuration
FTO/PEDOT:PSS (40 nm)/CH3NH3PbI3 (330 nm)/PC61BM (PC71BM, DMEC60 or DMEC70
fullerene derivatives) (100 nm)/LiF (0.5 nm)/Al (100 nm) were fabricated on FTO-coated glass
substrates with a resistivity of 10 Ω/cm2. Prior to fabrication, the patterned FTO glass substrates
were cleaned sequentially with detergent, deionized water, acetone, and isopropanol 10 min for
each step. Then the FTO glass substrates were dried with nitrogen gas and treated in a UV-ozone
oven for 30 min. After passing through a 0.45 μm PVDF filter, the PEDOT:PSS solution (Baytron
P VP AI 4083) was spin-coated onto the cleaned FTO substrates at 5000 rpm for 30 s, and baked
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at 150 ℃ for15 min in air. Then a solution of 1 M PbI2 in DMF was spin-coated at 3000 rpm for
30 s on top of the prepared substrates, and dried on a hot plate at 70 ℃ for 10 min. Then the
FTO/PEDOT:PSS/PbI2 substrates were transferred into a vacuum oven to be converted to
CH3NH3PbI3 by a vapor-assisted gas–solid crystallization process following previously reported
methods.20,44 After the CH3NH3PbI3 films were formed and then cooled to room temperature, 2
wt% PC61BM (PC71BM, DMEC60 or DMEC70) dissolved in chlorobenzene was spin-coated onto
the CH3NH3PbI3 layer at 1200 rpm for 30 s. To complete the devices, LiF (0.5 nm) and Al electrode
(100 nm) were deposited by thermal evaporation under a pressure of 2×10ˉ6 Torr through a shadow
mask. The active area of the devices was 7 mm2.
7.3

RESULTS AND DISCUSSION
The synthetic method followed to prepare DMEC60 and DMEC70 is presented in Scheme

7.1. These two fullerene derivatives were synthesized by a 1,3-dipolar cycloaddition reaction using
a modified procedure from previous work.[285] Detailed synthetic procedures and charaterizations
are described in the Experimental Section and the Supporting Information (SI). The two ester
groups enhance the solubility of the fullerene derivatives and improve solution processing during
device fabrication.
In order to assess the potential implementation of DMEC60 and DMEC70 as the ETMs for
PCSs, the electrochemical and optical properties of DMEC60 and DMEC70 were analyzed by cyclic
voltammetry (CV) and UV/vis absorption spectroscopy. As shown in Figure 7.1a, both of the
compounds exhibit three reversible reduction waves in the potential range between 0 and -2.0 V
vs. Fc/Fc+. The energy of the lowest unoccupied molecular orbital (LUMO) level was estimated
𝑜𝑛
𝑜𝑛
from their onset reduction potentials ( 𝐸𝑟𝑒𝑑
) and the equation: LUMO energy = -e (𝐸𝑟𝑒𝑑
+ 4.80)

(eV),[265] and the values are listed in Table 7.1. The LUMO energy levels were estimated at -3.91
eV and -3.90 eV, respectively, which are identical to that of PC61BM and PC71BM (-3.91 eV).[261]
In agreement with previous literature and our experimental data,[121, 286, 287] the LUMO energy
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levels of DMEC60 and DMEC70 suggest that both compounds could serve as effective ETMs in
PSCs.

Scheme 7.1 Synthesis of DMEC60 and DMEC70.
The absorption spectra of DMEC60 and DMEC70 in toluene solution at room temperature
are shown in Figure 7.1b. Both exhibit strong UV absorption from 300 to 400 nm. The absorptions
of DMEC60 and PC61BM are very similar over the whole region. The absorptions of DMEC70 are
much stronger than that of DMEC60 due to the extended conjugated structure. From the absorption
onset of DMEC60 and DMEC70, we can readily obtain the band gap for them. Combined with the
electrochemical results, they allow the determination of the HOMO energy levels of these two
compounds (Table 7.1).
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Figure 7.1 a) Cyclic voltammetric results for DMEC60 and DMEC70 at a scan rate of 100 mV/s.
b) UV-Vis absorption spectra of DMEC60 and DMEC70 in toluene solution.
Table 7.1 Electrochemical and photophysical data of DMEC60 and DMEC70.
Compound

λabs (nm)

Eg (eV)

𝑬𝒐𝒏
𝒓𝒆𝒅 (V)

LUMO (eV)

HOMO (eV)

DMEC60

714

1.74

-0.89

-3.89

-5.63

DMEC70

683

1.81

-0.90

-3.90

-5.71

The electron mobility of DMEC60 and DMEC70 based on electron-only devices was
evaluated by the space-charge limited current (SCLC) method and the Mott–Gurney law,[266] as
shown in Figure 7.14. Using this method, values of 7.21×10-4 and 9.07×10-4 cm2 V-1 s-1 were
obtained for DMEC60 and DMEC70, respectively, which are very close to the values from PC61BM
and PC71BM (6.85×10-4 cm2 V-1 s-1 and 9.19×10-4 cm2 V-1 s-1, respectively). Based on these relative
values, both DMEC60 and DMEC70 are good candidates for ETMs.[179, 288]
To evaluate the performance of DMEC60 and DMEC70 as the ETM in PSCs, devices with
a

configuration:

FTO/PEDOT:PSS/CH3NH3PbI3/PC61BM

(PC71BM,

DMEC60

or

DMEC70)/LiF/Al were fabricated. From the values in Table 7.1 and from previous reports, the
energy-level alignment is shown in Figure 7.2a. Since the LUMO energy level of CH3NH3PbI3 is
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-3.9 eV, the values are sufficient for electron extraction from the perovskite to the fullerene
derivative layer.

Figure 7.2 (a) Energy level diagram of the materials used in the PSCs, (b) Top-view SEM image
of the perovskite film, and (c) Cross-sectional SEM image of the device
FTO/PEDOT:PSS/perovskite/fullerene derivative film.
The device preparation process was similar to that reported in previous reports.[138, 279] The
morphology of the perovskite layer was studied by scanning electron microscopy (SEM). As
shown in Figure 7.2b, the perovskite films, which were formed on the PEDOT:PSS layers exhibit
full surface coverage and uniform microscale grain structure with no pinholes.
Additionally, the cross-section shown in Figure 7.2c allows the clear observation of all of
the layers. An extremely uniform and thick perovskite layer (ca. 330 nm) was obtained on the
PEDOT:PSS layer. The results from Figure 7.2b and Figure 7.2c clearly show that the microscale
and homogeneous grains of the perovskite layer should allow very good contact with the ETM
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layer, thus efficiently decreasing the grain boundary energy. This suggests that the perovskite films
prepared using this procedure should lead to high efficiency PSCs. The perovskite layer was also
analyzed by X-ray diffraction (XRD). As shown in Figure 7.15, the diffraction peaks were located
at 2θ values of 14.19, 20.09, 23.57, 24.56, 28.49, 31.95, 35.19, 40.69, and 50.29, corresponding to
planes (110), (112), (211), (202), (220), (310), (312), (224) and (404) of the perovskite tetragonal
structure,[154, 156, 289] which indicates that the PbI2 layer was fully converted into the perovskite
layer.
The current-voltage (J–V) characteristics of PSCs using PC61BM, PC71BM, DMEC60 and
DMEC70 as the ETMs were tested under AM 1.5G irradiation (100 mW cm-2). The best
performances of the cells are shown in Figure 7.3 and the key photovoltaic performance
parameters of Voc, Jsc, FF, and PCE of the devices are listed in Table 7.2. The best devices
employing DMEC60 and DMEC70 as ETMs resulted in PCEs of 15.2% and 16.4%, respectively.
The efficiencies are not only significantly higher than that of the devices with PC61BM as ETM,
which yielded a PCE of 14.5% under the same conditions, but also higher than that of PC71BM
based devices (15.1%).

Figure 7.3 J-V curves for perovskite solar cells fabricated by using DMEC60 and DMEC70 as
ETMs, and reference cells with PC61BM and PC71BM ETMs.
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Table 7.2 Summary of the device performance analysis in Figure 7.3. The calculated Jsc values
are obtained from the EQE results.

Type

Voc (V)

Jsc
(mA/cm2)

Calculated Jsc
(mA/cm2)

FF (%)

PCE (%)

PC61BM

0.91

20.92

20.1

76.0

14.5

PC71BM

0.95

21.03

20.3

75.5

15.1

DMEC60

0.92

21.73

20.5

75.8

15.2

DMEC70

0.95

22.44

21.3

77.1

16.4

As shown in Figure 7.4, a histogram of the PCEs of 30 individual devices based on
PC61BM, PC71BM, DMEC60 and DMEC70 as the ETLs are presented with average efficiencies of
13.5±0.9%, 14.0±1.2%, 14.1±1.1% and 15.2±1.2%, respectively. The statistical diagram of the
values of Jsc, Voc and FF for the devices with different fullerene derivatives is shown in Figure
7.16 and the average of these values is presented in Table 7.2.
Compared with the PC61BM- and DMEC60-based devices, the PC71BM- and DMEC70based devices displayed a slightly higher Voc. Based on previous reports, the higher Voc could be
attributed to the higher electron mobility of PC71BM and DMEC70 compared with those of
PC61BM or DMEC60, since the high electron mobility can effectively reduce charge recombination
at the perovskite/fullerene interface and minimize potential losses across this interface.[44]
In addition, the Jsc data of the devices involving DMEC60 and DMEC70 (21.73 and 22.44
mA cm-2 for DMEC60 and DMEC70, respectively) are higher than those of PC61BM (20.92 mA cm2

) and PC71BM (21.03 mA cm-2). The Jsc of PC61BM-, PC71BM-, DMEC60-, and DMEC70-based

devices can be verified by their external quantum efficiency (EQE) spectra. As shown in Figure
7.17, the EQE spectra of perovskite solar cells using PC61BM, PC71BM, DMEC60 or DMEC70 as
the ETMs were measured by IPCE measurements. The integrated current densities from the EQE
spectra for devices using PC61BM, PC71BM, DMEC60 and DMEC70 as ETMs are 20.1, 20.3, 20.5,
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and 21.3 mA cm-2, respectively, which is in accordance with the corresponding Jsc values obtained
from the J-V curves, with differences within 5%.

Figure 7.4 Histograms of device PCE measured for 30 individual devices based on PC61BM,
PC71BM, DMEC60 and DMEC70 ETMs.
In view of the very similar film quality of the perovskite layers for all fullerene ETMs, we
speculate that the increase in Jsc could be due to two possible reasons.
According to previous reports,[290] the ETM in PSCs usually plays two roles: to extract
electrons from the perovskite and to transport electrons to the cathode. As discussed above,
DMEC60 and DMEC70 have similar electron transporting abilities to those of PC61BM and
PC71BM, thus they can efficiently transfer electrons from the perovskite to the corresponding
electrode.
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As described in previous reports, lead atoms can not only readily coordinate with ligands
through lead-oxygen interactions to form lead complexes,[291-293] they can also coordinate with the
solvent (especially DMF and DMSO) through lead-oxygen interaction.[294, 295] In order to probe
the specific interfacial interactions between the perovskite and the fullerene layers, Fourier
Transform Infrared (FTIR) spectra of the films of different components were recorded. The FTIR
spectra of PC61BM, PC71BM, DMEC60, DMEC70, PC61BM/perovskite, DMEC60/perovskite,
PC71BM/perovskite, and DMEC70/perovskite are shown in Figure 7.18-7.20. The stretching C=O
vibrations appear at 1736 cm−1, 1749 cm−1, 1736 cm−1 and 1744 cm−1 for the pure PC61BM,
DMEC60, PC71BM and DMEC70, respectively, and these are shifted to 1732 cm−1, 1741 cm−1, 1733
cm−1 and 1738 cm−1 for the corresponding perovskite composite. These shifts are attributed to the
decrease in bond strength for C=O upon interfacial complexation. The stretching N-H vibrations
appear at 3295 cm−1 and 3293 cm−1 for the DMEC60 and DMEC70 films, respectively, and these
are not observed after combining the compounds with the perovskite layers as DMEC60/perovskite
and DMEC70/perovskite. Since similar phenomena have also been reported in previous articles,[296,
297]

we propose that the C=O peak shifts and N-H vibration disappearances can be attributed to

specific interactions between the oxygen and nitrogen atoms on the fullerene derivatives with the
lead atoms in the perovskites. These interfacial interactions between DMEC60 (or DMEC70) and
the perovskite layers may effectively reduce charge recombination at the DMEC 60 (or
DMEC70)/perovskite interfaces and increase the electron extraction efficiencies from the
perovskite to the fullerene layers.
In order to further probe the electron transporting property of DMEC60 and DMEC70 as
ETMs, time-resolved photoluminescence (TRPL) spectra were measured. As shown in Figure 7.5,
the films with perovskite/DMEC60 (or DMEC70) displayed shorter photoluminescence decay times
of 6.3 ns (or 6.1 ns) compared to those of PC61BM (8.5 ns) or PC71BM (7.8 ns). This shorter
photoluminescence decay time indicates that employing DMEC60 or DMEC70 as ETMs can
enhance the electron extraction efficiency from the perovskite layer to the DMEC60 (or DMEC70)
layer, thus leading to improved Jsc in DMEC60- and DMEC70-based PSCs.
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Since the observation of hysteretic behavior in PSCs has become an important issue, 57 the
hysteresis effects of the devices were measured. As shown in Figure 7.21, all the devices displayed
relatively consistent J-V curves regardless of the scan direction, indicating a negligible hysteresis
effect in the PSCs with PC61BM, PC71BM, DMEC60 or DMEC70 as the ETMs. The results also
indicate that the fullerene derivatives effectively reduce the charge traps at the fullerene/perovskite
interface, which is consistent with previous reports.[173, 201]

Figure 7.5 TRPL decay transient spectra of FTO/perovskite/PC61BM, FTO/perovskite/PC71BM,
FTO/perovskite/DMEC60 and FTO/perovskite/DMEC70.
Meanwhile, in order to avoid overestimation of device efficiencies, the maximal steadystate power and photocurrent output were tested (Figure 7.22). DMEC70 and PC71BM based cells
lead to 20.6 mA cm-2 and 19.0 mA cm-2 at 0.79 V, respectively, corresponding to PCEs of 16.3%
and 15.0%. DMEC60 and PC61BM based cells lead to 19.6 mA cm-2 and 18.6 mA cm-2 at 0.77 V,
respectively, corresponding to PCEs of 15.1% and 14.3%. Which are very close to the values
determined from the J-V curves.
The stability of the devices with DMEC60 and DMEC70 as the ETMs were tested under AM
1.5 illumination in air. Since the LiF/Al electrode can be corroded upon air exposure and thereby
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potentially affect the device stability, the devices were encapsulated by mounting a glass sheet on
top. As illustrated in Figure 7.6, the devices with PC61BM and PC71BM as the ETM lost ca. 60%
of their performance after 10 days, while the devices with DMEC60 and DMEC70 kept more than
80% of their original performance. As shown in Figure 7.23, water droplets on
perovskite/PC61BM, perovskite/PC71BM, perovskite/DMEC60, and perovskite/DMEC70 exhibit
contact angles of 83°, 85°, 85° and 86°, respectively. These values show the wetting capability of
the different substrate surfaces to water, and it appears that the pyrrolidine group on DMEC60 and
DMEC70 make them slightly more hydrophobic than PCBMs. Another possible reason for the
higher stability of the DMEC60- or DMEC70-based devices could be the result of the stronger
adhesion and enhanced interfacial coupling between DMEC60 (or DMEC70) and the perovskite,
preventing the Al from rapidly diffusing across the DMEC60 (DMEC70) layer into the perovskite
layer. This phenomenon has been observed for devices employing a spiro-MeOTAD HTM and a
Au or Ag back contact.[298] These results also highlight the importance of the structure and
composition of the attached group on the fullerene cage.

Figure 7.6 Normalized PCE of perovskite solar cells employing PC61BM, PC71BM, DMEC60 and
DMEC70 ETMs as a function of storage time in air.
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7.4

CONCLUSIONS
In conclusion, we designed and synthesized two ester based fulleropyrrolidine derivatives,

DMEC60 and DMEC70, as ETMs for PSCs. The devices based on DMEC60 and DMEC70 as ETMs
yield PCEs up to 15.2% and 16.4%, respectively, which are higher than those measured for devices
based on PC61BM (14.5%) and PC71BM (15.1%). The higher performance of the devices with
DMEC60 and DMEC70 as the ETMs can not only be attributed to the suitable LUMO energy level
and electron mobility, but also to the ability to extract electrons efficiently, likely the result of
specific interactions between the attached groups on the fullerene derivatives and the perovskite
layers. The stability of the devices was improved when using DMEC60 and DMEC70 as the ETMs.
DMEC60 and DMEC70 are also convenient due to their much easier synthesis and higher yield than
those of PC61BM and PC71BM. Therefore, these fullerene derivatives have the potential to become
highly desirable alternatives in perovskite solar cells.
7.5

SUPPORTING INFORMATION

7.5.1 Synthesis of DMEC60
C60 (72 mg, 0.10 mmol) were dissolved in chlorobenzene (20 mL) under sonication for 5
min, then DIB (200 mg, 0.62 mmol), glycine methyl ester hydrochloride (100 mg, 0.79 mmol) and
sodium carbonate decahydrate (100 mg, 0.35 mmol) were added. The flask was wrapped with
aluminum foil and sonicated for 30 min. The solution was directly poured onto a silica gel column
and CS2 was used to separate the non-reacted C60, and DMEC60 was the purified using a
toluene/ethyl acetate (9:1) mixture. Yield 81%.

116

Figure 7.7 MALDI-TOF-MS spectrum of DMEC60 using 1,8,9-trihydroxyanthracene (THA) as
matrix.

Figure 7.8 1H-NMR (600 MHz; CDCl3, 298 K) of DMEC60.
1

H NMR (600 MHz; CDCl3, 298 K) δ(ppm) 5.53 (d, J = 13.7 Hz, 2H), 4.50 (t, J = 13.7 Hz,

1H), 3.88 (s, 3H).
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Figure 7.9 13C-NMR (150 MHz; CDCl3, 298 K) of DMEC60.
13

C NMR (150 MHz; CDCl3, 298 K) δ (ppm) 169.2, 152.2, 149.8, 147.2, 146.4, 146.3,

146.2, 146.1 (X 2), 145.5, 145.5 (X 2), 145.4, 145.3, 145.0, 144.4, 144.3, 142.8, 142.8, 142.3,
142.2, 142.1, 142.0, 141.8, 140.0, 139.9, 136.8, 135.6, 130.6, 127.7, 77.2, 73.9, 53.0.
7.5.2 Synthesis of DMEC70
DMEC70 were synthesized following the procedure reported for DMEC60 (Scheme 7.1).
Yield 75%. The 1H NMR of the DMEC70 shows signals for amino group at 3.55, 3.44, and 3.23
ppm, which indicates the presence of three isomers. The ratio of the mono-adducts in the mixture
was 82:9:9 ((endoexo), respectively as determined by 1H NMR (Figure 7.11), and the
molecular mass was determined by matrix assisted laser desorption/ionization-time-of-flight-mass
spectrometry (MALDI-TOF-MS) (Figure 7.10). The 13C NMR of the DMEC70 shows 68 signals
for the carbon cage indicating the chirality of the isomer. We attributed all the 76 signals to the
major isomer, due to the low concentration of the minor isomers, their signals are not visible
(Figure 7.12). The other two compounds can correspond to the isomers in which, the methoxy
group can be cis-endo or cis-exo (Scheme 7.1).
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Figure 7.10 MALDI-TOF-MS spectrum of DMEC70 using 1,8,9-trihydroxyanthracene (THA) as
matrix.

Figure 7.11 1H-NMR (600 MHz; CDCl3, 298 K) of DMEC70.
1

H NMR (600 MHz; CDCl3, 298 K) δ (ppm) 4.89 (d, J = 13.7 Hz, 1.06 H, -CH), 4.84 (d,

J = 13.7 Hz, 0.26 H, -CH), 4.73 (d, J = 13.8 Hz, 1.05 H, -CH), 4.51 (d, J = 13.7 Hz, 0.26 H, CH), 4.20 (s, 3 H, - CH3), 3.94 (s, 0.72 H, -CH3), 3.75 (s, 3 H, -CH3), 3.67 (s, 0.72 H, -CH3),
3.56 (t, J = 13.7 Hz, 0.24 H, -NH), 3.46 (t, J = 13.8 Hz, 1.23 H, -NH), 3.24 (t, J = 13.7 Hz, 0.23
H, -NH).
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Figure 7.12 13C NMR (150 MHz; CDCl3, 298 K) of DMEC70.
13

C NMR (150 MHz; CDCl3, 298 K) δ (ppm) 169.4, 168.9, 158.4, 155.9, 154.7, 153.2,

151.5, 151.5, 151.5, 150.9, 150.9, 150.8, 150.8, 150.8, 150.7, 150.7, 150.6, 150.2, 150.1, 149.9,
149.9, 149.6, 149.4, 149.3, 149.2, 149.1, 149.1, 149.1, 148.8, 148.8, 147.5, 147.5, 147.5, 147.2,
147.1, 147.1, 147.1, 147.0, 146.3, 146.2, 146.1, 146.0, 145.8, 145.8, 143.5, 143.5, 143.4, 143.3,
143.2, 143.2, 142.3, 140.9, 140.5, 140.1, 140.0, 138.1, 137.2, 133.9, 133.7, 133.3, 133.2, 131.6,
131.6, 131.4, 131.3, 131.3, 129.1, 128.3, 125.4, 75.0, 71.5, 70.8, 69.3, 53.4, 52.9.
7.5.3 Electrochemical properties
The electrochemical properties of DMEC60 and DMEC70 were measured by cyclic
voltammetry (CV) on a glassy carbon minielectrode with o-dichlorobenzene (o-DCB) as solvent
and n-Bu4NPF6 as supporting electrolyte. The reduction potentials are shown in Table 7.1. The
reduction potentials of DMEC60 and DMEC70 are similar to the values of PC61BM.
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Figure 7.13 Cyclic voltammetric curves of DMEC60 and DMEC70 at a scan rate of 100 mV/s.
Table 7.3 Redox Potentials of DMEC60 and DMEC70.

Compound

E0/-

E-/-2

E-2/-3

DMEC60

-1.01

-1.38

-1.91

DMEC70

-0.98

-1.35

-1.72
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Figure 7.14 Measured space-charge limited J-V characteristics of the DMEC60 and DMEC70 for
electrononly devices. The devices with a structure of ITO/Cs2CO3/DMEC60
(DMEC70, PC61BM or PC71BM)/Ca/Al were fabricated.
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Figure 7.15 The XRD spectra of the perovskite films.

Figure 7.16 The statistic diagram of the device Jsc, Voc and FF measured for 30 individual
devices based on PC61BM, PC71BM, DMEC60 and DMEC70 ETMs.
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Figure 7.17 EQE spectra for perovskite solar cells fabricated by using DMEC60 and DMEC70 as
ETMs, and cells with PC61BM and PC71BM as ETMs.
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Figure 7.18 Fourier transform infrared (FTIR) spectra of the films with different components.
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Figure 7.19 The FTIR spectra of the films with different components (Expanded the region for
the N-H vibrations).
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Figure 7.20 The FTIR spectra of the films with different components (Expanded the region for
the C=O vibrations).
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Figure 7.21 J-V curves of the inverted planar perovskite solar cells based on DMEC60, DMEC70,
PC61BM and PC71BM with respect to forward and reverse scan directions (The
scanning rate was 100 mV/s).
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Figure 7.22 Maximal steady-state photocurrent output at the maximum power point (for PC61BM
and DMEC60 based device at 0.77 V, and PC71BM and DMEC70 based device at
0.79 V) and their corresponding power output.

Figure 7.23 The images of the water droplet contact angles on different surfaces of fullerene
derivativecoated perovskite.

129

Chapter 8: Impact of fullerene derivative isomeric purity on the performance
of inverted planar perovskite solar cells
Abstract: The effect of utilizing a pure cis--dimethoxy carbonyl fulleropyrrolidine C70
(DMEC70) isomer as the electron transporting material (ETM) in inverted perovskite solar cells
(PSCs) was evaluated. As-prepared C70 mono-adduct products are mixtures of regioisomers and
the interest was to evaluate these independently as ETMs. Three different cis-DMEC70 isomers (,
-endo and -exo) (mix-DMEC70) were synthesized and purified by HPLC. It was found that PSCs
based on the pure -DMEC70 exhibit a substantially enhanced maximum power conversion
efficiency (PCE) of 18.6% as compared to devices based on the mixed-DMEC70 isomers that
yielded PCEs of 16.4%. A maximum PCE of 15.7% was observed for devices based on [6,6]phenyl-C71-butyric acid methyl ester (PC71BM). This work points out the importance of using pure
fullerene derivative isomers as the ETMs to reduce the intrinsic energy disorder, which enhaces
overall device performance. Experimental procedures and figures presented here are a pre-peer
reviewed version of the following article: Castro, E.; Zavala, G.; Seethraraman, S.; D’Souza, F.;
and Echegoyen, L. J. Mater. Chem. A. 2017. 5, 19485. Reproduced by permission of the Royal
Society of Chemistry.
8.1

INTRODUCTION
Organic-inorganic halide PSCs offer great potential for cost-effective, solution-

processable, and large-area fabrication solar energy conversion technologies.[158, 299] PSCs can be
either fabricated using the conventional n-i-p or the inverted p-i-n configurations, and in both cases
the perovskite layer is in contact with a hole transporting layer (HTL) and an electron transporting
layer (ETL) on opposite sides. These selective interlayers not only improve the charge extraction
from the perovskite layer but also determine the polarity of the device.[131, 132] To date, PSCs
present the fastest growth in terms of PCE with certified efficiencies rising from 3.8% in 2009 to
22.1% in 2016 for small-area devices (0.1 cm2),[38, 39] whereas a PCE of 19.6% has been reported
for large-area devices (1 cm2).[111] It is worth mentioning that higher PCEs and long-term device
130

stability have been achieved after the first report of an all solid-state PSCs, introduced by Kim et
al. in 2009.[238]
In inverted PSCs, the HTL, typically PEDOT:PSS, modified PEDOT:PSS, or NiOx,[227, 270,
300-303]

is in contact with the anode (ITO or FTO), while the ETL, typically a fullerene derivative,

is in contact with the back electrode (Al or Ag). The standard fullerenes used in PSCs are the [6,6]phenyl-C61/71-butyric acid methyl esters (PC61/71BM), mainly due to their efficient electron
transporting and solution processable properties.[41,

208]

Inverted PSCs based on ITO/doped-

poly[bis(4-phenyl)(2,4,6-trimethylphenyl)amine](PTAA)/MA0.60FA0.40PI3/PC71BM/C60/2,9dimethyl-4,7-diphenyl-1,10-phenanthroline (BCP)/Ag have achieved a maximum PCE of
20.2%.[304]
Zhu[305] and Huang’s[306] groups have reported that charge trap states at the surfaces and
grain boundaries of perovskite crystals act as non-radiative recombination centers, which
drastically affect the optoelectronic properties of PSCs. Snaith[307] and co-workers proposed that
the non-coordinated halide ions on the surface of the perovskite crystals can be passivated using
iodopentafluorobenzene. The same group separately reported that the crystal surface vacancies can
be significantly passivated using organic Lewis bases such as thiophene and pyridine.[308] To
mitigate the effects on grain boundaries and trap states, the concept of perovskite/fullerene (P/F)
heterojunction has attracted considerable attention.[165, 190, 201, 202] Huang et al.[173] demonstrated
that the trap states on the surface and grain boundaries are the origin of photocurrent hysteresis
and that fullerene layers deposited on perovskites can effectively passivate these charge trap states
and eliminate the undesirable photocurrent hysteresis.[173]
We have recently reported that PSCs based on the isomeric mixture (mix-DMEC70)
exhibited both higher PCE and higher device-stability than devices based on PC71BM. These
results were attributed to the ability of the mix-DMEC70 to extract electrons efficiently, likely due
to specific interactions between the pyrrolidine groups (carbonyls and amino groups) and the
perovskite crystals at the interfaces.[162] There are three regioisomers in mix-DMEC70 (cis-, cis-endo and cis--exo) as shown in Figure 1a. It should be noted that the as-prepared mix-DMEC70
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was used as the ETL in PSCs without further purification. The effect of using pure fullerene C60
bis-adduct isomers as opposed to isomeric mixtures on bulk heterojunction solar cells (BHJ-SC)
was first studied by Imahori et al.[309] Pure isomers have been shown to have a smaller energy
disorder and a higher electron mobility than their corresponding regioisomeric mixtures, thus
leading to higher performance solar cells.[91, 93, 310-315] Imahori et al.[316] reported the photophysical
properties and remarkable photovoltaic performance improvement when using isomerically pure
C70 mono-adducts in BHJ-SC. Recently Huang et al.[161] reported the use of pure C60 bis-adducts
in PSCs to match the energy levels to obtain larger photovoltaic performance.
Shao et al.[173] reported a simple solvent annealing method to mitigate the energy disorder
in the PC61BM layer in PSCs, resulting in an improved open circuit voltage (VOC). Grätzel et al.[148]
recently reported that improved device performance and stability in PSCs can be obtained when
using a pure bis-adduct of PC61BM as an additive in the antisolvent chlorobenzene solution. Since
the packing of the C70 fullerene derivatives in the solid state should have an impact on their charge
separation and transporting properties in PSCs, the three obtained isomers were purified and
characterized in this work, but only the pure -DMEC70 was evaluated as the ETM in inverted
PSCs since this compound was the major regioisomer obtained.
8.2

RESULTS AND DISCUSSION
By changing the reaction conditions from sonication at room temperature to reflux, the

formation ratio of the -DMEC70 with respect to the other two isomers (Figure 8.1a) was
improved from 82% to 90% (Scheme 8.1). Detailed synthetic procedures and charaterizations are
described in the Supporting Information. The pure cis-DMEC70 isomers were purified by HPLC
from the as-obtained mix-DMEC70 using a 5PYE column. As shown in Figure 8.4, three peaks
that corresponded to the three DMEC70 isomers were observed. The three different isomers were
fully characterized by means of MALDI-TOF, 1D and 2D 1H and
absorption (Figures 8.5-8.10).
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13

C-NMR, and UV-vis

Figures 8.8 and 8.9 show the UV-vis absorption profiles of the three DMEC70 isomers in
chloroform and the structrure of the isomers were unambiguously assigned by comparing their
UV-vis profiles with those of known C70 fullerene analogs.[317]

Figure 8.1 a) Device structure of the inverted PSC using -DMEC70, mix-DMEC70, or PC71BM
as the ETMs. b) Schematic illustration of the estimated HOMO and LUMO energy
levels, calculated from CV and UV-vis. c) Top-view SEM image of CH3NH3PbI3
deposited on PEDOT:PSS. c) Cross-section SEM image of an inverted PSC.
The electrochemical properties of the three DMEC70 isomers were measured using cyclic
voltammetry (CV) (Figure 8.11). The DMEC70 isomers exhibit three reduction waves in the
negative potential range from 0 to -2.0 V vs. Fc/Fc+. The lowest unoccupied molecular orbital
(LUMO) energy levels were estimated from their onset reduction potentials (Eredon),[318] and the
corresponding values are listed in Table 8.1. The LUMO energy levels of cis-, cis--endo and
cis--exo were estimated at -4.24 eV, -3.96 eV and -3.93 eV, respectively. These results show that
the electrochemical properties of C70 fullerene mono-adducts are affected by changing the position
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of the addend. The energy-level diagram for -DMEC70 and mix-DMEC70 is shown in Figure
8.1b.
The electron mobilities of -DMEC70, mix-DMEC70 and PC71BM based on electron-only
devices (ITO/Al/fullerene/Al) were calculated by the space-charge limited current (SCLC) method
and the Mott–Gurney law,[319-322] and values of 9.98×10-4, 8.01×10-4 and 9.20×10-4 cm2 V-1 s-1 were
obtained, respectively.
Table 8.1 Electrochemical and photophysical data of -DMEC70, -endo-DMEC70 and -exoDMEC70.
Compound

λabs (nm)

Eg (eV)

𝑬𝒐𝒏
𝒓𝒆𝒅 (V)

LUMO (eV)

HOMO (eV)

-DMEC70

683

1.81

-0.78

-4.24

-6.05

-endo-DMEC70

705

1.76

-1.06

-3.96

-5.72

-exo-DMEC70

705

1.76

-1.09

-3.93

-5.69

As expected, the smaller energy disorder for the pure isomer leads to a larger electron
mobility compared to the regioisomeric mixture (Figure 8.12).
To further characterize the effect of pure -DMEC70 in PSCs, inverted planar PSCs using
this compound as the ETM with a configuration: ITO/PEDOT:PSS/CH3NH3PbI3/-DMEC70/Al
were fabricated (see experimental section). Scanning electron microscopy (SEM) (Figure 8.1c) of
the perovskite surface shows a uniform microscale grain structure (~300 nm) with no apparent
pinholes. Additionally, the cross-section shown in Figure 8.1d shows all of the different layers.
The perovskite layer was also analyzed by X-ray diffraction (XRD). Figure 8.13 shows diffraction
peaks for a pure perovskite material with no evidence of PbI2 or CH3NH2I.
The current density-voltage (J-V) curves of the inverted planar structures based on DMEC70, mix-DMEC70 and PC71BM are shown in Figure 8.2a. The photovoltaic parameters are
listed in Table 8.2. As shown in Figure 8.2a and in Table 8.2, the pure -DMEC70 regioisomer
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based devices exhibit higher PCEs (18.6%) than those of mix-DMEC70 and PC71BM (16.4% and
15.6%, respectively).
As shown in table 2, the Voc values obtained from the -DMEC70 based devices are higher
than those obtained from the mix-DMEC70. These results may seem counterintuitive solely based
on HOMO-LUMO values, but recent results have demonstrated that ETM layer order can affect
and even reverse the expected results based on energy level considerations.[173] EQE spectra in
Figure 8.2b show that the charge extraction efficiency of -DMEC70-based devices is higher than
the mix-DMEC70 and PC71BM.
The photocurrent density (Jsc) calculated from the EQE spectra agrees with the measured
Jsc from J-V curves, confirming the accuracy of the device efficiency. The higher Jsc and FF
obtained for -DMEC70-based devices can be associated with the higher electron mobility of DMEC70. The maximum steady-state photocurrent and PCE outputs were monitored by applying
a voltage near to the maximum power and plotted as a function of time.
Table 8.2 Summary of device performance of devices based on -DMEC70, mix-DMEC70, or
PC71BM as the ETMs.

ETM

Jsc (mA/cm2)*

Jsc (mA/cm2)

Voc (V)

FF (%)

PCE (%)

-DMEC70

22.88

22.90

1.02

0.80

17.9±0.7 (18.6)

mix-DMEC70

21.90

21.92

0.95

0.77

15.9±0.5 (16.4)

PC71BM

21.07

21.09

0.95

0.78

14.8±0.8 (15.6)

*Calculated

current, ( ) Highest PCE. The average was calculated from 20 devices.

Figure 8.2c shows that for devices based on -DMEC70, mix-DMEC70 and PC71BM
steady-state photocurrents of 21.31 mA cm-2, 19.81 mA cm-2, and 18.11 mA cm-2 and PCEs of
18.3%, 15.8%, and 14.5% were obtained, respectively. The stabilized power outputs were
calculated by multiplying the photocurrent and the applied voltage.
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Figure 8.2 a) J-V curves under 1 sun illumination. b) EQE spectra for perovskite solar cells
fabricated using -DMEC70, mix-DMEC70 or PC71BM as the ETMs. c) Power
output under maximum power point tracking for 60 s. d) The PCE histograms
measured for 20 independent devices.

Figure 8.3 a) J-V curves under 1 sun illumination in forward and reverse voltage scans. b)
Steady-state PL spectra of the perovskite and perovskite/ETM films. f) TR-PL
spectra of the perovskite and perovskite/ETM films. d) Normalized PCE of PSCs
measured as a function of the time in a ~20% humidity at room temperature.
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Statistical histograms of PCEs for 20 individual devices are shown in Figure 8.2d. The
distributions show average efficiencies of 17.9±0.7% 15.9±0.5% and 14.8±0.8% for -DMEC70,
mix-DMEC70 and PC71BM based devices, respectively. To investigate the hysteresis behavior,
devices were tested in both forward and reverse scan directions.
As shown in Figures 8.3a, all the devices displayed relatively consistent J-V curves
regardless of the scan direction, indicating negligible hysteretic effects in the PSCs.
To study the charge carrier recombination of devices based on DMEC70 (pure and mixture)
and PC71BM as the ETMs in PSCs, steady-state photoluminescence (PL) (Figure 8.3b) and timeresolved PL decay measurements (Figure 8.3c) were recorded for perovskite, perovskite/DMEC70
(pure and mixture), and perovskite/PC71BM films. As shown in Figure 8.3b the emission peak at
778 nm is attributed to the recombination process in the nanocrystalline perovskite.
A significant PL quenching effect was observed within perovskite/ETMs thin films, which
indicates that surface charge carrier recombination was suppressed.[257] Moreover, a more
pronounced PL quenching effect was observed within the perovskite/-DMEC70 thin film than for
the perovskite/mix-DMEC70 or perovskite/PC71BM thin films, which resulted in an enhanced Jsc
and FF, and thus in a higher PCE. Figure 8.3c shows shorter PL decay times for perovskite/ETMs
(0.10,

0.04

and

0.15

ns

for

perovskite/-DMEC70,

perovskite/mix-DMEC70,

and

perovskite/PC71BM, respectively) than for simple perovskite (0.21 ns) thin films.
The shortened decay lifetimes for the perovskite with any of the ETMs leads to faster
transport of charge carriers and more efficient charge carrier collection, which suppresses electronhole recombination and thus increases the Jsc and the FF.[152]
Air-stability is one of the major concerns for commercialization of PSCs.[125, 323] As shown
in Figure 8.3d, the stability of unencapsulated devices based on -DMEC70, mix-DMEC70, and
PC71BM as the ETMs was monitored for 10 days at room temperature with a relative humidity of
~20%. High stability was observed for devices based on -DMEC70, which retained more than
60% of their initial PCE. In contrast, the mix-DMEC70-based devices only retained 35% of their
initial PCE, whereas PC71BM-based devices retained less than 10% of their initial PCE after 10
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days. To understand the reasons for these differences, the contact angles of water droplets on
perovskite/-DMEC70, perovskite/mix-DMEC70 and perovskite/PC71BM were measured and the
values were 92o, 86o and 82o, respectively (Figure 8.14). These small but significant differences
clearly show that the improved stability of -DMEC70-based devices can be attributed to the better
packing of the pure isomer, which leads to a more hydrophobic and compact layer and thus reduces
water intrusion into the perovskite layer.
The surface morphologies of perovskite, perovskite/mix-DMEC70 and perovskite/DMEC70 films were characterized by atomic force microscopy (AFM). As shown in Figure 8.15a,
the perovskite film exhibits a crystalline structure with a calculated root-mean-square (RMS)
roughness of around 48 nm. The perovskite/mix-DMEC70 film shows a morphology with a reduced
RMS roughness of around 15.9 nm (Figure 8.15b), whereas a smoother morphology with a smaller
RMS roughness of around 8.5 nm was observed for the perovskite/-DMEC70 film (Figure 8.15c).
The pure-isomer film leads to a smoother ETL, likely due to better molecular packing.
8.3

CONCLUSIONS
By changing the reaction conditions, we improved the yield of the -DMEC70 Isomer.

Using this pure isomer as the ETM layer in PSCs resulted in considerably improved device
performance and long-term stabilities. These improvements are likely the result of structural and
energy advantages from using the single isomer and from improved hydrophobicity. To our
knowledge, this is the first example of such an improvement observed by using a pure C70-fullerene
isomer, and the stabilized PCE of 18.3% is among the highest for this simple inverted PSC
architecture. Our results highlight the importance of developing synthetic approaches that yield
pure C70-fullerene isomers without the need for HPLC purification.
8.4

EXPERIMENTAL SECTION

8.4.1 Synthesis of DMEC70
By changing the reaction conditions from sonication at room temperature to reflux, the
formation ratio of the -DMEC70 with respect to the other two isomers (Figure 8.1a) was
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improved from 82% to 90% (Scheme 8.1). C70 (84 mg, 0.10 mmol) were dissolved in
chlorobenzene (30 mL) under sonication for 5 min, then DIB (200 mg, 0.62 mmol), glycine methyl
ester hydrochloride (100 mg, 0.79 mmol) and sodium carbonate decahydrate (100 mg, 0.35 mmol)
were added. The flask was wrapped with aluminum foil and refluxed for 30 min. The solution was
directly poured onto a silica gel column and CS2 was used to separate the non-reacted C70, and
DMEC70 was purified using a toluene/ethyl acetate (9:1) mixture. Regioisomeric yield 85%. The
ratio of the mono-adducts in the mixture was 90:5:5 (endoexo), respectively as determined
by 1H NMR and the molecular mass was determined by matrix assisted laser desorption/ionizationtime-of-flight-mass spectrometry (MALDI-TOF-MS) (Figure 8.4).
8.4.2 Device fabrication
Methylammonium iodide (CH3NH3I) was prepared using a previously reported
procedure.[272] PSCs with a configuration of ITO/PEDOT:PSS/perovskite/fullerene derivative/Al
were fabricated on ITO-coated glass substrates with a resistivity of 10 Ω/cm2. The patterned ITO
glass substrates were cleaned sequentially with detergent, deionized water, isopropyl alcohol and
acetone, each step for 30 min, then dried with nitrogen gas and finally treated in a UV-ozone oven
for 30 min. After passing through a 0.45 μm PVDF filter, the PEDOT:PSS solution (Baytron P VP
AI 4083) was spin-coated onto the treated ITO substrates at 5000 rpm for 30 s, and heated at 150
o

C for 15 min in air. Then the substrates were transferred to a N2-filled glovebox where

CH3NH3PbI3 (1 M solution in DMF) was spin-coated on top of the PEDOT:PSS coated substrates
at 800 rpm for 10 s and at 4000 rpm for 25 s, 80 µL of toluene were added 5 s after the second step
and then the devices were annealed at 70 oC for 60 min and the fullerene derivatives dissolved in
chlorobenzene (20 mg/mL) were spin-coated onto the CH3NH3PbI3 layer at 5000 rpm for 30 s.
Finally, aluminum electrodes (100 nm) were deposited by thermal evaporation under a pressure of
1×10-6 Torr through a shadow mask. The active area of the fabricated devices was 6 mm2. The top
aluminum electrodes were encapsulated with a UV-curable epoxy resin and a glass slide before
testing.
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8.5

SUPPORTING INFORMATION

8.5.1 Experimental section

Scheme 8.1 Synthesis of DMEC70 fullerene derivatives. The structures of the chiral -type
isomer (left) and the two possible achiral -type isomers (right). The percentage
was calculated from 3 independent reactions.

Figure 8.4 HPLC chromatogram of the C70 mono-adducts regioisomeric mixture.
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Figure 8.5 MALDI-TOF spectrum of DMEC70 using 1,8,9-trihydroxyanthracene (THA) as matrix
C70.

Figure 8.6 1H-NMR of the DMEC70 fullerene derivatives, before and after HPLC purification
(CDCl3, 298 K, 600 MHz). a) -cis b) -cis exo c) -cis endo d) regioisomeric
mixture.
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-DMEC70 1H NMR (600 MHz; CDCl3, 298 K) δ (ppm) 4.89 (d, J = 13.7 Hz, 1 H, -CH),
4.73 (d, J = 13.8 Hz, 1 H, -CH), 4.20 (s, 3 H, -CH3), 3.75 (s, 3 H, -CH3), 3.46 (t, J = 13.8 Hz,
1 H, -NH).
-exo-DMEC70 1H NMR (600 MHz; CDCl3, 298 K) δ (ppm) 4.84 (d, J = 13.7 Hz, 2 H, CH), 3.67 (s, 6 H, -CH3), 3.24 (t, J = 13.7 Hz, 1 H, -NH).
-endo-DMEC70 1H NMR (600 MHz; CDCl3, 298 K) δ (ppm) 4.51 (d, J = 13.7 Hz, 2 H,
-CH), 3.94 (s, 6 H, -CH3), (t, J = 13.7 Hz, 1 H, -NH).

Figure 8.7 NOESY of the -DMEC70 isomer.
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Figure 8.8 UV-Vis spectra of -endo-DMEC70 (peak 1), -exo-DMEC70 (peak 2), α-pyrrolidineC70, β-pyrrolidine-C70 and γ-pyrrolidine-C70 in chloroform.

Figure 8.9 UV-Vis spectra of -exo-DMEC70 (peak 3), α-pyrrolidine-C70, β-pyrrolidine-C70 and
γ-pyrrolidine-C70 in chloroform.
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Figure 8.10 13C NMR (150 MHz; CDCl3, 298 K) of -DMEC70.
13

C NMR (150 MHz; CDCl3, 298 K) δ (ppm) 169.4, 168.9, 158.4, 155.9, 154.7, 153.2,

151.5, 151.5, 151.5, 150.9, 150.9, 150.8, 150.8, 150.8, 150.7, 150.7, 150.6, 150.2, 150.1, 149.9,
149.9, 149.6, 149.4, 149.3, 149.2, 149.1, 149.1, 149.1, 148.8, 148.8, 147.5, 147.5, 147.5, 147.2,
147.1, 147.1, 147.1, 147.0, 146.3, 146.2, 146.1, 146.0, 145.8, 145.8, 143.5, 143.5, 143.4, 143.3,
143.2, 143.2, 142.3, 140.9, 140.5, 140.1, 140.0, 138.1, 137.2, 133.9, 133.7, 133.3, 133.2, 131.6,
131.6, 131.4, 131.3, 131.3, 129.1, 128.3, 125.4, 75.0, 71.5, 70.8, 69.3, 53.4, 52.9.

Figure 8.11 Cyclic voltammetry of a) -DMEC70 b) -endo-DMEC70 and c) -exo-DMEC70 (oDCB containing 0.05 M n-Bu4NPF6; using the redox couple Fc/Fc+ as internal
reference).
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Figure 8.12 Measured space-charge limited J-V characteristics of a) PC71BM, b) mix-DMEC70
and c) -DMEC70 for electron only devices with ITO/Al/fullerene/Al structure.

Figure 8.13 The XRD spectra of the perovskite films.

Figure 8.14 Images of the water droplet contact angles on the surfaces of PC71BM, -DMEC70
and mix-DMEC70 thin films.
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Figure 8.15 AFM Images of a) perovskite layer, b) mix-DMEC70 deposited on top of the
perovskite layer and d) -DMEC70 deposited on top of the perovskite layer.
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Chapter 9: Fullerenes in biology and medicine
Abstract: Fullerenes and related carbon-based derivatives have shown a growing
relevance in biology and medicine, mainly due to the unique electronic and structural properties
that make them excellent candidates for multiple functionalization. This review focuses on the
most recent developments of fullerene derivatives for different biological applications.
Experimental procedures and figures presented here are a pre-peer reviewed version of the
following article: E. Castro, A. H. Garcia, G. Zavala, L. Echegoyen, J. Mater. Chem. B. 2017, 5,
6523. Reproduced by permission of the Royal Society of Chemistry.
9.1

INTRODUCTION
The research on fullerene C60 started in 1985 when Kroto, Curl and Smalley discovered

the third allotropic form of carbon after diamond and graphite.[1] The first functionalization
reaction[324] was reported soon after the fullerenes were synthesized in macroscopic amounts in
1990.[2] Functionalized fullerenes exhibit improved solubility and different chemical and physical
properties that allow applications in multiple fields.[325] In 1993 Wudl and coworkers reported the
first water-soluble fullerene derivative 1 (Fig. 9.1) that inhibited the activity of the HIV-1 Protease
(HIV-1 PR), as determined from the interaction of this compound and the HIV-1 PR on an in vitro
assay.[51] Since then, efficient synthetic methods for fullerene functionalization have been
developed.[12, 13] Functionalization with bioactive compounds that exhibit affinity to certain nucleic
acids, proteins or cell receptors such as peptides[326-328] or saccharides,[329, 330] functionalization
with polar or ionic groups such as hydroxyl,[331, 332] carbonyl[46, 333, 334] or quaternary ammonium
salts,[317, 335] and encapsulation with macromolecules[336, 337] are the most common approaches to
synthesize water-soluble fullerene derivatives for biomedical applications.[338-342]
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Fig. 9.1 First water-soluble and biologically active fullerene derivative reported.
Several reviews have been published that summarize the biological applications of
fullerene derivatives.[339, 343, 344] In this review, we summarize the biological properties of active
fullerene derivatives reported during the last 3 years along, with their biomedical applications.
9.2

PROPERTIES
The three-dimensional shape of fullerenes results in unique chemical and physical

properties. Chemical functionalization can be easily achieved to alter the properties of the new
compounds.[13, 19, 345, 346]
9.2.1 Chemical properties
Due to the spherical shape of fullerenes, carbon atoms are highly pyramidalized and are
thus highly reactive. The conjugated carbon atoms deviate from planarity by orbital
rehybridization of the sp² orbitals to sp2.27 orbitals with a p-character gain.[11]
C60 and C70 fullerenes can be reversibly reduced with up to six electrons.[347] This high
electron affinity results from the presence of triply degenerate low-lying lowest unoccupied
molecular orbitals (LUMOs).[348]
The chemical reactivity of fullerenes is similar to that of an electron deficient olefin,
yielding cycloaddition reaction products[349] where the addition takes place at a 6,6 ring junction.
Additions to 5,6 ring junctions have been reported as a result of rearrangements after the initial
kinetic addition to a 6,6 bond.[11]
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9.2.2 Physical properties
Fullerenes can resist high pressures and return to their original shape after being subjected
to over 3000 atmospheres.[350] It was theoretically calculated that a single C60 molecule has an
effective bulk modulus of 668 GPa when compressed to 75% of its size. This property makes
fullerenes harder than steel and diamond, whose bulk moduli are 160 GPa and 442 GPa,
respectively.[351]
Fullerenes are the only known allotropes of carbon that can be dissolved in some common
solvents at room temperature. Large indices of refraction, a dielectric constant of approximately
4, large molecular volumes, and Hildebrand solubility parameter equal to 10 cal1/2cm-3/2 have been
reported for C60 solutions.[15]
9.3

ANTIVIRAL ACTIVITY

9.3.1 Anti-HIV-1
In the absence of an effective vaccine, antiretroviral therapy (ART) is the only therapeutic
tool that can be used to treat HIV-1 infection. Usually, this protocol combines a nucleoside reversetranscriptase inhibitor (RTI) with either a non-nucleoside RTI or a protease inhibitor (PI).[352]
These ARTs efficiently suppress the spread of HIV in patients; however, the emergence of
multidrug resistant viruses is still a serious problem in anti-HIV therapy.[352-354] Therefore, the
development of new type of anti-HIV drugs that are structurally distinct from the currently used
pharmaceutical agents is a critical need.
It has been demonstrated in vivo and in vitro that impairment of viral maturation is a
powerful strategy to block HIV-1 replication. HIV-1 maturation can be inhibited by PIs or by
maturation inhibitors (MIs). The latter can bind to Gag and affect its processing or to CA, thus
impairing core assembly.[355] Currently, there are no maturation inhibitors used clinically.[356]
HIV PIs work by specifically binding to the active site and blocking the activity of the
protease. For 24 years, it was assumed that fullerene inhibition of HIV-1 was only due to the
interaction between the fullerene and the hydrophobic pocket of this enzyme, as determined by in
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silico predictions combined with an in vitro assay.[6, 51] This paradigm was recently challenged by
the fact that C60 and C70 fullerene derivatives do not inhibit the activity of HIV-1 PR at
concentrations (3 μM) that potently inhibit HIV-1 infection (see structures in Fig. 9.2).[317, 357]
Additionally, fullerenes 2-6 inhibited HIV-1 viruses resistant to multiple PR and MIs. Although
the mechanism of action is not known, it was suggested to be via impairment of virus maturation
as a result of a strong interaction with the immature capsid in pull-down experiments.[317] Fullerene
derivatives 2-6 were reported to exhibit no cytotoxicity, therefore they are excellent candidates as
anti-HIV-1 agents.[317, 357] Due to the solubility of [60]fullerene-peptide derivatives, they have also
been considered as potential inhibitors of HIV-1 replication.[358] Using drug screening and docking
calculations, a database of PI [60]fullerene derivatives and their binding constants were
predicted.[359] Strom et al.[360] determined that improved inhibition can be achieved with minor
modifications of both the peptide and the amino acid structure.

Fig. 9.2 Maturation inhibitor fullerene derivatives.
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PR inhibition by [60]fullerene peptides 7-11 (Fig. 9.3) was predicted in silico, and binding
constants were calculated experimentally using a cell-free fluorescence resonance electron transfer
(FRET) assay.[360] Recently Khakina et al.[361] reported a new fullerene derivative 12 (Fig. 9.3) that
exhibits low cytotoxicity (above 100 µM) and blocks the HIV-1 infection in vitro, with a minimum
inhibitory concentration (EC50) of 4.6 μM. Compound 12 showed higher anti-HIV-1 activity than
its pentasulfide analogue C60(SC2H4COOK)5H (EC50 = 45.2 µM).[362] However, no mechanism
of action was proposed for this antiviral compound.

Fig. 9.3 Structure of the anti-HIV-1 [60]fullerene derivatives 7-24.
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As previously mentioned, the HIV-1 reverse transcriptase (RT) is required for early
proviral DNA synthesis and thus inhibition of this enzyme results in inhibition of the virus
replication. The HIV-1 RT inhibitory activity of cationic, anionic and zwitterion fullerene
derivatives have been previously reported,[363] where cationic fullerenes showed lower activity.
Yasuno et al.[364] reported for first time that pyridine/pyridinium-type fullerene derivatives 13-15
(Fig. 9.3) without any carboxylic acid, inhibit the HIV-1 RT in a cell-free environment, with no
cytotoxicity and clearly showing that the fullerene cage was crucial for the inhibition of HIV-RT.
Compounds 16-24 (Fig. 9.3), were also active against HIV-RT.
9.3.2 Bacterial and viral inhibition via anti-adhesion to host cells
9.3.2.1 Anti-bacterial inhibition
Molecular recognition between carbohydrates and proteins play and essential role in many
biological processes.[365] One example is bacterial infection that begins with bacterial adhesion to
host cells. Inhibition of this step using glycoclusters or glycodendrimers that mimic multivalent
carbohydrates at the cell surface is one of the most studied mechanisms over the last decade.[365]
Protein-carbohydrate interactions exhibit high specificity and weak affinities toward carbohydrate
ligands. It has been demonstrated that ligand multivalency increases the low binding affinities of
monovalent glycosides.[365]
Nierengarten et al.[366] have demonstrated that fullerenes are very attractive spherical
scaffolds that can be functionalized with carbohydrates using a very straightforward approach.
Using this synthetic approach Sánchez-Navarro et al.[367] reported new hexakis adducts of C60
endowed with 24 sugars moieties. The carbohydrate recognition of these new derivatives by a
lectin was investigated by isothermal titration calorimetry (ITC) experiments. The results showed
that fullerene C60 is an efficient platform for the globular presentation of carbohydrates for proteincarbohydrate interactions. Buffet et al.[368] reported the synthesis and the multivalent effect against
two lectins, LecB and RSL (compounds 25A-25E) (Fig. 9.4). The results showed higher affinity
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for compound 25E, which contains higher valency and a longer linker between the core and the
sugar. This fullerene derivative appears to be one of the best inhibitors for both lectins.

Fig. 9.4 Fucofullerenes and their corresponding monomeric controls. Reproduced from Ref.[368]
with permission from The Royal Society of Chemistry.
9.3.2.2 Anti Ebola-virus
Ebola virus infection causes severe and often fatal hemorrhagic fever in humans and other
mammals. The 2013-2015 Ebola virus epidemic in West Africa[369] caused at least 11,310
confirmed deaths.[370] The virus initiates infection by binding to host receptors through its
glycoprotein surface. DC-SIGN, a C-type lectin receptor has been proposed as one of the receptors
for cell entrance for several microorganisms that contain glycoconjugates on their envelope.
Due to the important role of DC-SIGN in the first step of the viral infections such as HIV
and Ebola,[371, 372] the discovery of new compounds with higher affinity for this receptor is of great
importance.
The sugar residues in fullerenes act as solubilizing groups and induce remarkable
biological properties.[368, 373-376] In 2013, Luczkowiak et al.[377] reported for the first time the
potential application of glycodendrofullerenes as antiviral agents. In 2016 Muñoz et al.[330]
reported the synthesis of hexakis adducts of fullerene C60, with the most effective dendrimeric
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growth (compounds 26-28) (Fig. 9.5). Compounds 25 and 27 showed very potent antiviral activity
in the range of nM and pM concentrations, respectively. The results clearly showed the dependence
of the inhibition effect on mannoses, compound 26 with 120 galactoses was not active.[330]

Fig. 9.5 Giant globular multivalent glycofullerenes. Reprinted by permission from Macmillan
Publishers Ltd: Nature Chemistry, Muñoz et al.[330] copyright (2016).
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9.4

PHOTODYNAMIC THERAPY
Photodynamic therapy (PDT) is a clinically approved therapeutic technique for the

treatment of multiple diseases, mainly cancer.[378] It relies on the photoexcitation of an inactive
photosensitizer (PS) at a wavelength that matches the absorption of the PS, leading to localized
generation of cytotoxic reactive oxygen species (ROS). ROS cause oxidative damage to nearly all
types of biomolecules (proteins, lipids and nucleic acids) and tumor cell death. [379] PDT has
remarkably improved selectivity and fewer side effects than traditional anticancer therapies.[380]
Fullerenes C60 and C70 can effectively be excited to their triplet state and can efficiently
convert 3O2 to 1O2.[381, 382] Hamblin and coworkers[10, 383-385] have tested electron-transfer reactions
of photoexcited cationic fullerene derivatives both in vitro and in vivo on animal models with
localized bacterial infections. The activity of compound 29 (Fig. 9.6) was significantly improved
by the addition of potassium iodide (KI) salt, although how the iodide anion enhances the
antibacterial effects is not completely understood.[384]
Functionalization of C60 with n-butyl sulfonic acid salts to form self-assembled molecular
micellar nanospheres, as with compound 30 (Fig. 9.6), was found to retain high efficiency in
generating singlet oxygen upon irradiation with visible light.[386] The mechanism was correlated
to the facile intermolecular triplet energy-transfer from photoexcited 330* to molecular oxygen.
Guan et al.[387] reported nanovesicles of fullerene C70 tris-adducts conjugated with chlorin e6
(Ce6), compounds 31, (Fig. 9.6) through an oligo ethylene glycol linker. This system significantly
enhanced both cellular uptake efficiency and PDT in vitro and in vivo. Biocompatibility and total
body release of these particles are among the advantages of these conjugated nanovesicles.[387]
The production of ROS in mitochondria plays a critical role in photodynamic therapy. Li
et al.[388] investigated the generation of additional endogenous ROS in mitochondria using a
chitosan oligosaccharide grafted fullerene conjugate (CS–C60) compound 32 (Fig.9.6). The ROS
generated at low doses of CS-C60 was rich in mitochondria, enhancing the inhibition of human
malignant melanoma (A375) cells. Rotenone Assays showed that PDT-induced endogenous ROS
was generated through an electron transport chain (ETC).[388] Kim et al.[389] reported the synthesis
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of chitosan/fullerene nanogel compound 33 (Fig. 9.6) for efficient tumor therapy. At pH 7.4,
electrostatic interactions between the pendant carboxylic acid groups of 2,3-dimethylmaleic acid
(DMA) and the residual free amine groups of glycol chitosan (GC) resulted in the formation of
multinanogel aggregates. Nevertheless, dissociation of the nanogel aggregates was observed at pH
5.0, resulting in improved singlet oxygen generation and elevated photodynamic tumor cell
ablation.[389]

Fig. 9.6 Fullerene derivatives for PDT applications.
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Franskevych et al.[390] reported the cytotoxic effect of C60 in combination with visible light
irradiation on leukemic L1210 cell lines, both sensitive and resistant to cisplatin. Their results
suggest that C60-mediated photodynamic treatment is a good candidate for restoring drug-resistant
leukemic cells induced to mitochondrial apoptosis. C60-RITC compound 34 (Fig. 9.6) was
synthesized to monitor C60 entry into leukemic cells via confocal microscopy.[390]
Mion et al.[391] reported the synthesis of fullerene compound 35 (Fig. 9.6) for
photodynamic therapy and imaging applications. Although it was not completely isolated, its
presence was confirmed by MALDI-TOF. Ershova et al.[392] studied the cytotoxicity and
genotoxicity of a C60 fullerene derivative functionalized with five residues of 3-phenylpropionic
acid and a chlorine atom arranged around one cyclopentadienyl unit, compound 36 (Fig. 9.7), in
diploid human embryonic lung fibroblasts (HELFs). It was found to cause complex timedependent changes in ROS levels. At short exposure times, when it had not yet penetrated the
cytoplasm, compound 36 considerably decreased ROS levels in the medium and on the surface of
the cell membrane. Long-term exposure can induce secondary oxidative stress and possibly induce
pulmonary fibrosis.
Fullerene C60 derivatives 37-39 (Fig. 9.7) were incorporated into liposomes using a
fullerene exchange method involving the transfer of fullerenes from the cavity of two γcyclodextrin molecules to a liposome, as illustrated in Fig. 9.8.[336, 337]
The photodynamic activity of compound 38 incorporated into lipid membranes was much
higher than that of compounds 37 and 39 under the same conditions. The high photodynamic
activity of compound 38 was attributed to its increased 1O2 generating ability, as determined by
9,10-anthracenediyl-bis(methylene)dimalonic acid (ABDA) as a detector.[393]
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Fig. 9.7 Fullerene derivatives for photodynamic therapy.

Fig. 9.8 Exchange method used for the preparation of the LMIC60 derivatives. a) Rapid mixing of
two solutions and b) Injection. Reproduced from Ikeda et al.[337] with permission
from The Royal Society of Chemistry.
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Wang et al.[394] reported the synthesis and DNA cleavage activity of a -cyclodextrin
fullerene C60, compound 40 (Fig. 9.7). The DNA cleaving ability was tested by using pBR322
plasmid DNA containing more than 90% supercoiled DNA, NADH and compound 40. DNA
cleavage was observed after 4 h of visible light irradiation, but it was not observed under no light
in the presence or absence of both NADH and compound 40. Additionally, compound 40 showed
no significant cytotoxicity in human neuroblastoma SH-SY5Y cells, as determined by a 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.[394]
9.5

ANTIOXIDANT PROPERTIES OF FULLERENOL DERIVATIVES
Functionalization of fullerenes with polar functional groups is one of the approaches to

overcome their insolubility in water, while retaining their unique properties and to enhance their
biological activities.[395-397] fullerenes are commonly classified as a “radical sponges”,[398] due to
their remarkable reactivity with free radicals.[399-408]
The antioxidant capacity of Fullerenols and their derivatives have been measured by
DMPO-spin trap/ESR methods, and by using the -carotene and DPPH assays.[409] However, the
kinetics and radical scavenging mechanisms of these compounds are still not completely
understood. Density functional theory (DFT) calculations suggest that fullerenols with 6 and 12
hydroxyl groups are the most stable derivatives.[410]
Ueno et al.[411] studied the antioxidant activity of several hydroxylated fullerenols with 8,
10, 12, 24, 26, 36, and 44 hydroxyl groups by a 𝛽-carotene bleaching assay. The relative radical
scavenging rate of fullerenols toward radical species derived from linoleic acid under autoxidation
conditions indicated that C60(OH)12 and C60(OH)44 reacted 1.62 and 1.54 times faster than 𝛽carotene, respectively.
Based on the analysis of the possible products of both fullerenols and C 60 with radical
species generated from methyl linoleate under autoxidation conditions, the authors proposed two
antioxidant mechanisms dependent on the number of hydroxyl groups (Fig. 9.9).[411]
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The C-addition, which includes the peroxyl radical addition to a conjugated C=C double
bond (mechanism A), and the H-abstraction that involves hydrogen atom abstraction from –OH
groups and the subsequent of the fullerene radical rearrangement to form ether bridge (mechanism
B). Fullerenol C60(OH)10 with more π-conjugated double bonds undergoes the C-addition
mechanism similar to C60, while fullerenol C60(OH)40 undergoes H-abstraction because of the less
π-conjugated double bonds.

Fig. 9.9 Possible mechanisms for lipid peroxyl radical (LOO●) scavenging by fullerenols
C60(OH)n: a) addition to C=C bonds and b) H-abstraction from -OH groups.
Adapted from Ueno et al.[411] (2014).
Grebowski et al.[412] studied the rate constants of highly hydroxylated fullerene C60(OH)36
interacting with hydroxyl radicals (●OH) and hydrated electrons. The rate constant for the reaction
of C60(OH)36 with ●OH was 2.0×109 dm3mol-1s-1, which was similar to that for C60(OH)18), 4.5x108 dm3mol-1s-1.[413] These results showed that the decreased number of π bonds, due to the larger
number of OH groups attached to the fullerene, did not significantly affect the rate constant for the
reaction with hydroxyl radicals.
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Srdjenovic et al.[414] studied the influence of C60(OH)24 on Chinese hamster ovary cells
(CHO-K1). Their results showed strong antioxidant properties influencing the cellular redox state
and enzyme activities. Therefore, they reduce cell proliferation and were proposed as
cytoprotective agents.
Improved free radical scavenger properties were reported by Awan et al.[415] as a result of
functionalization of C60(OH)30 on the surface of cellulose nanocrystals (CNCs). The
immobilization appears to be due to the covalent interaction between the -OH groups on the CNC
and π-conjugation of the fullerenol. It was proposed that this results in a reduced tendency to form
clusters and greater accessibility to the free radicals (Fig. 9.10).

Fig. 9.10 Schematic illustrating the conjugation of fullerenols on CNC. Reprinted from Awan et
al.[415] (2016), with permission of Springer.
Mitochondrial dysfunction is considered a crucial mechanism of nanomaterial toxicity.
Yang et al.[416] investigated the effects of C60(OH)44 on isolated mitochondria. The exposure of
mitochondria to fullerenol not only affected the respiratory chain but also damaged the inner
membrane, allowing permeability to H+ and K+ in a concentration dependent manner.
9.6

ANTI-CANCER PROPERTIES
Recent studies illustrate the wide range of avenues of the use of fullerenes as anticancer

agents.[417-424] Pyrrolidinium fullerene derivatives have been shown to induce mitochondrion- and
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caspase-dependent apoptosis through the generation of ROS in human promyeloleukaemia (HL60) cells.[425]
It has also been reported that pyrrolidinium fullerene compounds 41-47 (Fig. 9.11) induced
apoptotic cell death of cells mutated on JAK2 V617F, which show resistance to multiple antitumor drugs.[426]
The results showed that replacement of one hydrogen atom (compound 42) or the N-methyl
group (compound 45) on compound 41 with a butyl group enhanced the ability of pyrrolidinium
fullerenes to induce apoptosis on VF-Ba/F3 cells.[426]
Attachment of structural conjugate drugs to C60 is a good strategy to confer biological
activity to fullerenes.[427] Magoulas et al.[428] studied the properties of fullerene C60 conjugated
with one (48) and two (49) units of doxorubicin (DOX), a potent anticancer agent (Fig. 9.11). To
avoid bis-adduct mixture of isomers, the authors opted for multiple arms on a monofulleropyrrolidine derivative (Fig. 9.11). These conjugates exhibited comparable, but with a more
delayed onset, antiproliferative effect compared to free (non-conjugated) DOX when incubated
with MCF-7 cells under the same conditions.

Fig. 9.11 Fullerene derivatives with anticancer properties.
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Probably, after conjugate entrance into the cells, the drug must be released from the
conjugate to become active.
The effect of sonodynamically activated pyrrolidine tris-acid fullerene derivative 50 (Fig.
9.11) in isolated sarcoma-180 cells, and mice bearing ectopically-implanted colon 26 carcinoma
was studied by Yumiko et al.[429] The results showed a 5-fold enhanced cell damage induced by
ultrasonic exposure in the presence of compound 50 (80 μM) and the growth of the implanted
colon 26 carcinoma was decreased both in vitro and in vivo experiments. Histidine, a singlet
oxygen and hydroxyl radical scavenger was used to determine whether reactive oxygen species
participate in sonodynamically inducing cell damage. The results suggest that the enhancement
was due to the generation of active oxygen. This work is the first step for clinical applications of
sonodynamic therapy using fullerene derivatives.[429]
9.7

IMMUNOLOGICAL PROPERTIES
It has been reported that C60 fullerene derivatives, when conjugated to bovine thyroglobulin

or rabbit serum albumin, induce the production of fullerene-specific IgG antibodies in immunized
mice.[430, 431],

[432, 433]

Turabekova et al.[434] reported a computational study where C60 fullerenes

can act as ligands for toll-like receptors and therefore can be recognized as pathogens, inducing
proinflammatory immune response.
The potential suppressive effects of compound 50 (Fig. 9.11) and fullerenol (C60(OH)36)
was studied on many in vitro and in vivo models of inflammatory diseases by Hirai et al.[435] Their
results suggest that both fullerene derivatives can suppress acquired immune responses that require
T cells in vitro. Additionally, compound 50 suppressed ovalbumin-specific antibody production
and ovalbumin specific T cell responses in vivo.
Funakoshi-Tago et at.[436] demonstrated that bis-malonic acid fullerene derivative
compound 51 (Fig. 9.12) suppressed the interleukin 33 (IL-33) induced expression of IL-6 in bone
marrow-derived mast cells (BMMC). IL-33 works both intra- and extracellularly as a nuclear
factor regulating gene transcription and as a traditional cytokine, respectively.[437] Intracellular IL163

33 is thought to be released after cell necrosis to alert the immune system of tissue damage or
stress, and extracellular IL-33 coordinates immune defense and repair mechanisms while also
initiating differentiation of helper T cells as the adaptive immune response is triggered. [438] This
has attracted attention as a new target for the treatment of inflammatory diseases.[439]

Fig. 9.12 Fullerene derivatives with immunological properties.
Pacor et al.[440] studied the interaction between fullerene derivatives 52 and 53 (Fig. 9.12)
and cells of the immune system and their results stress the important role of fullerene derivatives
in the control of inflammatory and cancer diseases.
52 showed biological properties that make it compatible with monocytes and macrophages,
remarking its potential use to deliver compounds capable of modulating the immune responses or
as a vehicle to deliver anticancer drugs.[440] Compounds 52 and 53 were more active on neoplastic
proliferating cells than on circulating monocytes. Compound 53 is more toxic than compound 52
against the tested cells. At active doses on tumor cells, 53 was found in the cell cytoplasm without
altering the cell membrane permeability. It was not clear why 53 was toxic to macrophages, but it
can be attributed to the high concentration to which the cells were exposed rather than a negative
effect on mitochondrial function.
9.8

BIOLOGICAL APPLICATIONS OF ENDOHEDRAL METALLOFULLERENES (EMFS)
EMFs are fullerenes that encapsulate metal atoms or clusters. Some of the encapsulated

species can be used in diagnostic or tumor therapy, but these properties are limited due to their
high toxicity. It is well known that the carbon cages of EMFs prevent the encapsulated species
164

from being released to or reacting with biological systems. Additionally, they retain enough
reactivity for exohedral-functionalization that transforms the hydrophobic cage into more
hydrophilic compounds as illustrated in Fig. 9.13.[441] The recent progress with gadolinium (Gd)
based EMFs for biomedical applications is described.
9.8.1 Magnetic resonance imaging (MRI) contrast agents
Gd-based metallofullerenes (Gd-MF) have attracted special interest as MRI contrast agents
due to their high paramagnetic properties and high relaxivity.[442-445]
Murphy et al.[446] reported the application of Gd3N@C80 for in vitro and in vivo imaging
and tracking of human amniotic fluid-derived stem cells within lung tissue. Gd3N@C80 was able
to specifically bind to damaged lung tissue, although the imaging intensity dissipated a month after
the initial dosage. This is the first reported use of a Gd-EMF to label and deliver exogenous cells
to tissue and perform longitudinal MRI to evaluate the dynamics of cell homing, migration and
clearance.
Zhang et al.[447] reported a hydroxylated Gd3N@Cs-C84, an “egg-shaped” EMF with fused
pentagons on its cage that increase the dipole moment of the compound, and thus its solubility in
water. Moreover, it exhibited enhanced relaxivity. Meanwhile, Li et al.[448] reported two
hydroxylated derivatives, Gd@C82(O)10(OH)16 and Gd@C82(O)10(OH)22, that exhibited similar
properties as those of Gd3N@Cs-C84.
Xiao et al.[449] synthetized a new Gd endohedral fullerene derivative, IL-13-TAMRAGd3N@C80(OH)30-(CH2CH2COOH)20, functionalized with a cytokine IL-3 that increases its
selectivity for IL-13Rα2 receptors. The former are important markers for Chronic Post-Traumatic
Osteomyelitis, an opportunistic infection of the bone marrow. Gd-EMFs functionalized with the
same IL-13 cytokine and additional positively charged amino groups (NH3+) have also been used
in imaging Glioblastoma tumor cells as represented in Fig. 9.14.[450] The positively charged groups,
coupled with the IL-3 functionalization, increased selectivity for tumor U-251 cells. Li et al.[451]
studied the improved relaxivity of Gd-EMF derivatives deposited on graphene oxide nanosheets
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(GO-Gd@C82). Their results showed that physicochemical properties and structure are important
factors that can affect relaxivity. Additionally, electron transfer between Gd-EMF and the GO
sheet was found to aid proton relaxation. This interaction is stronger than that of water and the Gd
ions.

Fig. 9.13 Functionalization of Gd-EMFs. Reprinted with permission from Li et al.[441] Copyright
(2016) Wiley-VCH and Sons
Pan et al.[452] investigated the mechanism of Gd@C82(OH)22 on epigenetic regulation of
human pancreatic cancer metastasis. From computational and experimental results both in vitro
and in vivo, it was concluded that Gd@C82(OH)22 inhibits histone deacetylase-1 (HDAC-1) and
suppresses pancreatic cancer cell invasion and metastasis.
Tang et al.[453] investigated the activity of Gd@C82(OH)22 in cancer immunotherapy by
regulating macrophage activity. The results showed enhanced macrophage viability, phagocytosis,
and secretion of cytokines by macrophages. The activated macrophages inhibited tumor formation
and metastasis in vivo, and induced cancer cell death in vitro, as represented in Fig. 9.15.
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Fig. 9.14 IL-13-Gd3N@C80(OH)x(NH2)y nanoparticles with positive charges illustrating facile
binding to a negatively charged phospholipid bilayer cellular surfaces. Reprinted
with permission from Li et al.[450] Copyright (2015) American Chemical Society.

Fig. 9.15 The possible mechanism by which back transfusion of macrophages activated by
Gd@C82(OH)22 nanoparticles inhibit tumor metastasis. Reprinted from Tang et
al.[453] Copyright (2016), with permission from Elsevier.
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The ability of Gd@C82(OH)22 on activating macrophages was also studied by Chen et
al.[454] using synchrotron-based scanning transmission X-ray microscopy (STXM) with high
spatial resolution of 30 nm. Gd@C82(OH)22 significantly activated primary mouse macrophages
and produced pro-inflammatory cytokines, evidencing the possible role of these fullerenols in
antitumor immune response.
9.9

FUTURE AND PERSPECTIVES
It is evident from the biological and medical applications of functionalized empty and

endohedral fullerenes that many studies including toxicity and solubility should be addressed.
However, many of the biological experiments are far from practical applications at this point. Most
of these fullerene derivatives have yet to prove their efficacy and safety in vivo, as most have been
conducted in vitro with a non-consistent variety of cell types. The compatibility of fullerene
derivatives with various biological systems ought to be established before any clinical studies are
attempted.
One of the biggest obstacles for the progress of fullerene-based treatments is the elevated
cytotoxicity due to their hydrophobic nature, which increases their likelihood of absorbing
biological species or accumulating in lipid membranes. However, multiple research studies have
presented evidence against this fear, or demonstrated that it can be circumvented via modification
with biocompatible moieties, as described in this review. Varied cytotoxicity levels and properties
are expected for the wide breadth of fullerene derivatives presented in this summary, as their
cytotoxic effects depend on different physical properties (size and shape), fabrication methods,
and surface functionalization. Systematic toxicological and pharmacokinetic investigations of
individual fullerene derivatives are expected to continue and become a more important topic in the
field of biomedicine. Beyond studying their therapeutic effects, bioaccumulation studies are just
as vital for their eventual translational use.
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9.10

CONCLUSIONS
In this short review we have summarized the biological application of empty as well as of

reported endohedral fullerene derivatives during the last 3 years, which include anti-viral agents,
PDT, antioxidants, anticancer, immunological properties, MRI contrast agents and tumor therapy.
Remarkable progress has been made on biological applications of fullerenes since the first report
in 1993. To solve the almost complete insolubility in aqueous media, several synthetic approaches
have been developed as discussed in this review.
Given the fast growth of these compounds for different biological applications combined
with low toxicity, it is anticipated that many more biomedical applications will be forthcoming for
these interesting compounds.
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Chapter 10: Fullerene derivatives strongly inhibit hiv-1 replication by
affecting virus maturation without impairing protease activity
Abstract: Three compounds (1, 2, and 3) previously reported to inhibit HIV-1 replication
and/or in vitro activity of reverse transcriptase were studied, but only fullerene derivatives 1 and
2 showed strong anti-viral activity on the replication of HIV-1 in human CD4+ T cells. However,
these compounds did not inhibit infection by single-round infection VSV-G pseudotyped viruses,
indicating no effect on the early steps of the viral life cycle. In contrast, analysis of single-round
infection VSV-G pseudotyped HIV-1 produced in the presence of 1 or 2 showed a complete lack
of infectivity in human CD4+ T cells, suggesting that the late stages of the HIV-1 life cycle were
affected. Quantification of virion-associated viral RNA and p24 indicates that RNA packaging and
viral production were unremarkable in these viruses. However, Gag-Pol processing was affected,
as evidenced by immunoblot analysis with an anti-p24 antibody and the measurement of virionassociated reverse transcriptase activity, ratifying the effect of the fullerene derivatives on virion
maturation of the HIV-1 life cycle. Surprisingly, fullerenes 1 and 2 did not inhibit HIV-1 protease
in an in vitro assay at the doses that potently blocked viral infectivity, suggesting a proteaseindependent mechanism of action. Highlighting the potential therapeutic relevance of fullerene
derivatives, these compounds block infection by HIV-1 resistant to protease and maturation
inhibitors. Experimental procedures and figures presented here are a pre-peer reviewed version of
the following article (See Appendix D for the copyright letter): Martinez, Z. S.; Castro, E.; Seong,
C. S.; Ceron, M. R.; Echegoyen, L.; Llano, M. Antimicrob. Agents Chemother. 2016, 60, 5731.
10.1

INTRODUCTION
Advances in anti-Human Immunodeficiency Virus (anti-HIV) retroviral drugs have led to

a significant reduction in acquired immune deficiency syndrome (AIDS) related deaths, delayed
disease progression, and diminished the rates of HIV transmission.[455] Current therapeutic
treatments for effective repression of HIV replication are administered in a cocktail regimen
known as highly active antiretroviral therapy. The antiretroviral activity of these drugs is mainly
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due to their inhibition of HIV reverse transcriptase and protease, essential enzymes for HIV
replication. Drugs targeting protease prevent the cleavage of the Gag and Gag-Pol polyprotein,
leading to immature virions. These therapies efficiently suppress the spread of HIV in patients;
however, the emergence of drug-resistant viruses is a continuous challenge to the effectiveness of
these interventions. In addition, these anti-retroviral drugs have important side effects that limit
their use.[352, 353, 456] Therefore the development of new and safer anti-HIV compounds is a critical
need.[455, 457, 458].
Fullerenes consist of carbon atom cages, some, like C60, have the shape of a hollow sphere,
similar to a soccer ball.[1] Due to their ability to be extensively derivatized, functionalized
fullerenes have shown several biological applications.[459,

460]

It has been hypothesized that

fullerene derivatives are capable of efficiently crossing the cell membrane due to their hydrophobic
core while water solubility can be achieved by attaching hydrophilic moieties.[459-461] The first
fullerene derivative that exhibited anti-HIV activity was reported in 1993 in the Journal of
American Chemical Society.[6, 462] However, the lack of comprehensive characterization of the
antiviral mechanisms of fullerene derivatives has hindered their further development into
therapeutic drugs.[6, 46, 47, 460, 463-466]
It has been reported that some fullerene derivatives are able to inhibit HIV-1 replication in
human cells at concentrations as low as 0.22 μM and display no cytotoxic effects at concentrations
higher than 100 μM.12-18 Yet the step of the viral life cycle targeted by these compounds is currently
unknown. Molecular docking simulations predict that fullerene derivatives can bind to the active
site of the HIV-1 protease due to the size and conformational complementarity.[6, 46-50] Since the
original report of fullerene anti-HIV activity in 1993, the proposed protease-fullerene interaction
as the mechanistic determinant has prevailed and never contested. In addition, in vitro assays
indicate that fullerene derivatives possess some anti-reverse transcriptase activity.[465]
Therefore, to better understand the mechanism of action of fullerene derivatives 1 and 2
(Figure 10.1) in HIV replication we investigated the effect of these compounds during the different
steps of the HIV-1 life cycle in human CD4+ T cells. We observed for the first time that the viral
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maturation process is the step of the HIV-1 life cycle affected by compounds 1 and 2. After 22
years of assuming that inhibition of HIV-1 was due to the interaction between the fullerene and
the hydrophobic pocket of the protease, unexpectedly we discovered that fullerene derivatives 1
and 2 do not inhibit HIV-1 protease at doses that potently inhibit HIV-1 infection. Furthermore,
we observed that compounds 1 and 2 are effective in blocking replication of viruses that are
resistant to the clinically approved protease inhibitors.

Figure 10.1 Fullerene derivatives 1 and 2 (C60-bis(N,N-dimethylpyrrolidinium iodide), 3
(fullereno-C60-pyrrole-2,5-dicarboxylic acid-1-(carboxymethyl)-1,5-dihydro and 4
cis-2-C60-bis(N,N-ethylmethylpyrrolidinium iodide).
10.2

MATERIALS AND METHODS

10.2.1 Synthesis of fullerene derivatives
Compounds 1, 3 and the regioisomeric mixture 2 have been previously reported,[55, 58, 464,
467]

here we report slight modifications for the synthesis of compounds 1, 2, 3 and the synthesis of

compound 4[468] (Figure 10.1). Please, refer to the supporting information for details on the
synthesis and physicochemical characterization of these compounds.
10.2.2 Plasmids
The plasmids used to generate retroviral vectors were described previously.[469] HIV-1derived vectors were produced using pHIV Luc and pMD.G. pHIV Luc was derived from pNL4172

3.Luc.R–E–[470] by introducing a deletion in the env open reading frame. pHIV Luc containing
multi-protease inhibitors resistant to protease mutants were constructed by swapping a 4.3 Kb Sal
I/Spe I fragment in pHIV Luc with this fragment from pNL4-3 containing the mutant proteases.
pMD.G encodes the Vesicular Stomatitis Virus Glycoprotein G (VSV-G). HIV-1NL4-3 was
produced from the corresponding expression plasmid whereas multi-protease inhibitor resistant
viruses were produced with plasmids obtained from the NIH AIDS Reagent Program.[471]
10.2.3 Cell lines
SupT1 and HEK293T cells were grown in RPMI 1640 and in DMEM, respectively. All
culture media were supplemented with 10% of heat-inactivated fetal calf serum, 2 mM Lglutamine and 1% penicillin/streptomycin.
10.2.4 Generation of retroviruses
Procedures previously described were followed.[472] Briefly, 3 x 106 HEK293T cells were
plated in a T75 cm2 tissue culture flask and co-transfected the next day with the corresponding
plasmids by the calcium-phosphate precipitation method. 18 h later the transfection medium was
replaced with fresh medium containing no drug, fullerene derivatives, Indinavir, or dimethyl
sulfoxide (DMSO, vehicle control). The cells were cultured for 48 h until the viral supernatant was
harvested and filtered. Single-round infection viral vectors were further concentrated by
ultracentrifugation at 124750 g for 2 h on a 20% sucrose cushion. Viral preparations were stored
at -80 °C until used.
VSV-G-pseudotyped HIV-derived reporter virus expressing firefly luciferase (HIVluc) and
harboring wild type or multi-protease inhibitor resistant protease mutants were prepared by cotransfection of 15 µg of the corresponding pHIV luc and 5 µg of pMD.G. HIV-1 wild type viruses
were produced by transfection of 15 µg of the corresponding expression plasmids.
10.2.5 Single-round infectivity assay
SupT1 cells were plated at 1 x 105 cells in 500 µL of RPMI 1640 culture medium in 24well plates and infected with HIVluc. 4 days post-infection, cells were collected by centrifugation
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at 1000 g for 6 min and the pellet resuspended in 200 μL of phosphate-buffered saline (PBS). Half
of the sample was mixed with 100 μL of luciferase substrate (Bright-Glow™ Luciferase Assay
System, Promega) and the other half with 100 μL of cell viability substrate (CellTiter-Glo® Assay,
Promega). Cell lysates were incubated for 10 min at room temperature in the dark and then
luminescence was measured in triplicate in 50 μL-samples using a microplate luminometer reader
(Thermo Scientific, Luminoskan Ascent).
10.2.6 Single-round infectivity assay
SupT1 cells were plated at 1 x 105 cells in 500 µL of RPMI 1640 culture medium in 24well plates and infected with HIVluc. 4 days post-infection, cells were collected by centrifugation
at 1000 g for 6 min and the pellet resuspended in 200 μL of phosphate-buffered saline (PBS). Half
of the sample was mixed with 100 μL of luciferase substrate (Bright-Glow™ Luciferase Assay
System, Promega) and the other half with 100 μL of cell viability substrate (CellTiter-Glo® Assay,
Promega). Cell lysates were incubated for 10 min at room temperature in the dark and then
luminescence was measured in triplicate in 50 μL-samples using a microplate luminometer reader
(Thermo Scientific, Luminoskan Ascent).
10.2.7 HIV-1 replication assays
SupT1 cells (0.25 x 106 cells in 3 mL RPMI 1640) were infected with HIV-1NL4-3 (2.1 ng
of HIV-1 p24) wild type or multi-protease inhibitor resistant viruses in the presence of fullerene
derivatives or DMSO. 24 h after infection, the cells were washed 3 times by centrifugation in 10
mL (total 30 mL) of culture medium to remove the input virus and compounds. Cell supernatant
was then collected at different days post-infection and used for HIV-1 p24 quantification by
ELISA.
10.2.8 HIV-1 p24 ELISA
HIV-1 p24 levels were determined by a sandwich ELISA following manufacturer
instructions. Briefly, 200 μL of the viral samples were diluted appropriately and incubated on the
ELISA wells overnight at 37 °C. Unbound proteins were removed by washing the wells 6 times
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with 200 μL of washing buffer, and bound HIV-1 p24 was detected by incubating each well with
100 μL of the anti-HIV-1 p24 secondary antibody for 1 h. Unbound antibodies were removed by
washing as described above and bound antibodies were detected by incubating each well with 100
μL of substrate buffer for 30 min at room temperature until the reaction was stopped by adding
100 μL of stop solution into each well. The absorbance of each well was determined at 450 nm
using a microplate reader (Molecular Devices, Versa max microplate reader).
10.2.9 Cellular viability assay
1 x 104 SupT1 cells were plated in a 96-well plate in 100 µL RMPI1640 culture media and
left untreated or treated with fullerene derivatives, DMSO (control), or 2 mM hydrogen peroxide
(positive control). Fullerene derivatives were evaluated at a concentration that ranged from 3 µM
to 32 µM. The cells were cultured in the presence of the indicated compounds for 24 h and then
20 µL of the MTS were added to each well of cells. Incubation with the reagent for an additional
3 h was allowed. The colored formazan product was measured by absorbance at 490 nm with a
reference wavelength of 650 nm using a microplate reader (SpectraMax 190, Molecular Devices).
Control wells containing the same volumes of culture medium and MTS reagent were used to
subtract background absorbance.
10.2.10

Exogenous reverse transcriptase assay

Reverse transcriptase levels in HIV-1 reporter viruses produced in the presence of DMSO,
fullerene derivatives 1 and 2, and Indinavir were measured using the EnzChek® Reverse
Transcriptase Assay following the manufacturer instructions. HIV-1 p24-normalized amounts
(4.34 μg) were analyzed for each compound treated virus.
10.2.11

HIV-1 protease in vitro activity assay

The effect of DMSO, compounds 1 and 2 (3 and 10 μM), and Indinavir (0.1 μM) on HIV1 protease activity was measured using the ProAssayTM HIV-1 Protease Assay Kit. This assay uses
purified recombinant HIV-1 protease and a fluorescence resonance energy transfer (FRET) peptide
derived from the native p17/p24 cleavage site of HIV-1 protease on Gag. Briefly, HIV-1 protease
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(0.2 µL) and FRET peptide (final concentration 0.5 μM) were mixed in HIV-1 protease buffer
supplemented with 1 mM DTT (final concentration) on ice and protected from light, and
immediately transferred into a black 96-wells plate that contain the compounds being evaluated.
The reaction was measured by determining the Relative Fluorescing Intensity (RFI) with a
fluorometer at excitation/emission wavelengths of 490 nm / 530 nm every 5 min during 90 min.
10.2.12

Quantification of virion associated ribonucleic acid (RNA)

Real-time quantitative reverse transcription-PCR was used to quantify virion associated
RNA. RNA was purified from HIV-1 p24-normalized compound-treated virions (5 ng) after their
treatment with 1 μg of RNase and 2 units of DNase (Qiagen® RNAEasy™ Miniprep kit). cDNAs
were generated from all the viral RNA extracted with random oligonucleotides using the High
Capacity RNA-to-cDNA Kit from Applied Biosystems®. cDNA (1 μg) was then analyzed using
qPCR using Gag-hybridizing primers (iQTM SYBR® Green Supermix BIO-RAD®). The sequences
of the oligonucleotides used in the qPCRs are available upon request.
10.2.13

Immunoblotting

Proteins of HIV-1 p24-normalized amounts of virions (0.38 μg) were resolved by 13%
SDS-PAGE and transferred overnight to PVDF membranes at 100 mAmp at 4 °C. Membranes
were blocked in TBS containing 10% milk for 1 h and then incubated in the corresponding primary
antibody diluted in TBS-5% milk-0.05% Tween 20 (antibody dilution buffer) overnight at 4 °C.
HIV-1 p24 was detected with anti-p24 obtained from the NIH AIDS Reagent Program (Catalog #
1513). HIV-1 integrase was detected with anti-integrase (Catalog # sc-69721, Santa Cruz
Biotechnology). Primary antibody-bound membranes were washed in TBS-0.1% Tween 20 and
all bound antibodies detected with goat anti-mouse IgG-HRP (1/2000, KPL, 074-1806) followed
by chemo-luminescence detection.
10.2.14

Real time PCR analysis of early steps of the HIV-1 life cycle

Procedures previously described were followed.[471] Briefly, 1 x 106 SupT1 cells were
challenged with DNase-treated single-round infection HIVluc virus produced in the presence of
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fullerenes or DMSO and 24 h later 90% of the cells were used for DNA extraction (High pure PCR
template preparation kit, Roche) whereas 10% were cultured for four days to evaluate infectivity.
Extracted DNA (20 ng) was used for the detection of total HIV-1 cDNA, mitochondrial DNA, and
2LTR circles while 0.2 ng of DNA were used for the Alu-LTR junctions PCR. Total HIV-1 cDNA,
Alu-LTR junctions, and 2LTR circle products were normalized to mitochondrial DNA. Real time
PCRs were performed in a MiniOpticon system (Bio-rad) with primers and conditions previously
described.[471] Fold change was calculated using the ∆Ct method as recommended in the thermocycler manual.
10.2.15

Mycobacterium smegmatis growth assay

Mycobacterium smegmatis strain mc155 grown in Middlebrook 7H9 medium with 0.2%
glycerol was supplemented with 10% AD (145 mM NaCl, 5% Albumin Fraction V, and 2%
dextrose), 50 µg/mL of carbenicillin, 10 µg/mL of cyclohexamide, and 1 mM CaCl2. Cultures were
incubated at 37 °C for 6 h in 10 mL media until 0.044 - 0.079 OD640 were reached. Culture aliquots
(1 mL) were then placed in 15 mL conical tubes and fullerene derivatives or rifampicin were added
at 10 µM or 0.5 mg/mL, final concentrations, respectively. Equivalent volumes of DMSO were
added for the solvent control. Cultures were allowed to incubate at 37 ˚C for 16 h and then the
OD640 was measured.
10.3

RESULTS AND DISCUSSION

10.3.1 Effect of fullerene derivatives on HIV-1 replication in human CD4+ T cells
Compound 1 was previously shown to inhibit HIV-1 replication in CEM cells and primary
lymphocytes, but its effect on the different steps of the viral life cycle was not evaluated. [464] In
addition, compounds 1, 2, and 3 have been shown to inhibit reverse transcriptase in vitro.[465]
Therefore, to fully characterize the anti-HIV-1 activity of fullerene derivatives in biologically
relevant environments, compounds 1, 2, and 3 were evaluated for their ability to affect HIV-1
replication in human CD4+ T cells (Figure 10.2). SupT1 cells were infected with HIV-1NL4-3 in the
presence of compounds 1, 2, and 3 at 1, 3, and 10 μM concentrations, and compounds and input
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viruses were removed 24 h later. Infected cells were cultured for approximately 2 weeks and HIV1 p24 levels in the cell supernatant were measured by ELISA.

Figure 10.2 Effect of fullerene derivatives on HIV-1 replication. SupT1 cells were treated with
DMSO (+) or compounds 1 a) and the regioisomeric mixture 2 b) at 1 μM (□), 3
μM (Δ), or 10 μM (х) at the time of infection with HIV-1 NL4-3. 24 h later the
compounds and virus were removed and infected cells were cultured for up to 2
weeks. The amount of HIV-1 p24 antigen was determined in cell supernatant by
ELISA. Results from one experiment are shown.
Data in figure 2 indicate that compounds 1 and 2 potently inhibited viral replication at 3
μM. Similarly, compound 1 was active at 10 μM (Figure 10.2a). The effect of compound 1 on
HIV-1 replication at 3 and 10 μM were indistinguishable and showed a 300-fold inhibition of HIV1 viral replication. The regioisomeric compound mixture 2 at 3 μM inhibited HIV-1 replication to
a similar extent as compound 1 (Figure 10.2b). However, the inhibitory activity of compounds 1
and 2 dropped at 1 μM to 3-fold and 5-fold, respectively (Figure 10.2). Contrary to the effect of
compounds 1 and 2 on HIV-1 replication, no effect was observed when cells were treated for 24 h
at the time of infection with compound 3 at 1, 3 and 10 μM (data not shown). Therefore, our data
support the anti-HIV-1 activity reported for compounds 1 and 2[464] but failed to validate in human
cells the effect reported for compound 3 using in vitro assays.[465]
Function/structure analysis of the fullerene derivatives characterized (Figure 10.1) indicate
that similar chemical addends present in the regioisomeric mixture 2 and the pure regioisomer
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(trans-3) compound 1 most likely explain their comparable inhibitory effect on HIV-1 replication.
However, when the quaternized nitrogen in 1 and 2 was eliminated and the pyrrolidine ring was
modified with carboxylic acids, compound 3, the anti-HIV activity was completely lost, indicating
the relevance of the addends in the activity of the fullerene derivatives.
10.3.2 Effect of fullerenes on cellular viability
We have observed that compounds 1 and 2 potently inhibit HIV-1 infection (Figure 10.2).
A possibility is that these compounds compromise cellular viability affecting viral infection
nonspecifically. To rule out this possibility, the effect of compounds 1 and 2 on cell viability was
evaluated by the tetrazolium dye reduction assay. In these experiments, SupT1 cells were treated
with compounds 1 and 2 at concentrations of 3 and 6 μM, or similar amounts of DMSO, for 24 h
and then cell viability was measured. At these concentrations none of these compounds showed
cytotoxic activity (Figure 10.3). Therefore, the effects on HIV-1 infection observed with
compounds 1 and 2 at 3 μM most likely are not due to cell toxicity.
To further define the cytotoxic activity of these compounds the drug concentration that
kills approximately 50% of SupT1 cells (LC50) was determined for compounds 1 and 2 after 24 h
of treatment. In these experiments, compound 1 at 18 μM and the regioisomeric mixture 2 at 26
μM killed 60% and 52% of the treated cells, respectively, as compared to DMSO-treated cells
(Figure 10.3). These data correlated with results of an independent experiment that indicated that
compound 1 at 15 μM and the regioisomeric mixture 2 at 26 μM killed 41% and 34%, respectively,
of the treated cells. In further correspondence with these observations, only 10% and 15% of the
cells were killed after 24 h treatments with compounds 1 and 2 at 6 μM, respectively, while 30%
of the cells died after treatment with the regioisomeric mixture 2 at 20 μM. These results also
indicate that the doses evaluated in the HIV-1 infection experiments unlikely impaired HIV-1
replication by affecting cellular viability.
In summary, experiments in figure 3 indicate that compounds 1 and 2 inhibit HIV-1
infection at doses that are not toxic to the target cells.
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Figure 10.3 Assessing the cytotoxicity of compounds 1 and 2. SupT1 cells were treated with
DMSO, compound 1 (□), or regioisomeric mixture 2 (x) at varying concentrations
for 24 h and the amounts of viable cells were determined by the tetrazolium dye
reduction assay. Cell viability values were normalized to DMSO-treated cells.
Results shown are representative of two independent experiments.
10.3.3 Effect of fullerene derivatives on single-round infection
We have provided evidence that fullerene derivatives, specifically compounds 1 and 2,
inhibit HIV-1 replication; however, the viral step implicated in this effect is unknown. In order to
determine the step in the viral life cycle that is affected, the early phase of HIV-1 infection was
first analyzed. The effect of compounds 1, 2 and 3 on the infection of VSV-G pseudotyped HIV1 single-round infection viruses expressing luciferase was evaluated in SupT1 cells. Although
compound 3 showed no signs of inhibition of HIV-1 replication, it was evaluated as a control. In
addition, we analyzed the activity of compound 4 (Figure 10.1), an isomerically pure regioisomer
(cis-2, endo-endo)[468] with two pyrrolidinium rings connected by a benzene bridge. This
compound was incorporated in the analysis to provide additional information about the
involvement of different addends attached to fullerene and their anti-HIV-1 activity. Cells were
exposed to 1, 3, and 10 μM of each compound and infected with the reporter virus. 24 h later,
drugs and input virus were removed, and four days post-infection luciferase and ATP levels were
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measured. Luciferase was normalized to ATP to standardize for cell viability and number. Data in
figure 10.4a clearly indicate that none of the fullerene derivatives affect the early steps of the viral
life cycle. These results also demonstrated that LTR-driven transcription and translation of viral
proteins, or cellular viability, was not affected by fullerene derivatives. Combined analysis of data
in figures 10.2 and 10.4a suggest that the late phase of the viral life cycle is targeted by compounds
1 and 2.

Figure 10.4 Analysis of the viral life cycle step affected by compounds 1, 2, 3 and 4. a) Effects
on the early stages of HIV-1 viral life cycle. SupT1 cells were infected with a
single-round infection HIV-1 virus in the presence of 10 μM of each compound and
24 h later compounds and input virus were removed. Cells were analyzed 3 days
later for luciferase expression and cellular viability (ATP content). Luciferase
values were normalized to cellular viability. b) Effects of compounds 1, 2, 3 and 4
on the late phase of HIV-1 infection. VSV-G pseudotyped, single-round HIV-1
expressing luciferase were produced in the presence of DMSO or fullerene
derivatives (3 μM) and then concentrated by ultracentrifugation and analyzed.
Indinavir (0.1 μM) was used as a control. The infectivity of these viruses was
analyzed in single-round infection assays using HIV-1 p24-normalized viruses.
Results shown are the average and standard deviation of triplicate readings of one
experiment representative of three independent experiments.
10.3.4 Effect of fullerene derivatives on the late phase of the HIV-1 life cycle
Compounds 1, 2, 3 and 4 were further evaluated to determine their effect on the late phase
of the HIV-1 life cycle. VSV-G pseudotyped, HIV-1 single-round infection viruses expressing
181

luciferase were produced in the presence of DMSO, compounds 1, 2, 3 (3 μM) and/or Indinavir
(0.1 μM) in HEK293T cells cotransfected with plasmids expressing these retoviruses and plasmids
encoding eGFP. Then, produced viruses were concentrated by ultracentrifugation on a sucrose
cushion and HIV-1 p24 levels were measured by ELISA. Transfection efficiency was quantified
by FACS analysis of eGFP.
In order to analyze the effect of fullerene derivatives on HIV-1 infectivity, SupT1 cells
were infected with p24-normalized single round infection viruses and luciferase and ATP levels
were determined four days later. Data in figure 4b indicate that infectivity of viruses produced in
the presence of compounds 1 and 2 was dramatically reduced by more than 99%. This inhibitory
effect was similar to the impairment caused by Indinavir (95%). In contrast, compounds 3 and 4
did not affect the infectivity of the viruses produced, again highlighting the functional relevance
of the addends modifying the fullerene cage.
HIV-1 p24 levels were similar among viruses produced in the presence or absence of
fullerene derivatives or Indinavir, indicating that these compounds did not affect LTR
transcription, translation, and viral budding, nor cellular viability (Figure 10.5a).

These

observations also correlate with the lack of an effect for compounds 1, 2, 3 and 4 on the expression
of luciferase in the single-round infection assays (Figure 10.4a). The similar levels of HIV-1 p24
also correlated with equivalent eGFP expression in the producer cells (Data not shown), indicating
comparable transfection efficiency.
To further investigate the effect of fullerene derivatives on viral assembly, we determined
whether compounds 1 and 2 as well as Indinavir affected the amount of virion-associated viral
RNA. HIV-1 RNA was extracted from p24-normalized amounts of compound-treated virions and
then converted into cDNA that was quantified by real time PCR with primers hybridizing to Gag.
Using this method, similar RNA levels were found in virions produced in the presence of DMSO,
compounds 1, 2, and Indinavir, indicating that these compounds do not affect RNA packaging
(Figure 10.5b). Altogether, the data shown in figures 10.4b and 10.5a-b show that fullerene
derivatives target the viral maturation process.
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Figure 10.5 Effects of compounds 1, 2, 3 and 4 on virion production. VSV-G pseudotyped,
single-round HIV-1 expressing luciferase were produced in the presence of DMSO
or fullerene derivatives (3 μM) and then concentrated by ultracentrifugation and
analyzed. Indinavir (0.1 μM) was used as a control. a) Virion production as
determined by HIV-1 p24 levels quantified by ELISA. b) Virion-associated RNA as
quantified by real time PCR analysis of reverse transcribed cDNA using primers
that hybridize to Gag. Results represent two experiments; standard deviation
indicate the variability of multiple readings.
10.3.5 Characterization of the early steps of the viral life cycle of virions produced in
fullerene derivative-treated cells
We have shown that compounds 1 and 2 impair the maturation step of HIV-1 drastically
reducing virion infectivity. Using real time PCR analysis, we determined the competence of
fullerene derivative-treated viruses to complete the different steps of the early phase of the HIV-1
viral life cycle. SupT1 cells were infected with DNase-treated HIV-1 p24-normalized amounts of
concentrated HIV-1 produced in the presence of DMSO, Indinavir, or compounds 1 and 2. DNA
was extracted from these cells 24 h and 4 days after infection and total HIV-1 cDNA that is formed
only after efficient reverse transcription, 2LTR circles that is synthesized upon nuclear import of
the linear HIV-1 cDNA, and Alu-LTR junctions, products indicative of HIV-1 DNA integration,
were quantified by real-time PCR.
In these analyses, we found that total HIV-1 cDNA was dramatically reduced in viruses
produced in the presence of compounds 1 and 2, and this effect was of a higher magnitude than in
virions produced in Indinavir-treated cells (Figure 10.6a I). As a consequence, 2LTR circles and
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Alu-LTR junctions were also markedly diminished in cells infected with fullerene-treated than
DMSO-treated viruses (Figure 10.6a II and III, respectively). As expected, this inhibitory effect of
fullerene derivatives was also observed in DNA extracted four days after infection (Figure 10.6b).
Importantly, findings in figure 10.6 correlated with the lack of infectivity reported in figure 10.4b,
indicating a severe defect in the infectivity of viruses produced in the presence of compounds 1
and 2.

Figure 10.6 Evaluation of the early steps of the HIV-1 life cycle of virions produced in cells
treated with compounds 1 or 2. VSV-G pseudotyped, single-round HIV-1
expressing luciferase was produced in the presence of DMSO or fullerene
derivatives (3 μM) and then concentrated by ultracentrifugation. Indinavir (0.1 μM)
was used as a control. SupT1 cells were infected with HIV-1 p24-normalized,
DNase-treated viruses and DNA was extracted from infected cells 24 h (a I to III)
and 4 days post-infection (b I to III). Primers hybridizing on Gag were used to
determine total HIV cDNA (a and b I), on LTRs detected 2LTR junctions (a and b
II), and on Alu repeats and the LTR followed by a nested PCR of the LTR region
amplified Alu-LTR junctions resulting from HIV-1 cDNA integration (a and b III).
Results shown are the average of triplicate readings of one experiment.
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10.3.6 HIV-1 Gag processing in fullerene-treated virions
The fact that fullerene severely blocks infectivity of viruses produced in their presence
(Figure 10.4b and 10.6) but not mature viruses (Figure 10.4a) suggests that these compounds affect
virion maturation. This step of the viral life cycle is initiated by the required proteolytic processing
of Gag and Gag-Pol polyproteins by HIV-1 protease and the further assembly of the viral
components. To formally evaluate the effect of fullerenes on maturation we determined Gag-Pol
processing in virions treated or not with fullerene derivatives. HEK293T cells were transfected
with pHIV luc and pMD.G and the next day the transfection medium was replaced with culture
medium containing DMSO, compounds 1 and 2 (3 μM), or Indinavir (0.1 μM or 10 μM). Produced
viruses were concentrated by ultracentrifugation on a sucrose cushion and used for quantification
of HIV-1 p24 by ELISA. Then, HIV-1 p24-normalized amounts of viruses were used for Gag and
Pol processing analysis. As shown in figure 10.7a, Gag processing was affected by compounds 1
or 2 at 3 μM to a similar extent of Indinavir at 0.1 μM. However, integrase processing was not
altered by fullerene derivatives at 3 μM or Indinavir at 0.1 μM (Figure 10.7b I) although at these
doses these drugs significantly affected HIV-1 infection (Figure 10.2 and 10.4b). Nevertheless,
Indinavir at higher doses (10 μM) severely impair Gag and integrase processing (Figure 10.7a II
and b II). Therefore, data in figures 10.7a and b indicate that fullerene derivatives impair Gag
processing.
To further evaluate the effects of fullerene derivatives (3 μM) and Indinavir (0.1 μM) on
HIV-1 maturation, we also determined the virion-associated reverse transcriptase activity of p24normalized viruses using an exogenous ssDNA template (exogenous reverse transcription assay).
Although Indinavir impaired reverse transcriptase activity, the effect of fullerenes, and in
particular of the regioisomeric mixture 2, were more pronounced (Figure 10.7c), indicating a
defect in HIV-1 maturation in these viruses. The fact that the inhibitory effect on reverse
transcriptase activity of the regioisomeric mixture 2 was more potent than compound 1 (Figure
10.7c) highlights the relevance of the fullerene addend groups in their activity. Future work will
address the effects of specific regioisomers in 2.
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Figure 10.7 Effects of compounds 1 and 2 on HIV-1 protease. a) Protease-mediated processing
of HIV-1 p24, and b) integrase in virions was determined by immunoblot analysis
with specific antibodies. c) Reverse transcriptase activity of virions was measured
by the exogenous reverse transcription assay. Results are representative of one (a
and b) or three c) independent experiments, standard deviation in c) indicates the
variability of multiple readings.
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10.3.7 Effect of fullerene derivatives on HIV-1 protease activity
In silico analysis suggest that fullerene derivatives 1 and 2 could bind to the active site of
HIV-1 protease.[6, 46-50] This enzyme is essential for viral maturation, the step of the viral life cycle
that we have identified to be affected by fullerenes. However, fullerenes 1 and 2 did not affect
integrase processing (Figure 10.7b) although this event also depends on the HIV-1 protease
activity. Therefore, to further characterize the specific mechanism of action of these compounds,
we determined their effect on the in vitro activity of HIV-1 protease using a FRET peptide-based
assay. Recombinant protease was incubated with the substrate, an HIV-1-derived FRET peptide
containing the native p17/p24 cleavage site of HIV-1 protease on Gag, in the presence of DMSO,
fullerene derivatives, or Indinavir, and fluorescence emission was tracked for 90 mins (Figure
10.8).
As expected, Indinavir completely blocked the activity of protease but surprisingly,
compounds 1 and 2 were inactive at 3 μM (Figure 10.8a), a concentration that severely impairs
HIV-1 infection (Figures 10.2 and 10.4b). In further support, even at 10 μM, fullerene derivatives
only minimally affect protease activity (Figure 10.8b). Only at toxic concentrations (Figure 10.3),
above 40 μM, fullerenes 1 and 2 inhibited protease activity (Data not shown). Therefore, our data
definitively demonstrate that fullerene derivatives fail to inhibit HIV-1 protease at doses that
potently block HIV-1 maturation. These results conclusively show that fullerenes 1 and 2 are
strongly anti-HIV active, but not via HIV-1 protease, contradicting the multiple in silico studies
previously reported.[6, 46-50]
Given that our results challenge the existing fullerene-protease paradigm, for completeness
we decided to study the HIV-1 protease activity of the originally reported compound by Friedman
in 1993 (scheme 10.4, compound 5).[6] As expected, compound 5 inhibited HIV-1 viral replication
(Figure S12) as compounds 1 and 2 did, but was inactive in the in vitro activity of HIV-1 protease
using the FRET peptide-based assay at 3 and 10 μM (Figure 10.23). Therefore, our results clearly
show that fullerene derivatives are potent anti-HIV agents but their mechanistic activity does not
involve HIV-1 protease binding.
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Figure 10.8 Effect of compounds 1 and 2 on the in vitro activity of HIV-1 protease. The cleavage
of an HIV-derived FRET peptide by recombinant HIV-1 protease in the presence of
compounds 1 (Δ) and 2 (x) at 3 μM a) or 10 μM b) was determined by fluorescence
measurements. DMSO (◊) and Indinavir (□) were used as negative and positive
controls, respectively. Experiments were performed in duplicates.
10.3.8 Inhibitory activity of fullerene derivatives on multi-protease inhibitor resistant
HIV-1 viruses
Our data indicate that fullerene derivatives do not affect HIV-1 protease; thus it is possible
that these compounds could inhibit the infectivity of HIV-1 viruses that are resistant to the
clinically used protease inhibitors. To test this hypothesis, we determined the sensitivity to
fullerene derivatives of multi-protease inhibitor-resistant HIV-1 recombinant infectious molecular
clones previously described.[471] The mutant viruses analyzed included 11803, 11806, 11807,
11808, and 11809 that are resistant to nelﬁnavir, Fosamprenavir, Saquinavir, Indinavir,
Atazanavir, Lopinavir, Tipranavir, and Darunavir; and 11805 that is also resistant to these drugs
except for Tipranavir and Darunavir. The protease (99 amino acids) in these viruses contains
between 10 and 24 point mutations.[472]
Single-round infection HIV-1 expressing luciferase that harbor the multi-protease
inhibitor-resistant protease mutants were produced in HEK293T cells as described above in the
presence of DMSO, compound 1 (3 μM), or Indinavir (0.1 μM). The viruses were concentrated by
ultracentrifugation on a sucrose cushion, normalized for p24 content, and used to infect SupT1
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cells. In these experiments we observed that compound 1, but not Indinavir, potently blocked the
infectivity of all the mutant viruses with a similar efficiency (Figure 10.9a).
To further verify these data, the effect of fullerenes on the replication of HIV-1 11803 was
evaluated. This mutant was selected for analysis because, although it contains 18 point mutations
in protease that renders the virus resistant to eight different protease inhibitors, it has a replication
capacity of 63% of protease wild type HIV-1.[472] SupT1 cells were infected with NL4-3 or 11803
in the presence of DMSO or compound 1 (3 μM) and 24 h later the cells were washed to remove
the input drugs and viruses, and viral replication was evaluated by quantification of HIV-1 p24 in
the cell supernatant at different times post-infection.

Figure 10.9 Activity of compound 1 on the infectivity of HIV-1 harboring multi-protease
inhibitor resistant protease mutants. a) VSV-G pseudotyped multi-protease
inhibitor-resistant HIV-1 recombinant infectious molecular clones were produced in
the presence of DMSO, compound 1 (3 μM), or Indinavir (0.1 μM) and their
infectivity evaluated in SupT1 cells. b) SupT1 cells were infected with HIV-1
NL4-3 harboring wild type protease or c) a multi-protease inhibitor resistant
protease mutant (virus 11803) in the presence of DMSO (o) or compound 1 (□) (3
μM) for 24 h and viral replication was tracked by quantifying HIV-1 p24 by ELISA
in the cell supernatant at different days post-infection (PI). Results in a) are
representative of one experiment, and in b) of two independent experiments for
HIV-1 11803, and more than four for NL4-3.
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Viruses were used at p24 levels that result in robust viral replication one week after
infection to compensate for differences in viral fitness. Data in figure 10.9b confirmed that
compound 1 strongly inhibits viral replication of the multi-protease inhibitor-resistant virus 11803
to a similar extent than the protease wild type NL4-3 virus. Therefore, data in figure 10.9 highlight
the potential clinical relevance of fullerene derivatives to block replication of multi-protease
inhibitor resistant viruses.
10.3.9 Effect of fullerene derivatives on the growth of Mycobacterium smegmatis
Mycobacterium tuberculosis is the most common co-infection in HIV-infected
individuals.[472] Therefore, we evaluated the effect of fullerene derivatives on the growth of M.
smegmatis, a biosafety level 1 close relative of M. tuberculosis. These microorganisms share
different biological characteristics and M. smegmatis is being evaluated as a potential candidate
for developing new tuberculosis vaccines.[473]
M. smegmatis was cultured for 16 h in the presence of fullerene 1, 2, 3, or 4 (10 μM),
DMSO, or Rifampicin (0.5 mg/mL) and growth was evaluated by measuring the culture OD640.
Among the different fullerene derivatives evaluated only the regioisomeric mixture 2 inhibited
bacterial growth showing a 61% inhibition compared to DMSO (Figure 10.10a). This inhibitory
activity persisted at 5 μM concentration, but was lost at 2.5 μM (Figure 10.10b). Rifampicin, a
clinically used drug for treating tuberculosis, exhibited an inhibition of 91%. These results indicate
that isomer trans-3 (1) is not active, thus one of the bis-adduct isomers contained in the
regioisomeric mixture 2 is the active compound against this bacterium. This regiomeric specificity
observed in this case is remarkable and further work is being done to determine the identity of the
active isomer.
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Figure 10.10 Activity of fullerene derivatives on the growth of Mycobacterium smegmatis. M.
smegmatis growing in the exponential phase was cultured for 16 h in the presence
of DMSO (+), a) a panel of fullerene derivatives (10 μM) that include compounds 1
(Δ), 2 (◊), 3 (x), and 4 (ο), or b) compound 2 at 1.25 μM (Δ), 2.5 μM (x), 5 μM (◊),
and 10 μM (ο). Rifampicin (□) was used at 0.5 mg/mL as a control. Results of one
experiment are shown.
10.4

DISCUSSION
Fullerene derivatives have been demonstrated to impair HIV-1 replication in human cells;[6,

46, 47, 462-466]

however, detailed virological characterization of the activity of these compounds is

absent, limiting their development as anti-HIV therapeutic agents. Defining the step in the viral
life cycle affected by fullerene derivatives allows for a better understanding of their anti-HIV
mechanism. Molecular docking predictions have proposed that fullerene derivatives could bind to
the active site of HIV-1 protease while the enzyme is in its catalytically active conformation as a
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homodimer.[6,

46, 48, 49, 462, 466]

Other groups have proposed that certain derivatives inhibit

recombinant HIV-1 reverse transcriptase in vitro activity.[465]
Encouraged by these initial findings and the need for novel anti-HIV therapeutics, we
decided to fully characterize the anti-HIV-1 activity of fullerene derivatives 1 and 2. Our data has
corroborated the reported anti-HIV-1 activity of compounds 1 and 2 but do not support findings
or predictions indicating reverse transcriptase[465] or protease[6, 46-49, 466] as their targets. Instead,
we have demonstrated for the first time that these compounds strongly inhibit viral maturation by
a protease-independent mechanism. As a consequence, multi-protease inhibitor resistant viruses
are susceptible to the inhibitory effects of fullerene derivatives, as we showed here, highlighting
the potential clinical relevance of fullerene derivatives to block resistant viruses.
HIV-1 produced in the presence of fullerenes showed a severe defect in infectivity that
correlated with a defect in virion-associated Gag processing. Gag is produced as a polyprotein that
is cleaved by protease at specific sites to generate several mature proteins including matrix, capsid,
nucleocapsid, p6, and two spacer peptides SP1 and SP2. Gag processing occurs in a strictly
organized manner and interfering with this highly ordered process results in immature virions.[474,
475]

As a consequence of their mechanism of action, virions produced in the presence of fullerenes

exhibited a defect in virion-associated reverse transcription activity and a blockage in post-entry
reverse transcription and viral integration. On the contrary, fullerenes do not affect the infectivity
of mature virions, indicating that they target the maturation step. Similar to our findings, the
maturation inhibitor 3-O-(3’,3’-dimethylsuccinyl)betulinic acid (bevirimat) impairs Gag
processing affecting the infectivity of immature, but not mature, viruses.[476-478]
We have also demonstrated that the addends on the C60 fullerenes have pronounced effects
on their anti-HIV-1 activity, beyond simple water solubility effects. The difference in anti-HIV-1
activity between compounds 1, 2, 3 and 4 is completely reliant on the chemical nature of their side
chains. Previously it has been reported that different regioisomers of 2 exhibit similar HIV-1
inhibitory activity and it was concluded that the trans-3 compound 1 is more potent than the
corresponding cis-3 isomer.[463, 464] The fact that the regiochemistry influences the anti-HIV-1
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activity of these fullerene derivatives is important and is currently under investigation in our
laboratories.
In summary, our data indicate that fullerene derivatives affect virion maturation of HIV-1
wild type and multi-protease inhibitor resistant viruses. We also observed that the chemical nature
of the addends and their regiochemistry importantly affect the HIV-1 inhibitory activity of these
compounds. Furthermore, the action mechanism does not target the HIV-1 protease, a paradigmshifting finding. We have synthesized new C70–based compounds, which are more potent and were
used to establish that p24 is the likely inhibitory target protein, see results in the accompanying
article.
10.5

SUPPORTING INFORMATION

10.5.1 Synthesis of compounds 1 and 2
A mixture of C60 (72.00 mg, 0.10 mmol), N-methyl glycine (35.40 mg, 0.40 mmol), and
paraformaldehyde (18.00 mg, 0.60 mmol) was refluxed in toluene (100 mL) for 2 h.[58] The
solution was evaporated under reduced pressure, and the mixture of bis-adducts was isolated by
column chromatography on silica gel using toluene:ethyl acetate (10:1) as eluent. The first fraction
after the pristine fullerene was eluted corresponded to the monoadduct and the next 5 fractions
were collected in one flask and corresponded to the regioisomeric mixture of bis-adducts. Bisadduct trans-3 isomer was purified from the regioisomeric mixture of bis-adducts by column
chromatography on silica gel using toluene:ethyl acetate (20:1.5) as eluent. The third fraction
corresponded to the trans-3 isomer, which was confirmed by 1H-NMR, matrix assisted laser
desorption ionization-time of flight (MALDI-TOF) and UV-Vis. The trans-3 isomer or the
regioisomeric mixture of bis-adducts (10.00 mg, 0.01 mmol) were dissolved in methyl iodide (10
mL) and stirred at room temperature for 48 h to give a brown precipitate.[55, 463] The precipitate
was collected by filtration, and then washed with CS2, CHCl3, toluene, MeOH and acetone in this
order; to afford a brown powder corresponding to compounds 1 or 2 (Scheme 10.1).
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Scheme 10.1 Synthesis of C60-bis(N,N-dimethylpyrrolidinium iodide).
10.5.2 Synthesis of compound 3
Diethyl iminodiacetate (28.35 mg, 0.150 mmol) and glyoxylic acid ethyl ester (0.03 mL,
~0.150 mmol) were added to a solution of C60 (72.00 mg, 0.100 mmol) in toluene (100 mL).3,[464]
The mixture was refluxed for 30 min, and then the solvent was evaporated under reduced pressure.
The tricarboxylic ethyl ester C60 derivative was purified by column chromatography on silica gel
using toluene:ethyl acetate (15:1) as the eluent. The first fraction after pristine fullerene was eluted
corresponded to the tricarboxylic ester C60 derivative. The tricarboxylic ethyl ester C60 derivative
(15.00 mg, 0.015 mmol) was dissolved in toluene (20 mL), and NaH (120.00 mg, ~0.120 mmol)
50-60% in oil was slowly added and the reaction was stirred at room temperature for 1 h, then
ethanol (3 mL) was added followed by the addition of HCl (3M, 2 mL), then the reaction was
stirred at room temperature overnight.3,[464] The solvent was evaporated under reduced pressure,
the precipitate was washed with chloroform, methanol and cold water, and finally compound 3
was recrystallized from methanol/acetone. The structures of the compounds were confirmed by
1

H-NMR and MALDI-TOF (Scheme 10.2).
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Scheme 10.2 Synthesis of fullereno-C60-pyrrole-2,5-dicarboxylic acid-1-(carboxymethyl)-1,5dihydro.
10.5.3 Synthesis of compound 4
Bis-adduct cis-2 isomer was synthesized following a previously reported procedure,[479] the
cis-2 isomer (15.00 mg, 0.016 mmol) was dissolved in ortho-dichlorobenzene (o-DCB, 4 mL), and
methyl iodide (4 mL) and stirred at 40 ºC for 2 weeks to give a brown precipitate. The precipitate
was collected by filtration and washed with CS2, CHCl3 and MeOH in this order; to afford a brown
powder corresponding to compound 4 (Scheme 10.3).

Scheme 10.3 cis-2-C60-bis(N,N-ethylmethylpyrrolidinium iodide).
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Figure 10.11 1H-NMR (600 MHz; CDCl3, 298 K) of trans-3-C60-bis(N-methylpyrrolidine).
δ 4.38 (2H, d, CH3-N-CH2), 4.37 (2H, d, CH3-N-CH2), 4.31 (2H, d, CH3-N-CH2), 4.30 (2H,
d, CH3-N-CH2), 4.14 (2H, d, CH3-N-CH2), 4.12 (2H, d, CH3-N-CH2), 4.05 (2H, d, CH3-N-CH2),
4.04 (2H, d, CH3-N-CH2), 2.90 (6H, s, CH3-N-CH2) ppm.

Figure 10.12 MALDI-TOF of trans-3-C60-bis(N-methylpyrrolidine) using 1,1,4,4-tetraphenyl1,3-butadiene (TPB) matrix.
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Figure 10.13 UV-Vis of trans-3-C60-bis(N-methylpyrrolidine) in chloroform solution.

Figure 10.14 1H-NMR (600 MHz; DMSO-d6, 298 K) of trans-3-C60-bis(N,Ndimethylpyrrolidinium iodide) (1).
δ 5.76 (2H, m, N-CH2), 5.62 (2H, m, N-CH2), 5.51 (2H, m, N-CH2), 5.38 (2H, m, N-CH2),
4.07 (6H, s, CH3-N), 3.92 (6H, d, CH3-N) ppm.

Figure 10.15 MALDI-TOF of trans-3-C60-bis(N,N-dimethylpyrrolidinium iodide) (1) using TPB
matrix.
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Figure 10.16 1H-NMR (600 MHz; CDCl3, 298 K) of Fullereno-C60-pyrrolidine-2,5-di(carboxylic
ethyl ester)-1-(2-ethyl acetate).
δ 6.14 (2H, s, C60-CH), 4.34 (2H, q, O-CH2-CH3), 4.33 (4H, q, O-CH2-CH3), 4.28 (1H, d,
N-CH2-CO), 4.12 (1H, d, N-CH2-CO), 1.39 (3H, t, CH2-CO-O-CH2-CH3), 1.24 (6H, t, N-CO-OCH2-CH3) ppm.

Figure 10.17 MALDI-TOF of fullereno-C60-pyrrolidine-2,5-di(carboxylic ethyl ester)-1-(2-ethyl
acetate) using TPB matrix.
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Figure 10.18 1H-NMR (600 MHz; DMSO-d6, 298 K) of Fullereno-C60-pyrrolidine-2,5di(carboxylic acid)-1-(acetic acid) (3).
δ 4.24 (2H, s, N-CH-CO), 5.65 (2H, s, N-CH2-CO) ppm

Figure 10.19 MALDI-TOF of Fullereno-C60-pyrrolidine-2,5-di(carboxylic acid)-1-(acetic acid)
(3) using TPB matrix.
1

H-NMR (600 MHz; DMSO-d6, 298 K) of compound 4; δ 8.21 (1HAr, d, J= 7.75), 8.00

(1HAr, d, J= 7.68), 7.66 (1HAr, t), 7.56 (1HAr, t), 5.78 (1H, d, N-CH2, J = 11.91), 5.24 (1H, d, NCH2, J = 12.01), 4.94 (1H, d, N-CH2, J = 10.44), 4.70 (1H, s, N-CH-Ph), 4.60 (2H, m, N-CH2CH3), 4.44 (2H, m, N-CH2-CH3) 4.13 (3H, s, N-CH3), 3.83 (1H, d, N-CH2, J = 10.38), 3.55 (1H,
s, N-CH-Ph), 3.50 (3H, s, N-CH3), 3.25 (6H, t, N-CH2-CH3) ppm.
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Figure 10.20 MALDI-TOF of compound 4 using TPB matrix. The deviations from the calculated
isotopic distribution is due to pronation of the sample.
10.5.4 Synthesis of compound 5
Compound 5 was synthesized following a previously reported procedure,[6] (Scheme 10.4).

Scheme 10.4 Synthesis of compound 5.
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Figure 10.21 MALDI-TOF of compound 5 using 1,8,9-trihydroxyanthracene (THA) matrix.

Figure 10.22 Effect of compound 5 on HIV infection. a) Effects on the early stages of HIV-1
viral life cycle. SupT1 cells were treated with compound 5 (3 μM) and infected with
a single-round infection HIV-1 virus for 24 h followed by removal of remind
compound and input virus. Cells were used 3 days later to measure luciferase
activity and cellular viability (ATP content). Luciferase values were normalized to
cellular viability. b) Effects of compound 5 on the late phase of HIV-1 infection.
VSV-G pseudotyped, single-round HIV-1 expressing luciferase were produced in
the presence of DMSO or compound 5 (3 μM) and then concentrated by
ultracentrifugation and analyzed. The infectivity of these viruses was analyzed in
single-round infection assays using HIV-1 p24-normalized viruses.
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Figure 10.23 Effect of compound 5 on the in vitro activity of HIV-1 protease. The cleavage of an
HIV-derived FRET peptide by recombinant HIV-1 protease in the presence of
compound 5 at 3 μM (□) and 10 μM (∆) was determined by fluorometry. DMSO (◊)
and Indinavir (x) were used as negative and positive controls, respectively.
Experiments were performed in duplicates.
10.5.5 Plasmids
Retroviruses expressing plasmids. HIV-1NL4-3 was produced from the corresponding
expression plasmid whereas multi-protease inhibitors resistant viruses were produced with
plasmids obtained from the NIH AIDS Reagent Program (Catalog numbers 11801, 11803, 11805,
11806, 11807, 11808, and 11809) as previously described.[480]
10.5.6 HIV-1 p24 ELISA
HIV-1 p24 levels were determined by a sandwich ELISA (ZeptoMetrix Corporation,
catalog number 0801008) following manufacturer instructions.
10.5.7 Cellular viability assay
Cell Titer 96 Aqueous One Solution Cell Proliferation Assay, catalog number G3582,
Promega.
10.5.8 Exogenous reverse transcriptase assay
EnzChek® Reverse Transcriptase Assay Kit (Life Technologies, catalog number E22064).
10.5.9 HIV-1 protease in vitro activity assay
ProAssayTM HIV-1 Protease Assay Kit (ProteinOne, catalog number P9003).
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10.5.10

Immunoblotting

HIV-1 p24 was detected with anti-p24 (1/2, catalog number 1513, a gift from the NIH
AIDS reagent program), HIV-1 integrase was detected with anti-integrase (1/200, catalog number
sc-69721, Santa Cruz Biotechnology).
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Chapter 11: Characterization of new cationic N,Ndimethyl[70]fulleropyrrolidinium iodide derivatives as potent HIV-1
maturation inhibitors
Abstract: HIV-1 maturation can be impaired by altering protease (PR) activity, the
structure of the Gag-Pol substrate, or the molecular interactions of viral structural proteins. Here
we report the synthesis and characterization of new cationic N,N-dimethyl[70]fulleropyrrolidinium
iodide derivatives that inhibit more than 99% of HIV-1 infectivity at low micromolar
concentrations. Analysis of the HIV-1 life cycle indicated that these compounds inhibit viral
maturation by impairing Gag and Gag-Pol processing. Importantly, fullerene derivatives 2a-c did
not inhibit in vitro PR activity and strongly interacted with HIV immature capsid protein in pulldown experiments. Furthermore, these compounds potently blocked infectivity of viruses
harboring mutant PR that are resistant to multiple PR inhibitors or mutant Gag proteins that confer
resistance to the maturation inhibitor Bevirimat. Collectively, our studies indicate fullerene
derivatives 2a-c as potent and novel HIV-1 maturation inhibitors. Experimental procedures and
figures presented here are a pre-peer reviewed version of the following article: Castro, E.;
Martinez, Z. S.; Seong, C. S.; Cabrera-Espinoza, A.; Ruiz, M.; Hernandez, G., A; Valdez, F.;
Llano, M.; Echegoyen, L. A. (See Appendix E for the copyright letter) J. Med. Chem. 2016, 59,
10963-10973.
11.1

INTRODUCTION
The emergence of resistant human immunodeficiency virus (HIV) strains limits the

therapeutic efficiency of current anti-retroviral therapies.[481] Therefore, discovery of new antiviral
agents remains an important goal for HIV-1 infection treatment. These agents may act by impairing
viral maturation, a process in which Gag and Gag-Pol polyproteins are sequentially cleaved by PR
to produce viral enzymes and structural proteins that are required for viral replication.[482-484]
Pharmacological and genetic evidence demonstrates that impairment of viral maturation is
a powerful strategy to block HIV-1 replication in vivo and in vitro. HIV-1 is released from infected
cells in the form of immature, non-infectious virions that must undergo maturation before
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acquiring full infectivity. Viral maturation is triggered by proteolytic processing of Gag and GagPol polyproteins by HIV-1 PR. This processing results in the production of functional viral proteins
including capsid (CA) proteins, which assemble into the viral core. HIV-1 maturation can be
hindered by drugs that act as PR inhibitors (PIs) or as maturation inhibitors (MIs). The latter can
bind to Gag and affect it’s processing or to CA, thus impairing core assembly. MIs binding to
mature CA do not affect PR-mediated processing, whereas those targeting CA-SP1 selectively
block the cleavage between CA and SP1, allowing normal processing of Gag and Gag-Pol at other
cleavage sites.[355, 476, 477, 485-496] Currently, there are no maturation inhibitors used clinically.[356]
Since the discovery of fullerene C60,[1] efficient synthetic methods for fullerene
functionalization have been developed.[12, 13] Functionalization with highly polar or ionic groups
is the most commonly used approach to obtain water soluble fullerene derivatives for biomedical
applications.[497,

498]

C60 and C70 fullerene derivatives have been shown to affect HIV-1

replication.[6, 46] The currently accepted fullerene-induced inhibition mechanism suggests binding
to the PR active site[52, 462] as was determined by analysis of the effect of these compounds on the
in vitro activity of this enzyme combined with in silico predictions of the interaction of these
compounds with the active site of HIV-1 PR. However, this paradigm has recently being
challenged[357] by the fact that C60 fullerene derivatives failed to significantly inhibit HIV-1 PR in
in vitro assays at doses that potently blocked HIV-1 maturation and infection.
To date, there are only a few examples of water-soluble C70 derivatives,[46, 54] partly due to
the challenges involved in regioselective functionalization. N-quaternization of C60fullerenopyrrolidines is an excellent and high-yielding reaction to synthesize water-soluble C60fullerenopyrrolidium salts.[55] In this study we report the first synthesis and characterization of C70
quaternary ammonium salts, and their strong anti-HIV properties. Our data demonstrated that these
compounds blocked HIV-1 maturation. Importantly, at doses that potently blocked Gag and GagPol processing, these compounds did not affect HIV-1 PR in vitro activity; therefore, not
supporting the current paradigm that fullerene derivatives are HIV-1 PR inhibitors. Furthermore,
pull-down experiments using magnetic bead-immobilized fulleropyrrolidinium derivatives
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demonstrated their strong interaction with immature HIV-1 CA proteins and this specificity
correlated with the anti-HIV-1 activity of these compounds. However, further studies are necessary
to validate immature CA as the molecular target of the anti-HIV activity of C70 fullerene
derivatives.
11.2

RESULTS

11.2.1 Design and synthesis of C70 fullerene derivatives
The synthesis and characterization of C70 pyrrolidinium iodide salts 2a-c, 3 and 5, is
schematically represented in Figure 11.1, as described in the methods section. The structure of the
C70 derivatives 2b and 2c was confirmed by 1H-,

13

C-NMR and by matrix assisted laser

desorption/ionization-time-of-flight-mass spectrometry (MALDI-TOF-MS) (Figures 11.12 and
11.13). Their synthesis is very reproducible, and their high purity is optimal for virological assays.
Functionalization of 1b with malonate addends I and II yielded the regioisomeric mixtures 3 and
5, respectively (detailed synthesis and characterization of malonates I and II is presented in the
Figures 11.9, 11.14 and 11.15). N-quaternization of these compounds afforded the corresponding
regioisomeric mixtures 11.4 (Figures 11.14, 11.18, and 11.19) which were characterized by
MALDI-TOF-MS (Figures 11.16 and 11.17).
11.2.2 Effect of C70 fullerene derivatives on the early stages of the HIV-1 life cycle
The effect of compounds 2a-c on the infectivity of VSV-G pseudotyped HIV-1 singleround infection viruses expressing LTR-driven luciferase (HIV-luc) was evaluated using the
human CD4+ T cell line SupT1. These cells were infected with HIV-luc in the presence of DMSO
(vehicle control) or fullerene derivatives 2a-c (10 µM) and 24 h later the compounds and the input
virus were removed. After three days cellular luciferase and ATP levels were measured and
luciferase was normalized to ATP to adjust for cell viability and number. In these experiments,
compound 2a only minimally affected HIV-1 infectivity whereas compounds 2b and 2c were
inactive (Figure 11.2a).
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Figure 11.1 Chemical structures of the C70 fullerene derivatives 2a-c, 4 and 6 synthesized in this
work.
Having prepared the cationic C70 derivatives, we first studied their anti-HIV-1 activity and
the viral life cycle step affected by the regioisomeric mixture 2a, and the pure compounds 2b and
2c.
These data indicate that fullerene derivatives did not significantly affect the early steps of
the HIV-1 life cycle required for HIV–driven luciferase expression including viral entry and
uncoating, reverse transcription, integration of viral cDNA, and HIV-1 Tat-mediated gene
expression. These results also demonstrated that these compounds were not toxic to SupT1 cells
at 10 µM.
11.2.3 Effect of C70 fullerene derivatives on the late stages of the HIV-1 life cycle
To evaluate whether the fullerene derivatives affect the late steps of viral development, we
produced HIV-luc by plasmid transfection in HEK293T cells in the presence of DMSO, fullerene
derivatives 2a-c (0.1, 0.5, and 1 µM), or indinavir[483] (0.1, 0.01, and 0.001 µM). The latter is a PR
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inhibitor known to potently inhibit HIV-1 maturation. Viruses were concentrated by
ultracentrifugation through a sucrose cushion, normalized for p24 levels, and their infectivity
evaluated in untreated SupT1 cells as described in figure 11.2a. As expected, indinavir produced
96%, 56% and 14% inhibition at 0.1 μM, 0.01 μM and 0.001 μM, respectively (Figure 11.2b), as
compared to DMSO. Importantly, compounds 2a-c caused more than 99% reduction of infectivity
at 1 μM, whereas at 0.5 μM these compounds inhibited 87.4% (2a), 99.2% (2b) and 76% (2c) of
viral infectivity (Figure 11.2b).

Figure 11.2 Effect of fullerene derivatives 2a-c on HIV-1 infection. (a) Effect on the early steps
of the viral life cycle. (b) Effect on the infectivity of the viruses produced in the
presence of fullerene derivatives. (c) Effect on the amount of virions produced in
the presence of fullerene derivatives. Means and standard deviations in (a and b)
represent luciferase values normalized to ATP from three independent experiments,
while data in (c) correspond to two independent viral productions (Viruses
produced in the presence of compound 2c at 3 μM were generated only once).
However, none of the compounds were significantly active at 0.1 μM. Linear regression
analysis of these data also indicated that the concentration at which 50% of their maximum
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response was reached (EC50) was 0.41 μM, 0.33 μM, and 0.54 μM for compounds 2a, 2b, and 2c,
respectively. Comparison with indinavir (EC50 39.23 nM) indicates that compounds 2a-c were
between 8-13-fold less potent than this therapeutic drug.
To evaluate the late step of the viral life cycle affected by fullerene derivatives we analyzed
their effect on viral particle production by measuring the levels of p24 (Capsid protein, CA) in
virions concentrated by ultracentrifugation through a 20% sucrose cushion. Importantly, the
ELISA used to quantify p24 detects both HIV-1 PR-fully processed mature CA and partially- or
non-processed immature CA (Figure 11.21). Data in Figure 11.2c indicate that at either 0.5 μM
or 3 μM fullerene compounds minimally affected virion production, although viral infectivity was
blocked at these concentrations (Figure 11.2b). These findings indicate that fullerene derivatives
did not affect LTR-driven gene expression, virion production, or cellular viability.
In addition, results in Figure 11.2 clearly indicate that fullerene derivatives drastically
reduce the infectivity of virions produced in their presence.
11.2.4 Effect of C70 fullerene derivative 2a and 2b on HIV-1 replication
Since fullerene derivatives 2a and 2b were more potent than 2c (Figure 11.2b), we
characterized them in further details by evaluating their effect on HIV-1 replication in SupT1 cells.
Cells were infected with HIV-1 NL4-3 for 24 h. Then the input virus was removed and the infected
cells distributed in cultures containing DMSO or fullerene derivatives 2a and 2b at 3 or 1.5 μM.
Cells were cultured for two weeks by replacing every 48 h half of the culture with fresh medium
containing no drugs. Supernatant was collected every 48 h, before feeding the cells, and used for
quantification of HIV-1 p24 by ELISA. In these experiments we observed a robust inhibitory effect
of fullerene derivatives 2a and 2b at 3 μM, but this activity decayed at 1.5 μM (Figure 11.3a i-iv).
At the replication peak (day 10 post-infection) fullerene derivatives inhibited more than 92 % of
viral replication and that effect dropped to 71-80% inhibition at 1.5 μM, whereas at 1 μM these
compounds did not inhibit viral replication (Data not shown).
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The inhibitory potency of fullerene derivatives 2a and 2b was markedly different between
wild type and single-round infection, VSV-G-pseudotyped HIV-1 (Figure 11.3a vs. 11.2b). To
exclude any potential effect of fullerene derivatives on VSV-G virion incorporation, we
determined the effect of fullerene 2b, the most potent of all the compounds evaluated, on the
replication of the Rhabdovirus Vesicular Stomatitis Virus which requires VSV-G for infection.
Findings represented in Figure 11.3b indicated that fullerene 2b at 3 μM did not interfere with the
replication of Vesicular Stomatitis Virus in SupT1 cells, thus excluding any deleterious effect of
fullerene derivatives on VSV-G-dependent functions. Furthermore, these data indicate the HIV-1specificity of these compounds, excluding any toxic effect on the target cells.
11.2.5 Effect of C70 fullerene derivatives on cell viability
Several experimental evidences (Figures 11.2a, 11.2c, and 11.3b) demonstrated that at
doses that fullerene derivatives block HIV-1 infectivity (Figure 11.2b and 11.3a) other viral
processes that requires preservation of cell viability are not affected, indirectly indicating that the
inhibitory effects observed with these compounds are not due to cellular toxicity. To further
evaluate the toxicity of these compounds we calculated the concentration of fullerene derivatives
2a-c that kills approximately 50% of SupT1 cells (LC50). SupT1 were treated with different doses
of the compounds for 24 h and then cell viability was measured by quantifying the cellular ATP
levels. In these experiments we observed approximately 92% of viability in cells treated with 3
μM of fullerene derivatives 2a-c (Figure 11.3c), whereas at 48 μM the viability dropped to 6070%. Linear regression analysis of these data indicated an LC50 of 60.6 μM, 53.8 μM , and 104.2
μM for compounds 2a, 2b, and 2c, respectively. This indicated more than 148-fold difference
between the LC50 and EC50 of these compound; therefore, ratifying that the inhibitory effects
observed on HIV-1 infection are not due to decreased viability of the target cells.
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Figure 11.3 (ai-iv) Effect of fullerene derivatives 2a and 2b on NL4-3 replication. SupT1 cells
were infected and then cultured in the presence of DMSO (continuous lines) or
fullerene derivatives (discontinuous lines). Concentration and fullerene derivative
used are indicated in the graphics. HIV-1 p24 was quantified in the cell supernatant
collected at different days post-infection (P.I.). Two independent experiments are
represented for each dose and compound. (3b) Effect of fullerene derivative 2b on
the infectivity of a Vesicular Stomatitis Virus engineered expressing eGFP. SupT1
cells were infected at MOIs 0.1 and 1 in the presence of DMSO (blue bars) or 2b (3
M, green bars) and eGFP was determined 24 h later by FACS analysis. Average
and standard deviations of two experiments are represented. (3c) Effect of C70
fullerene derivatives 2a-c on cell viability. SupT1 cells were treated with different
concentrations of fullerenes 2a-c and DMSO for 24 h before cell viability was
measured. Values detected in the cells treated with fullerene derivatives were
expressed as a function of those found in DMSO-treated cells. Means and standard
deviations in figures (a and b) are representative of two independent experiments,
and in figure (c) of three independent experiments.
11.2.6 Effect of fullerene derivatives 2a-c on HIV-1 Gag and Gag-Pol processing
Our data clearly show that fullerenes 2a-c impair HIV-1 viral infectivity by affecting virion
maturation. To evaluate this inhibition mechanism, we determined the effect of these compounds
on PR-mediated Gag and Gag-Pol processing. HEK293T cells were transfected with the HIV-luc
expression plasmid and culture for 24 h in the presence of DMSO, fullerenes 2a-c (3 μM), and
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indinavir (0.1 μM). Then cell lysates were analyzed by immunoblot using an anti-capsid (CA, p24)
monoclonal antibody. Capsid is a domain in Gag, therefore, non- or partially processed Gag and
Gag-Pol proteins containing CA are detected in this assay. Data in Figure 11.4a indicate a
pronounced defect in Gag and Gag-Pol processing of virions produced in the presence of C70
fullerene derivatives, which directly correlate with the decreased infectivity observed for these
viruses (Figure 11.4b). Fullerene-treated virions presented partially processed Gag-Pol in contrast
with virions produced in the presence of indinavir. HIV-1 proteins in Gag are ordered from the Nto the C-terminus as matrix (p17, MA, 17 kDa), capsid (p24, CA, 24 kDa), spacer peptide 1 (SP1,
2 kDa), nucleocapsid (NC, 7 kDa), spacer peptide 2 (SP2, 1 kDa), and late domain containing
protein P6 (P6, 6 kDa).[484, 499] PR-mediated Gag processing occurs in a fixed order that results in
several processing intermediates, some of which are indicated in Figure 11.4a. Several CAcontaining Gag fragments, presumably identified as CA-SP1-NC (~33 kDa) and CA-SP1 (~25
kDa),[484] were enriched in the fullerene- but not in the indinavir-treated virions. Therefore,
indinavir and C70 fullerene derivatives 2a-c affect Gag and Gag-Pol processing by different
mechanisms.

Figure 11.4 Effect of fullerene derivatives on PR-mediated Gag and Gag-Pol processing and
infectivity. (a) Immunoblot analysis of Gag and Gag-pol processing in virions. (b)
Infectivity of virions evaluated in panel (a). Data are representative of two
independent experiments.
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11.2.7 Anti-viral activity of C70 fullerene derivative 2a on drug-resistant HIV-1
The effect of fullerene derivatives on HIV-1 molecular clones harboring a panel of PR
mutants that are resistant to multiple PR inhibitor or Gag mutants resistant to the maturation
inhibitor Bevirimat[494] was determined to assess the potential clinical relevance of the molecular
target of fullerene inhibitors. HIV-luc-derived viruses harboring the PR mutants were produced by
plasmid transfection in HEK293T cells in the presence of DMSO, indinavir (0.1 µM), or
compound 2a (3 µM). The mutant viruses analyzed included 11803, 11806, 11807, 11808, and
11809 that are resistant to nelﬁnavir,[471] fosamprenavir,[471] saquinavir,[471] indinavir,
atazanavir,[471] lopinavir,[471] tipranavir,[471] and darunavir;[471] and 11805 that is resistant to these
drugs except for tipranavir and darunavir. The PR (99 amino acids) in these viruses contains
between 10 and 24 point mutations that evolved in patients subjected to highly active antiretroviral
therapy. The produced viruses were normalized for p24 and used to infect SupT1 cells. Four days
after infection, luciferase levels were measured and normalized to ATP. In these experiments, we
found that compound 2a potently inhibited all the multi-protease inhibitor resistant viruses (Figure
11.5) and the reporter viruses harboring wild type protease to a similar extent (Figures 11.2b). As
expected, indinavir failed to significantly affect the infection of the resistant viruses.

Figure 11.5 Effect of fullerene derivative 2a (3 M) and indinavir (0.1 M) on the infectivity of
HIV-luc-derived viruses carrying PR mutants resistant to multiple clinically
approved PR inhibitors. Mean and standard deviation values represent the
variability of triplicate readings of one experiment.
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We also evaluated the effect of fullerene 2b on the infectivity of HIV-1 NL4-3 harboring
Gag mutations at the C-terminus of CA [L363F and V362L/L363M (VL/LM)], as well as wild
type SIV. These viruses are resistant to the maturation inhibitor Bevirimat.[485, 495] Viruses were
produced by plasmid transfection in HEK293T cells in the presence of DMSO or fullerene 2b (3
μM) and their infectivity was determined in SupT1 cells or TZM-bl cells using p24- or p27normalized HIV-1 or SIV, respectively. Comparison of the infectivity of viruses produced in the
presence of DMSO or fullerene 2b demonstrated that this compound potently inhibits the ability
of these viruses to replicate in SupT1 cells (Figures 11.6a and 11.6b) or to infect the reporter cell
line (Figure 11.6c), demonstrating no cross-reactivity between fullerene 2b and Bevirimat. This
is expected since Bevirimat only impairs processing of CA-SP1, whereas the effect of fullerene
2b on Gag processing is much broader.

Figure 11.6 Effect of fullerene 2b on the infectivity of wild type SIV and HIV-1 NL4-3
harboring mutations at the C-terminus of CA. Replication of HIV-1 produced in the
presence of DMSO or fullerene 2b (3 M) in SupT1 cells was evaluated by HIV-1
p24 ELISA. (a) NL4-3 VL/LM CA mutation. (b) NL4-3 L363F CA mutation. (c)
The infectivity of HIV-1 NL4-3 CA mutants L363F and V362L/L363M (VL/LM)
and wild type SIV produced in the presence of DMSO or fullerene 2b (3 M) was
analyzed in the reporter cell line TZM-bl. Data in figures (a) and (b) correspond to
one experiment. Mean and standard deviation values in figure (c) represent the
variability of three independent experiments.
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In addition, these findings highlight the potential clinical relevance of the molecular target
of fullerene derivatives.
11.2.8 Effect of derivatives 2a and 2b on HIV-1 PR in vitro activity
Our data indicate that fullerene derivatives impair HIV-1 maturation by affecting Gag and
Gag-Pol processing. This effect could be the result of direct inhibition of HIV-1 PR or due to a
modification of the substrate or its accessibility to this enzyme. To understand better the
mechanism and to test the established paradigm that HIV-1 PR is the target for fullerene inhibition,
we determined their effect on the activity of HIV-1 PR in vitro.
Enzymatic assays are the oldest and still the most common approach to test the inhibition
of HIV-1 PR.[500, 501] The assay we used is based on the PR cleavage of a fluorogenic substrate
derived from the native p17/p24 (MA/CA) cleavage site on Gag. As expected, indinavir at 0.1 µM
completely inhibited processing of the substrate (Figure 11.7). However, C70 derivatives 2a and
2b at concentrations that inhibit more than 99% of viral infectivity (~7-9-fold IC50) showed no
effect on PR activity (Figure 11.7).

Figure 11.7 Effect of compounds 2a and 2b on the in vitro activity of HIV-1 PR. The cleavage of
an HIV-derived FRET peptide by recombinant HIV-1 PR in the presence of
compounds 2a (a) and 2b (b) at 3 μM determined by fluorescence measurements.
Indinavir at 0.1 M was used as the control. Mean and standard deviation values
represent the variability of three independent experiments.
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11.2.9 Effect of C70 fullerene derivatives on the early stages of the HIV-1 life cycle
Having established that PR is not the direct target of these fullerenes against HIV-1
infection, and considering that these compounds generate more CA-containing Gag processing
intermediates than indinavir (Figure 11.4a), which also suggest that compounds 2a-c likely act
through a different mechanism of inhibition, we evaluated the interaction of Gag-derived proteins
with compound 2b.
Azide magnetic beads (7) were functionalized using fullerene derivatives 2b as bait. The
synthesis of functionalized magnetic beads starts from the -isomer 1b, which after a Bingel
nucleophilic cyclopropanation with acetylenes I or II yields the regioisomeric mixtures 3 and 5
respectively (Figure 11.1). After quaternization of these compounds to yield 4 and 6 respectively,
they were coupled to the azide magnetic beads via “click chemistry” to obtain functionalized
magnetic beads with one (8) and two (9) acetylene groups respectively, as described in the
materials and methods section. Proof that the ‘click reaction’ was successful comes from the
disappearance of color when a magnet is placed close to the reaction vessel (Figure 10). Additional
proof comes from infrared (IR) spectroscopy (Figure 11.20), which showed the disappearance of
the azide and acetylene stretching vibration bands near 2100 cm-1 and the appearance of new bands
between 900 to 1700 cm-1 and 2900 and 3000 cm-1, confirming the presence of the fullerene cage.
Magnetic beads coupled to fullerene 6 showed similar IR characteristics.
To evaluate whether the functionalization of 2b with malonates I and II disrupted its antiHIV-1 activity, HIV-luc was produced by plasmid transfection in HEK293T cells in the presence
of fullerene derivatives 11.2b, 11.4, 11.6 (3 µM), or DMSO. The infectivity of the produced viruses
was evaluated in single-round infection assays in SupT1 cells as described in Figure 2b. Data in
Figure 11.8a shows that functionalization of fullerene 2b using a symmetric dihexynyl malonate
II (compound 6) resulted in the total loss of its anti-HIV-1 activity, whereas substantial inhibitory
activity was preserved for compound 4, which has only one acetylene group (Figure 11.1). These
findings highlight the relevance of the addends in the anti-HIV activity of fullerene derivatives.
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Next, we determined the interaction of fullerene derivatives with HIV-1 Gag. Cell lysates
obtained from HEK293T cells that were transfected with a plasmid expressing Gag and Gag-Pol
polyproteins (pCMVΔR8.91) were incubated overnight with pristine beads, beads coupled to
fullerenes 4 and 6 followed by washing and boiling of the beads. Bound proteins were analyzed
by immunoblot with an anti-p24 (HIV-1 CA) monoclonal antibody (183-H12-5C). This antibody
recognizes non-processed and processed Gag proteins containing the p24 domain. Data in Figure
11.8b demonstrate that an immature CA-containing Gag product of ~25 kDa, potentially
corresponding to the CA-SP1 fragment, strongly and specifically binds to beads coupled to
fullerenes 4. This protein was not recovered from the non-functionalized beads or beads coupled
to fullerenes 6 pull-down experiments, in accordance with the anti-HIV-1 activity of compounds
4 and 6.

Figure 11.8 (a) Effect on HIV-1 infectivity of fullerene 2b, and compounds 4 and 6. (b) Analysis
of the pull-down products using beads functionalized with active or inactive
fullerene derivatives 4 and 6, respectively. Mean and standard deviation values in
figure (a) represent the variability of two independent experiments, and data in
figure (b) is representative of three independent experiments.
Similar results were obtained with an anti-p24 monoclonal antibody that reacts against an
epitope located within amino acids 48-62 of CA, highlighting the identity of the pulled-down
protein (Data not shown).
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11.3

RESULTS AND DISCUSSION
C70 and C60 fullerene derivatives have been reported to impair HIV-1 replication in human

cells by ill-defined mechanisms.[6,

46, 462-466]

Only recently,[357] our group systematically

characterized the anti-HIV-1 activity of C60 fullerene derivatives, discovering that these
compounds severely impair HIV-1 maturation at doses that do not affect the in vitro activity of
HIV-1 PR. Here, we described the synthesis and potent anti-HIV-1 activity of novel C70 derivatives
and confirmed that C70 and C60 fullerene derivatives share a similar mechanism of action. We
demonstrated, for the first time, that C70 fullerene derivatives 2a-c inhibit HIV-1 maturation by
blocking Gag and Gag-Pol processing. The mechanism seems to be PR independent since these
compounds did not inhibit in vitro PR activity at doses that potently block Gag and Gag-Pol
processing. These findings, however, contrast with a previous report[6] indicating that fullerene
derivatives affect in vitro PR activity. Important differences in the methodology used could explain
these contradictory findings. Perhaps the most relevant is the nature of the substrate used in the
assays; the previous study used a non HIV peptide as substrate, whereas we used a peptide
representing the natural substrate found at the MA-CA cleavage site. The artificial peptide
substrate has a 3-fold higher turnover rate (kCat) than the peptide that we used. According to
calculations using the Hopp–Woods hydrophilicity scale, the artificial peptide was significantly
more water soluble than the HIV-derived peptide that we used, potentially explaining its higher
kCat. Aqueous solubility is an important property of peptide substrates with improved kCat.[501,
502]

Therefore, the addition of hydrophobic compounds to the in vitro PR assay, such as the C60

fullerene derivatives assayed in the reported study, could have compromised the aqueous solubility
of the peptide affecting its rate of cleavage by PR. Thus, our findings illustrate the relevance of
studying natural vs. artificial substrates in the case of HIV-1 PR. Another important difference
between our assay and the one previously reported is that we used a continuous assay that allowed
analysis of the enzymatic activity at multiple time points, whereas the previous report used a single
point assay that measured the effect of the compounds when <15% of the product was generated.
Then, our findings also point out another advantage of continuous vs. single point assays to
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evaluate inhibitors of HIV-1 PR. Therefore our data here, and recently published,[357] alter the
long-established and unchallenged paradigm that fullerene-derivatives inhibit HIV-1 infectivity
via binding to PR.[6, 47, 52, 360, 462, 465, 466, 503-505]
Importantly, the antiviral activity of fullerene derivatives correlated with their interaction
with an immature CA protein of ~25 kDa, presumably CA-SP1. However, we have not
unequivocally demonstrated that the binding to immature CA proteins is responsible for the antiviral activity of fullerene derivatives. Nevertheless, we propose a model indicating that interaction
of fullerene derivatives to CA in unprocessed Gag or Gag-Pol modifies the conformation or
assembly of these substrates, altering the specificity and/or activity of PR and therefore causing
defective processing. Importantly the parameters that regulate the interaction of PR with its
multiple natural, nonhomologous, substrates is unclear; thus clarification of the mechanism of
action of the C70 fullerene derivatives will potentially increase our understanding of this process.
Similar to C70 fullerenes 2a-c, Bevirimat and 1-[2-(4-tert-butylphenyl)-2-(2,3-dihydro-1Hinden-2-ylamino)ethyl]-3-(trifluoromethyl)pyridin-2(1H)-one

(PF-46396)[506]

interact

with

immature CA. However, in contrast with these compounds that affect Gag processing only at the
binding site, CA-SP1,

[485, 491, 506, 507]

fullerene derivatives 2a-c produce a global impairment of

processing indicating a distinct mechanism of action. In further support of this, fullerene
derivatives block the infectivity of Bevirimat-resistant HIV-1 molecular clones and viruses.
Similarly, HIV-1 viruses resistant to multiple PR inhibitors are also blocked by C 70 fullerenes.
These findings highlight the potential clinical relevance of the molecular target of fullerene
derivatives.
In summary, our studies show that fullerene derivatives 2a-c act through a novel anti-HIV1 mechanism not yet reported for other CA-interacting compounds. Unraveling the details of this
unprecedented mechanism will open new avenues for the discovery of novel anti-HIV-1 inhibitors.
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11.4

EXPERIMENTAL SECTION

11.4.1 Chemical synthesis of C70 fulleropyrrolidium derivatives
We initially synthesized the neutral C70 pyrrolidine derivatives 1a-d,[508] and the key
intermediates for the synthesis of the quaternary ammonium salts 2a-c, 4 and 6, the purity of these
compounds was higher than 99% as determined by HPLC. Subsequent N-methylation of
compounds

1a-c

yielded

the

regioisomeric

mixture

2a

and

the

pure

C70-(N,N-

dimethylpyrrolidinium iodide) isomers 2b and 2c. Malonates I and II were synthesized by the
reaction of hexynyl alcohol S1 with the corresponding acid chlorides S2 and S3, see Figure 11.9.
These addends were used to strategically introduce the acetylene functionalities (compounds 3 and
11.5) starting with 1b. The C70 fulleropyrrolidinium iodides 4 and 6 were synthesized following a
similar procedure to that used for the synthesis of compounds 2a-c. Finally, magnetic beads were
independently functionalized using compounds 4 and 6 using ‘click chemistry’ (Figures 11.1 and
11.7). Detailed descriptions of the synthetic procedures can be found in the Supporting
information.
11.4.2 Plasmids
HIV-1-derived vectors were produced using pHIV-luc and pMD.G. pHIV-luc was derived
from pNL4-3.Luc.R–E[470] by introducing a deletion in the env open reading frame. pMD.G
encodes the Vesicular Stomatitis Virus Glycoprotein G (VSV-G). Gag and Gag Pol were expressed
with the HIV-1 packaging plasmid pCMVΔR8.91 (a gift of D. Trono) and Gag with the expression
plasmid p96ZM651gag-opt (8675, NIH AIDS Reagent Program).[509]
11.4.3 Cell lines
SupT1 cells were grown in RPMI 1640, and HEK293T, TZM-bl and A-172 in DMEM.
Both culture media were supplemented with 10% of heat-inactivated fetal calf serum, 2 mM Lglutamine and 1% penicillin/streptomycin.
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11.4.4 Generation of retroviruses
HEK293T cells were co-transfected with the corresponding plasmids by the calciumphosphate precipitation method.[472] VSV-G-pseudotyped HIV-derived reporter virus expressing
firefly luciferase (HIV-luc) was prepared by co-transfection of 15 µg of pHIV-luc and 5 µg of
pMD.G. Replicating competent virus [HIV-1NL4-3 wild type and Gag mutants, and SIV
(SIVmac239 SpX)] were produced by transfection of 15 µg of the corresponding expression
plasmids. After 18 h the transfection medium was replaced with fresh medium containing no drug,
fullerene derivatives 2a-c, indinavir or DMSO. The cells were cultured for 48 h until the viral
supernatant was harvested and filtered. Single-round infection viral vectors were further
concentrated by ultracentrifugation through a 20% sucrose cushion.
11.4.5 Single-round infectivity assay
SupT1 cells were plated at 1 x 105 cells in 500 µL of RPMI 1640 culture medium in 24well plates and infected with HIV-luc. Four days post-infection, cells were collected by
centrifugation at 1000 G for 6 min and the resulting pellet was resuspended in 200 μL of phosphatebuffered saline PBS. Half of the sample was mixed with 100 μL of luciferase substrate (BrightGlow™ Luciferase Assay System, Promega) and the other half with 100 μL of cell viability
substrate (CellTiter-Glo® Assay, Promega). Cell lysates were incubated for 10 min at room
temperature in the dark and then luminescence was measured in triplicate in 50 μL-samples using
a microplate luminometer reader (Thermo Scientific, Luminoskan Ascent).
11.4.6 HIV-1 replication assays
SupT1 cells were infected with HIV-1NL4-3 wild type or mutants in the presence or absence
of fullerene derivatives 2a-c or DMSO. 24 h after infection, the cells were extensively washed and
viral replication was monitored for several days by quantification of HIV-1 p24 in the cell
supernatant by ELISA.
In experiments described in Figure 11.3a, SupT1 cells were infected with HIV-1NL4-3 wild
type (92 pg of p24) and 24 h later the input virus was extensively washed and then the cells were
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distributed in cultures containing DMSO or fullerene derivatives (3, 1.5, and 1 µM). During the
two weeks analysis, half of the culture medium was replaced every 48 h with fresh medium
containing no drugs. Viral replication was monitored by HIV-1 p24 ELISA analysis of the cell
culture supernatants that were collected every 48 h before culture feeding.
TZM-bl cells were also used for evaluation of the infectivity of replication competent HIV1 and SIV. This HeLa-derived indicator cell line expresses CD4, CXCR4, CCR5 and HIV-1
promoter-driven luciferase and -galactosidase expression cassettes. These cells are permissive to
infection by different isolates of HIV-1, HIV-2, and SIV.[510-514] TZM-bl cells (1x105/well) were
plated in a p24-well plate and the next day infected with p24 or p27-normalized HIV-1 or SIV,
respectively. 72 h post-infection cells were lysed in PBS-1% Triton X-100 and luciferase activity
was measured.
11.4.7 Vesicular stomatitis virus replication assay
SupT1 were infected in the presence of DMSO or fullerene derivative 2b (3 µM) with
different multiplicities of infection (MOIs) of the Rhabdovirus Vesicular Stomatitis Virus, that
was engineered to express eGFP (VSV-eGFP).[515] 24 h later the cells were analyzed for eGFP
expression by FACS.
11.4.8 HIV p24 and SIV p27 ELISAs
The instructions of commercially available ELISA kits were followed (HIV, zeptometrix,
and SIV, XpressBio). Briefly, 200 μL of the viral samples were diluted and incubated on the
ELISA wells overnight (HIV p24) or 1 h (SIV p27) at 37 °C. Unbound proteins were removed by
washing the wells 6 times with 200 μL of washing buffer. Bound HIV-1 p24 or SIV p27 was
detected by incubating each well with 100 μL of the respectively anti-CA HRP-labeled secondary
antibodies for 1 h. Unbound antibodies were removed by washing as described above. Bound
antibodies were detected by incubating each well with 100 μL of substrate buffer for 30 min at
room temperature, after the reaction was stopped by adding 100 μL of stop solution into each well.
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The absorbance of each well was determined at 450 nm using a microplate reader (Molecular
Devices, Versa max microplate reader).
11.4.9 Cellular viability assay
25 x 104 SupT1 cells were plated in a 96-well plate in 50 µL RMPI1640 culture media and
left untreated or treated with fullerene derivatives 2a-c, DMSO, or 2 mM hydrogen peroxide
(positive control). Fullerene derivatives 2a-c were evaluated at concentrations ranging from 3 µM
to 48 µM, with each concentration evaluated in triplicate. The cells were cultured in the presence
of the indicated compounds for 24 h and then 50 µL of cell viability substrate (CellTiter-Glo®
Assay, Promega) was added to each well of cells. Cells were incubated for 10 min at room
temperature in the dark and then luminescence was measured using a microplate luminometer
reader (Thermo Scientific, Luminoskan Ascent). Control wells containing the same volumes of
culture medium were used to subtract the background.
11.4.10

Immunoblotting

Proteins of HIV-1 p24-normalized amounts of virions (0.38 μg p24) were resolved by 13%
SDS-PAGE and transferred to PVDF membranes at 100 mAmp at 4 °C. Membranes were blocked
in TBS containing 10% milk for 1 h and then incubated in the corresponding primary antibody
diluted in TBS-5% milk-0.05% Tween 20 (antibody dilution buffer) overnight at 4 °C. HIV-1 p24
was detected with anti-p24 monoclonal antibodies 183-H12-5C, obtained from the NIH AIDS
Reagent Program (Catalog # 1513), and SC-130531 (Santa Cruz Biotechnology). Primary
antibody-bound membranes were washed in TBS-0.1% Tween 20, all bound antibodies were
detected with goat anti-mouse IgG-HRP (1/2000, KPL, 074-1806), followed by chemoluminescence detection.
Cells of the glioblastoma cell line A172 were transfected with 1ug of either pCMVΔR8.91
or p96ZM651gag-opt plasmids using Lipofectamine 3000 (Invitrogen) according to
manufacturer's protocol. 4h later the transfection media was replaced with fresh culture medium.
24h post-transfection, supernatants were collected and cell lysates were prepared and analyzed by
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immunoblotting with an anti-p24 monoclonal antibody (183-H12-5C). HIV-1 p24 levels were
determined by ELISA analysis of the cell supernatants.
11.4.11

HIV-1 PR in vitro activity assay

We measured the effect of fullerene derivatives on the in vitro activity of HIV-1 PR with
a commercially available kit (Protein One, catalog number P9003). This assay uses purified
recombinant HIV-1 PR and a fluorescence resonance energy transfer (FRET) peptide derived from
the native p17/p24 cleavage site of HIV-1 PR on Gag. HIV-1 PR (0.2 µL) and FRET peptide (final
concentration 0.5 μM) were mixed in HIV-1 PR buffer supplemented with 1 M DTT (final
concentration) on ice and protected from light, and immediately transferred into a black 96-wells
plate that contain the compounds being evaluated. The reaction was measured by determining the
relative fluorescing units (RFU) with a fluorometer at excitation/emission wavelengths of 490 nm
/ 530 nm every 5 min during 90 min.
11.4.12

Pull-down assay

3 x 106 HEK293T cells were plated in a T75 cm2 tissue culture flask and transfected the
next day with 20 μg of the Gag-Pol expression plasmid pCMVΔR8.91 by the calcium-phosphate
precipitation method. After 18 h, the transfection medium was replaced with fresh medium, and
24 h later the cells were washed in 1x PBS and lysed in 500 μL of 0.5% Triton in 1x PBS. The cell
lysate was incubated on ice for 15 min, centrifuged at 22000 g for 10 min, and the supernatant was
incubated with 50 μL of AMB for 1 h at 4 °C to remove proteins binding non-specifically to the
beads. 50 μL of the precleared lysate were saved as input sample, and 150 μL were mixed with
100 μL of non-functionalized magnetic beads (AMB) or functionalized with fullerene derivative
4 (FMB-1) or fullerene derivative 6 (FMB-2). Beads and cell lysates were then rotated overnight
at 4 °C, followed by one 5 min wash using 0.5% Triton in 1x PBS. Washed beads were boiled 10
min at 100 °C in 50 μL of 2x Laemmli buffer, and the eluted proteins were analyzed by
immunoblotting with anti-HIV-1 p24 monoclonal antibodies as described above.
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11.5

SUPPORTING INFORMATION

11.5.1 Syntheses of C70-(N,N-dimethylpyrrolidinium iodide) 2a-c
The regioisomeric mixture 1a and the pure isomers 1b-d were each dissolved in methyl
iodide (6 mL) and stirred for 48 h at room temperature to give a black precipitate. The precipitate
was collected by filtration, and washed with CS2, CHCl3, toluene, MeOH and acetone, in this order,
to give the corresponding C70-(N,N-dimethylpyrrolidinium iodide) 2b,c and those of the
regioisomeric mixture of 2a Fig. 11.1. The ratio of the monoadducts in the mixture was 25:64:11
(), respectively as determined by 1H NMR (Figure 11.11), and their molecular masses were
determined by MALDI-TOF.
11.5.2 Syntheses of malonates I and II
Malonyl chloride S2 (300 mg, ~2.00 mmol) or dichloride S3 (140 mg, ~1.00 mmol) was
added to a stirred solution of 5-hexyn-1-ol (200 mg, ~2.00 mmol) S1 and trimethylamine (TEA)
(250 mg, ~2.50 mmol) in dry THF (15 mL) at room temperature, the reaction was stirred at this
temperature overnight. The solution was evaporated under reduced pressure and the corresponding
compounds I and II were purified using a column chromatography on silica gel and a hexane:ethyl
acetate (5:1) mixture. KMNO4 solution was used as the revelator for the TLC plates.

Figure 11.9 Synthesis of mono- and bis-acetylene malonate derivatives I and II.
11.5.3 Syntheses of C70 mono and bis acetylene derivatives 3 and 5
DBU (0.025 mL, 0.172 mmol) was added to a stirred solution of 1b (30 mg, 0.033 mmol),
CBr4 (0.331 mg, 0.100 mmol), and 3 or 5 (0.066 mmol) in toluene (20 mL) at room temperature.
The solution was stirred overnight at this temperature, then evaporated under reduced pressure,
and the mixture of bis-adducts was isolated by column chromatography on silica gel using
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toluene:ethyl acetate (10:1) as eluent. The first fraction after the starting material corresponded to
the mixture of bis-adducts 3 or 5, respectively. Compounds 3 and 5 were separately dissolved in
methyl iodide (6 mL) and stirred for 48 h at room temperature to give a brown precipitate. The
precipitate was collected by filtration, and washed with CS2, CHCl3, toluene and acetone, in this
order, to give the corresponding salts 4 and 6.
11.5.4 Functionalized magnetic beads
Immobilized fullerene derivatives were prepared by ‘click chemistry’ using a freshly
prepared copper catalyst solution CuSO4 (10 mmol/L) and ascorbic acid (20 mmol/L) in H2O:THF
(1:1) ratio. Then, one equivalent of azide with one equivalent of alkyne or half equivalent of bis
alkyne were added and the resulting mixture was shaken for 6 h at room temperature. Finally, the
immobilized fullerene derivatives were washed with water in the presence of a magnetic field and
stored in DMSO at 4 °C until used.

Figure 11.10 a) C70 fullerene derivatives 4 dissolved in H2O:THF (1:1) mixture, before azide
magnetic beads addition. b) After 6 h reaction with the magnetic beads at room
temperature. c) Magnetic beads functionalized with cationic C70 fullerene
derivatives 4 in the presence of a magnetic field.
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Figure 11.11 1H-NMR of the regioisomeric mixture 2a in DMSOd-6, 298 K, 600 MHz.

Figure 11.12 a) 1H-NMR of the -C70 fulleropyrrolidinium iodide 2b in DMSOd-6, 298 K, 600
MHz.
δ 5.25 (2H, s, CH2), 4.91 (2H, s, CH2), 3.68 (6H, s, CH3) ppm. b) 13C-NMR (150 MHz) δ
156.5, 155.2, 151.4, 151.0, 150.8, 150.8, 150.5, 150.4, 149.8, 149.8, 149.4, 149.0, 148.7, 148.6,
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147.4, 147.2, 147.1, 146.6, 146.3, 146.0, 145.2, 143.4, 143.4, 143.3, 143.1, 140.5, 140.0, 137.5,
133.9, 133.4, 131.7, 131.5, 131.2, 63.0, 61.8, 52.4 ppm.

Figure 11.13 a) 1H-NMR of the -C70 fulleropyrrolidinium iodide 2c in DMSOd-6, 298 K, 600
MHz.
δ 4.90 (4H, ABq, JAB = 208.8 Hz, ΔδAB = 12.7 Hz, CH2), 3.82 (3H, s, CH3), 3.45 (3H, s,
CH3) ppm. b) 13C-NMR (150 MHz) δ 154.6, 151.7, 151.4, 150.5, 149.9, 149.8, 149.5, 149.4, 149.1,
148.4, 148.1, 148.1, 147.4, 147.1, 146.9, 146.7, 146.6, 146.1, 145.9, 145.5, 145.4, 144.9, 144.7,
144.4, 144.3, 144.1, 142.9, 142.4, 140.0, 132.3, 132.1, 131.3, 130.8, 126.0, 72.4, 59.4, 53.2, 50.7
ppm.
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Figure 11.14 a) 1H-NMR of compound I in CDCl3, 298 K, 600 MHz.
δ 4.09 (2H, q, J = 7.1 Hz, CH2), 4.07 (2H, t, J = 6.5 Hz, CH2), 3.26 (2H, s, CH2), 2.12 (2H,
td, J = 7.1, 2.7 Hz, CH2), 1.88 (1H, t, J = 2.7 Hz, CH), 1.70-1.65 (2H, m, CH2), 1.52-1.46 (2H, m,
CH2), 1.17 (3H, t, J = 7.1 Hz, CH3) ppm. (b) 13C-NMR (CDCl3, 298 K, 150 MHz) δ 166.6, 166.5,
83.7, 77.5, 77.2, 77.0, 68.9, 64.9, 61.5, 41.6, 27.5, 24.7, 18.0, 14.0 ppm.

229

Figure 11.15 a) 1H-NMR of compound II in CDCl3, 298 K, 600 MHz.
δ 4.15 (4H, t, J = 6.7 Hz), 3.35 (2H, s,), 2.20 (4H, td, J = 7.2, 2.7 Hz), 1.94 (2H, t, J = 2.8
Hz), 1.80-1.69 (4H, m), 1.63-1.48 (4H, m) ppm. (b) 13C-NMR (CDCl3, 298 K, 150 MHz) δ 166.6,
83.7, 68.9, 65.0, 41.6, 27.5, 24.7, 18.0 ppm

Figure 11.16 (a) MALDI-TOF of the regioisomeric mixture 3. (b) MALDI-TOF of the
regioisomeric mixture 4, using 1,1,4,4-tetraphenyl-1,3-butadiene (TPB) matrix.
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Figure 11.17 (a) MALDI-TOF of the regioisomeric mixture 5. (b) MALDI-TOF of the
regioisomeric mixture 6, using 1,1,4,4-tetraphenyl-1,3-butadiene (TPB) matrix.

Figure 11.18 HPLC chromatogram of the regioisomeric mixture 3, after 5 cycles using
preparative 5PBB column, 2.5 mL/min and toluene.
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Figure 11.19 HPLC chromatogram of the regioisomeric mixture 5, after 6 cycles using
preparative 5PBB column, 2.0 mL/min and toluene.

Figure 11.20 IR of the magnetic beads functionalized with cationic C70 fullerene derivatives 4.
Magnetic beads coupled to fullerene derivatives 6 showed similar IR characteristics.

232

Figure 11.21 Detection of processed and unprocessed HIV-1 CA. A172 cells were transfected
with a plasmid expressing Gag and Pol proteins, including HIV-1 protease
(Gag/Pr), or only Gag. Then, cell lysates were analyzed by immunoblot with an
anti-p24 (CA) Mab (a) and cell supernatants for HIV-1 p24 by ELISA (b).
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Glossary
Acronym

Definition

Buckyclutcher

3,3,3-tri-dinitrobenzoxyl-propyl

Buckyprep

Pyrenylpropyl

Buckyprep-M

Phenothiazinyl

COSY NMR

Correlation Spectroscopy Nuclear Magnetic Resonance

CV

Cyclic Voltammetry

DCTB

trans-2-[3-(4-t-butyl-phenyl)-2-methyl-2-propenylidene]malononitrile

DFT

Density Functional Theory

FTIR

Fourier Transform Infrared

HMQC NMR

Heteronuclear Multiple Quantum Coherence Nuclear Magnetic Resonance

HPLC

High Performance Liquid Chromatography

LD FT ICR

Laser Desorption Fourier Transform Ion Cyclotron Resonance

MALDI-TOF

Matrix Assisted Desorption Ionization-Time of Flight

NMR

Nuclear Magnetic Resonance

NOESY NMR

Nuclear Overhauser Effect Spectroscopy Nuclear Magnetic Resonance

o-DCB

Ortho-Dichlorobenzene

5PBB

Pentabromobenzyl

PCnBM

Phenyl Cn Butyric Acid Methyl Ester (n = 61, 71)

PYE

Pyrenylethyl

SWV

Square Wave Voltammetry

THA

1,8,9-trihydroxyanthracene

TLC

Thin Layer Chromatography

TPB

1,1,4,4-tetraphenyl-1,3-butadiene

UV/vis

Ultra Violet/visible

254

Appendix A

255

Appendix B

256

Appendix C

257

Appendix D

258

Appendix E

259

Appendix F
PRESENTATIONS
1.

227th ECS Meeting, invited speaker 2015. An Easy Stereo-Specific and Regio-Selective
Reaction for the Synthesis of Ester-[70]-Fullerene Derivatives.

2.

231st ECS Meeting, invited speaker 2017. Synthesis and characterization of unprecedented
D2h-symmetrical trans-1-(S,R,R,S-bis-pyrrolidine)-tetra-malonate hexakis adducts of C60.

3.

231st ECS Meeting, invited speaker 2017. Improved Performance and Stability of Inverted
Planar Perovskite Solar Cells Using New Fullerene Layers.

4.

231st ECS Meeting 2017. Gas-Phase Self-Assembly of Group III-Based Nitride
Clusterfullerenes By Laser Plasma Synthesis.

5.

Chemistry Department seminar, oral presentation 2017. Synthesis of Fullerene Derivatives
for Potential Photovoltaic and Biological Applications.

6.

MIT-Harvard Center for Excitonics 2017, oral presentation 2017. Improved Performance
and Stability of Inverted Planar Perovskite Solar Cells Using Fullerene Layers.

7.

COURI, poster presentation 2014. Synthesis and Characterization of Carbazole-Based
Donor-Acceptor-Donor (D-A-D) Compounds.

8.

COURI, poster presentation 2015. Synthesis of [60]Fullerene Derivatives for Biological
Applications.

9.

COURI, poster presentation 2015. Water-soluble [70] fullerene derivatives for anti-HIV
activity.

10.

BBRC, poster presentation 2015. Synthesis and Anti-HIV Study of Cationic [70]Fullerene
Derivatives.

11.

COURI, poster presentation 2016. Synthesis of C60 and C70 fullerene derivatives for bulk
heterojunction organic solar cells.

12.

COURI, poster presentation 2016. New C60 and C70 methanofullerene derivatives
substituted with electron-donating or electron-withdrawing groups.
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13.

PREM, poster presentation 2017. Synthesis of C60 and C70 fullerene derivatives for
perovskite solar cells.

14.

COURI, poster presentation 2017. Diplatinum Acetylide Donor Complexes Based on
Thiophene and Benzothiadiazol for Bulk Heterojunction Solar Cells.

15.

COURI, poster presentation 2017. Synthesis and Characterization of Variable Chainlength Fullerene Derivatives for Perovskite Solar Cells.

16.

PREM, poster presentation 2017. Curcumin C60 Fullerene Derivatives as Electron
Transporting Materials in Inverted Perovskite Solar Cells.

17.

PREM, poster presentation 2017. New Fullerene Derivatives as Electron Transporting
Materials in Perovskite Solar Cells.

18.

PREM, poster presentation 2017. Impact of Fullerene Derivative Isomeric Purity on the
Performance of Inverted Planar Perovskite Solar Cells.

19.

COURI, poster presentation 2017. External Effects on the Glass Substrate used in the
Perovskite Solar Cell Devices: Electron Spin Resonance Investigation.

20.

PREM, poster presentation 2017. One-step rapid synthesis of atomically-precise
Au25(SG)18 nanoclusters toward applications in photothermal therapy.
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